



B1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification:		(11) International Publication Number:	WO 00/34477
C12N 15/12, C07K 14/47, C12Q 1/68, A61K 38/17, C07K 16/18		A2	(43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/30408		(72) Inventors; and	
(22) International Filing Date: 10 December 1999 (10.12.99)		(75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). LU, Duyng, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US).	
(30) Priority Data:		(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	
Not furnished 09/210,083 60/119,365 60/124,687	11 December 1998 (11.12.98) 11 December 1998 (11.12.98) 9 February 1999 (09.02.99) 16 March 1999 (16.03.99)	US US US US US	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications		Published Without international search report and to be republished upon receipt of that report.	
US Filed on US Filed on US Filed on	Not furnished (CIP) 11 December 1998 (11.12.98) 60/119,365 (CIP) 9 February 1999 (09.02.99) 60/124,687 (CIP) 16 March 1999 (16.03.99) 09/210,083 (CIP) 11 December 1998 (11.12.98)		
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).			

(54) Title: NEURON-ASSOCIATED PROTEINS

1 MA-GSPSRAAGRRLOLP 2417014
 1 MEF SLLLPRLECNGAISAHRNLRLP GSSDS GI 3002527

17 -LLCLFLQ- 2417014
 31 PASASPVA GITGMCTHARLILYFELVEMEP GI 3002527

24 GATAVLFAVE -VRYNHK 2417014
 61 LHV[GQAGLELPTSDDPSVSASQSARXRTGH GI 3002527

41 DAAL-WH- 2417014
 91 HARLCLANFCGRNRVSLMCPSWSPELKQST GI 3002527

47 RSNHSNADNEFYFRY-PKESHS 2417014
 121 CLSLPKCWDYRRAAVPGLFILFFLRHRCPT GI 3002527

68 VAQAGVQRNLGSLOPSPPR 2417014
 151 LTODEVQWCDHSSLOPSTPEIKHPPASASQ GI 3002527

88 W-SFALVA 2417014
 181 VAGTKDMHHYTWLIFIFIFNFLRQS LNSVT GI 3002527

(57) Abstract

The invention provides human neuron-associated proteins (NEUAP) and polynucleotides which identify and encode NEUAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of NEUAP.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

NEURON-ASSOCIATED PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of neuron-associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders.

BACKGROUND OF THE INVENTION

The human nervous system, which regulates all bodily functions, is composed of the central nervous system (CNS), consisting of the brain and spinal cord, and the peripheral nervous system (PNS), consisting of afferent neural pathways for conducting nerve impulses from sensory organs to the CNS, and efferent neural pathways for conducting motor impulses from the CNS to effector organs. The PNS can be further divided into the somatic nervous system, which regulates voluntary motor activity such as for skeletal muscle, and the autonomic nervous system, which regulates involuntary motor activity for internal organs such as the heart, lungs, and viscera.

The central nervous system (CNS) is composed of more than 100 billion neurons at the spinal cord level, the lower brain level, and the higher brain or cortical level. Neurons transmit electric or chemical signals between cells. The spinal cord, a thin, tubular extension of the central nervous system within the bony spinal canal, contains ascending sensory and descending motor pathways, and is covered by membranes continuous with those of the brainstem and cerebral hemispheres. The spinal cord contains almost the entire motor output and sensory input systems of the trunk and limbs, and neuronal circuits in the cord also control rhythmic movements, such as walking, and a variety of reflexes. The lower areas of the brain such as the medulla, pons, mesencephalon, cerebellum, basal ganglia, substantia nigra, hypothalamus, and thalamus control unconscious activities including arterial pressure and respiration, equilibrium, and feeding reflexes, such as salivation. Emotions, such as anger, excitement, sexual response, and reaction to pain or pleasure, originate in the lower brain. The cerebral cortex or higher brain is the largest structure, consisting of a right and a left hemisphere interconnected by the corpus callosum. The cerebral cortex is involved in sensory, motor, and integrative functions related to perception, voluntary musculoskeletal movements, and the broad range of activities associated with consciousness, language, emotions, and memory. The cerebrum functions in association with the lower centers of the nervous system.

A nerve cell (neuron) contains four regions, the cell body, axon, dendrites, and axon terminal. The cell body contains the nucleus and other organelles. The dendrites are processes which extend

outward from the cell body and receive signals from sense organs or from the axons of other neurons. These signals are converted to electrical impulses and transmitted to the cell body. The axon, whose size can range from one millimeter to more than one meter, is a single process that conducts the nerve impulse away from the cell body. Cytoskeletal fibers, including microtubules and neurofilaments, run 5 the length of the axon and function in transporting proteins, membrane vesicles, and other macromolecules from the cell body along the axon to the axon terminal. Some axons are surrounded by a myelin sheath made up of membranes from either an oligodendrocyte cell (CNS) or a Schwann cell (PNS). Myelinated axons conduct electrical impulses faster than unmyelinated ones of the same diameter. The axon terminal is at the tip of the axon away from the cell body. (See Lodish, H. et al.

10 (1986) Molecular Cell Biology Scientific American Books New York NY, pp. 715-719.)

CNS-associated proteins have roles in neuronal signaling, cell adhesion, nerve regeneration, axon guidance, neurogenesis, and other functions. Certain CNS-associated proteins form an integral part of a membrane or are attached to a membrane. For example, neural membrane protein 35 (NMP35) is closely associated with neuronal membranes and is known to be highly expressed in the 15 rat adult nervous system. (Schweitzer, B. et al. (1998) Mol. Cell. Neurosci. 11:260-273.)

Synaptophysin (SY) is a major integral membrane protein of small synaptic vesicles. The chromosomal location of SY in human and mouse is on the X chromosome in subbands Xp11.22-p11.23. This region has been implicated in several inherited diseases including Wiskott-Aldrich syndrome, three forms of X-linked hypercalciuric nephrolithiasis, and the eye disorders retinitis 20 pigmentosa 2, congenital stationary night blindness, and Aland Island eye disease. (Fisher, S. E. et al. (1997) Genomics 45:340-347.) Peripherin or retinal degeneration slow protein (rds) is an integral membrane glycoprotein that is present in the rims of photoreceptor outer segment disks. In mammals, rds is thought to stabilize the disk rim through heterophilic interactions with related nonglycosylated proteins. Rds is a mouse neurological mutation that is characterized by abnormal development of rod 25 and cone photoreceptors followed by their slow degeneration. (Kedzierski, W.J. et al. (1999) Neurochem. 72:430-438.)

43 KD postsynaptic protein or acetylcholine receptor-associated 43 KD protein (RAPSYN) is thought to play a role in anchoring or stabilizing the nicotinic acetylcholine receptor at synaptic sites. RAPSYN is involved in membrane association and may link the nicotinic acetylcholine receptor to 30 the underlying postsynaptic cytoskeleton. (Buckel, A. et al. (1996) Genomics 35:613-616.) Neuritin is a protein whose gene is known to be induced by neural activity and by neurotrophins which promotes neuritogenesis. Neuraxin is a structural protein of the rat central nervous system that is believed to be immunologically related to microtubule-associated protein 5 (MAP5). Neuraxin is a novel type of neuron-specific protein which is characterized by an unusual amino acid composition,

12 central heptadecarepeats and putative protein and membrane interaction sites. The gene encoding neuraxin is unique in the haploid rat genome and is conserved in higher vertebrates. Neuraxin is implicated in neuronal membrane-microtubule interactions and is expressed throughout the rodent central nervous system (CNS). (Rienitz, A. et al. (1989) EMBO J. 8:2879-2888.)

- 5 NudC, a nuclear movement protein, interacts with the lissencephaly gene product Lis1, a protein involved in neuronal migration. People with Miller-Dieker syndrome (MDS) or isolated lissencephaly sequence (ILS) have a hemizygous deletion or mutation in the LIS1 gene. Both conditions are characterized by a smooth cerebral surface, a thickened cortex with four abnormal layers, and misplaced neurons. LIS1 is highly expressed in the ventricular zone and the cortical plate.
- 10 10 The interaction of Lis1 with NudC, in conjunction with the MDS and ILS phenotypes, raises the possibility that nuclear movement in the ventricular zone is closely related to neuronal fates and to cortical architecture. (Morris, S. M. et al. (1998) Curr. Biol. 8:603-606.)

15 CNS-associated proteins can also be phosphoproteins. For example, ARPP-21 (cyclic AMP-regulated phosphoprotein) is a cytosolic neuronal phosphoprotein that is highly enriched in the striatum and in other dopaminoceptive regions of the brain. The steady-state level of ARPP-21 mRNA is developmentally regulated. But, in the neonatal and mature animal, ARPP-21 mRNA is not altered following 6-hydroxydopamine lesions of the substantia nigra or by pharmacologic treatments that upregulate the D1- or D2-dopamine receptors. (Ehrlich, M. E. et al. (1991) Neurochem. 57:1985-1991.)

20 20 CNS-associated signaling proteins may contain PDZ domains. PDZ domains have been found in proteins which act as adaptors in the assembly of multifunctional protein complexes involved in signaling events at surfaces of cell membranes. PDZ domains are generally found in membrane-associated proteins including neuronal nitric oxide synthase (NOS) and several dystrophin-associated proteins. (Ponting, C. P. et al. (1997) Bioessays 19:469-479.)

25 25 CNS-associated proteins may also contain epidermal growth factor (EGF) domains. The Notch proteins are transmembrane proteins which contain extracellular regions of repeated EGF domains. Notch proteins, such as the Drosophila melanogaster neurogenic protein Notch, are generally involved in the inhibition of developmental processes. Other members of the Notch family are the lin-12 and glp-1 genes of Caenorhabditis elegans. Genetic studies indicate that the lin-12 and glp-1 proteins act as receptors in specific developmental cell interactions which may be involved in certain embryonic defects. (Tax, F. E. et al. (1994) Nature 368:150-154.) Pecanex, a maternal-effect neurogenic locus of D. melanogaster is believed to encode a large transmembrane protein. In the absence of maternal expression of the pecanex gene, an embryo develops severe hyperneuralization similar to that characteristic of Notch mutant embryos. (LaBonne, S. G. et al. (1989) Dev. Biol.

136:1-116.) Other CNS-associated signaling proteins contain WW domains. The WW domain is a protein motif with two highly conserved tryptophans. It is present in a number of signaling and regulatory proteins, including Huntingtin interacting protein.

Alzheimer's disease (AD) is a degenerative disorder of the CNS which causes progressive
5 memory loss and cognitive decline during mid to late adult life. AD is characterized by a wide range of neuropathologic features including amyloid deposits and intra-neuronal neurofibrillary tangles. Although the pathogenic pathway leading to neurodegeneration and AD is not well understood, at least three genetic loci that confer genetic susceptibility to the disease have been identified.
10 (Schellenberg, G.D. (1995) Proc. Natl. Acad. Sci. 92:8552-8559; Sherrington, R. et al. (1995) Nature 375:754-760.)

Neuronal Thread Proteins (NTP) are a group of immunologically related molecules found in the brain and neuroectodermal tumor cell lines. NTP expression is increased in neuronal cells during proliferation, differentiation, brain development, in Alzheimer's disease (AD) brains, and in pathological states associated with regenerative nerve sprouting (de la Monte, S.M. et al. (1996) J. Neuropathol. Exp. Neurol. 55:1038-1050). Monoclonal antibodies generated to a recombinant NTP, AD7c-NTP, isolated from an end-stage AD brain library, showed high levels of NTP immunoreactivity in perikarya, neuropil fibers, and white matter fibers of AD brain tissue. In vitro studies also demonstrated NTP upregulation, phosphorylation, and translocation from the perikarya to cell processes and growth cones during growth factor-induced neuitic sprouting and neuronal differentiation. Additionally, increased NTP immunoreactivity was found in Down syndrome brains beginning in the second decade, prior to establishment of widespread AD neurodegeneration, and at an age when a low-level or an absence of NTP expression was observed in control brains. These findings indicated that abnormal expression and accumulation of NTP in brain may be an early marker of AD neurodegeneration in Down syndrome (de la Monte, S.M. et al. (1996) J. Neurol. Sci. 135:118-125). Furthermore, the increased expression and accumulation of NTP in AD brain tissue was paralleled by corresponding elevations of NTP in cerebrospinal fluid (CSF), and elevated levels of NTP were detectable in the CSF early in the course of the disease.

Astrocytomas, and the more malignant glioblastomas, are the most common primary tumors of the brain, accounting for over 65% of primary brain tumors. These tumors arise in glial cells of the 30 astrocyte lineage. Following infection by pathogens, astrocytes function as antigen-presenting cells and modulate the activity of lymphocytes and macrophages. Astrocytomas constitutively express many cytokines and interleukins that are normally produced only after infection by a pathogen (de Micco, C. (1989) J. Neuroimmunol. 25:93-108). In the course of identifying genes related to astrocyte differentiation, one cDNA was isolated from an astrocytoma cDNA library that encodes a

protein structurally related to the plant pathogenesis-related (PR) proteins (Murphy, E.V. et al. (1995) Gene 159:131-135). The glioma pathogenesis-related protein (GliPR) is highly expressed in glioblastoma, but not in fetal or adult brain, or in other nervous system tumors. PR proteins are a family of small (10-20 kDa), protease resistant proteins induced in plants by viral infections, such as 5 tobacco mosaic virus. The synthesis of PR proteins is believed to be part of a primitive immunological response in plants (van Loon, L.C. (1985) Plant Mol. Biol. 4:111-116). GliPR shares up to 50% homology with the PR-1 protein family over a region that comprises almost two thirds of the protein, including a conserved triad of amino acids, His-Glu-His, appropriately spaced to form a metal-binding domain (Murphy et al., supra).

10 Fe65-like protein (Fe65L2), a new member of the Fe65 protein family, is one of the ligands that interacts with the cytoplasmic domain of Alzheimer beta-amyloid precursor protein (APP). Transgenic mice expressing APP are known to simulate some of the prominent behavioral and pathological features of Alzheimer's disease, including age-related impairment in learning and memory, neuronal loss, gliosis, neuritic changes, amyloid deposition, and abnormal tau 15 phosphorylation. Proteins that interact with the cytoplasmic domain of APP provide new insights into the physiological function of APP and, in turn, into the pathogenesis of Alzheimer's disease. (Duilio, A. et al. (1998) Biochem. J. 330:513-519.)

Contact from one neuron to another occurs at a specialized site called the synapse. At this site, the axon terminal from one neuron (the presynaptic cell) sends a signal to another neuron (the 20 postsynaptic cell). Synapses may be connected either electrically or chemically. An electrical synapse consists of gap junctions connecting the two neurons, allowing electrical impulses to pass directly from the presynaptic to the postsynaptic cell. In a chemical synapse, the axon terminal of the presynaptic cell contains membrane vesicles containing a particular neurotransmitter molecule. A change in electrical potential at the nerve terminal resulting from the electrical impulse triggers the 25 release of the neurotransmitter from the synaptic vesicle by exocytosis. The neurotransmitter rapidly diffuses across the synaptic cleft separating the presynaptic nerve cell from the postsynaptic cell. The neurotransmitter then binds receptors and opens transmitter-gated ion channels located in the plasma membrane of the postsynaptic cell, provoking a change in the cell's electrical potential. This change in membrane potential of the postsynaptic cell may serve either to excite or inhibit 30 further transmission of the nerve impulse.

Neurotransmitters comprise a diverse group of some 30 small molecules which include acetylcholine, monoamines such as serotonin, dopamine, and histamine, and amino acids such as gamma-aminobutyric acid (GABA), glutamate, and aspartate, and neuropeptides such as endorphins and enkephalins. (McCance, K.L. and Huether, S.E. (1994) PATHOPHYSIOLOGY, The Biologic

Basis for Disease in Adults and Children, 2nd edition, Mosby, St. Louis, MO, pp 403-404.) Many of these molecules have more than one function and the effects may be excitatory, e.g. to depolarize the postsynaptic cell plasma membrane and stimulate nerve impulse transmission, or inhibitory, e.g. to hyperpolarize the plasma membrane and inhibit nerve impulse transmission.

5 Neurotransmitters and their receptors are targets of pharmacological agents aimed at controlling neurological function. For example GABA is the major inhibitory neurotransmitter in the CNS, and GABA receptors are the principal target of sedatives such as benzodiazepines and barbiturates which act by enhancing GABA-mediated effects (Katzung, B.G. (1995) Basic and Clinical Pharmacology, 6th edition, Appleton & Lange, Norwalk, CT, pp. 338-339). Diazepam
10 binding inhibitor (DBI), also known as endozepine and acyl-Coenzyme (CoA)-binding protein, is an endogenous GABA receptor ligand which is thought to down-regulate the effects of GABA. DBI binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an intracellular carrier of acyl-CoA esters (*125950 Diazepam Binding Inhibitor; DBI, Online Mendelian Inheritance in Man (OMIM); PROSITE PDOC00686 Acyl-CoA-binding protein
15 signature). Aberrant activity of neurotransmitters and their receptors is involved in various neurological conditions, including Alzheimer's disease, myasthenia gravis, stroke, epilepsy, and Parkinson's disease. (See Planells-Cases, R. et al. (1993) Proc. Natl. Acad. Sci. USA 90:5057-5061.)

20 Each of over a trillion neurons in adult humans connects with over a thousand target cells (Tessier-Lavigne, M. et al. (1996) Science 274:1123-1133). These neuronal connections form during embryonic development. Each differentiating neuron sends out an axon tipped at the leading edge by a growth cone. Aided by molecular guidance cues, the growth cone migrates through the embryonic environment to its synaptic target. Semaphorins are growth cone guidance signals that may function during embryogenesis by providing local signals to specify territories inaccessible to growing axons (Puschel, A.W. et al. (1995) Neuron 14:941-948).

25 Axon growth is guided in part by contact-mediated mechanisms involving cell surface and extracellular matrix (ECM) molecules. Many ECM molecules, including fibronectin, vitronectin, members of the laminin, tenascin, collagen, and thrombospondin families, and a variety of proteoglycans, can act either as promoters or inhibitors of neurite outgrowth and extension (Tessier-Lavigne et al., supra). Receptors for ECM molecules include integrins, immunoglobulin superfamily members, and proteoglycans. ECM molecules and their receptors have also been implicated in the adhesion, maintenance, and differentiation of neurons (Reichardt, L.F. et al. (1991) Ann. Rev. Neurosci. 14:531-571). The proteoglycan testican is localized to the post-synaptic area of pyramidal cells of the hippocampus and may play roles in receptor activity, neuromodulation, synaptic plasticity, and neurotransmission (Bonnet, F. et al. (1996) J. Biol. Chem. 271:4373-4380).

Other nervous system-associated proteins have roles in neuron signaling, cell adhesion, nerve regeneration, axon guidance, and neurogenesis. The neurexophilins are neuropeptide-like proteins which are proteolytically processed after synthesis. They are ligands for the neuron-specific cell surface proteins, the α -neurexins. Neurexophilins and neurexins may participate in a neuron signaling pathway (Missler, M. and T.C. Sudhof (1998) J. Neurosci. 18:3630-3638; Missler, M. et al. (1998) J. Biol. Chem. 273:34716-34723). Ninjurin is a neuron cell surface protein which plays a role in cell adhesion and in nerve regeneration following injury. Ninjurin is up-regulated after nerve injury in dorsal root ganglion neurons and in Schwann cells (*602062 Ninjurin; NINJ1 OMIM; Araki, T. and Milbrandt, J. (1996) Neuron 17:353-361). Mammalian Numb is a phosphotyrosine-binding (PTB) domain-containing protein which may be involved in cortical neurogenesis and cell fate decisions in the mammalian nervous system. Numb's binding partner, the LNX protein, contains four PDZ domains and a ring finger domain and may participate in a signaling pathway involving Numb. PDZ domains have been found in proteins which act as adaptors in the assembly of multifunctional protein complexes involved in signaling events at surfaces of cell membranes (Ponting, C.P. (1997) Bioessays 19:469-479). LNX contains a tyrosine phosphorylation site which may be important for the binding of other PTB-containing proteins such as SHC, an adaptor protein which associates with tyrosine-phosphorylated growth factor receptors and downstream effectors (Dho, S.E. et al. (1998) J. Biol. Chem. 273:9179-9187).

The discovery of new neuron-associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders.

SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, neuron-associated proteins, referred to collectively as "NEUAP" and individually as "NEUAP-1," "NEUAP-2," "NEUAP-3," "NEUAP-4," "NEUAP-5," "NEUAP-6," "NEUAP-7," "NEUAP-8," "NEUAP-9," "NEUAP-10," "NEUAP-11," "NEUAP-12," "NEUAP-13," "NEUAP-14," "NEUAP-15," "NEUAP-16," "NEUAP-17," "NEUAP-18," "NEUAP-19," "NEUAP-20," "NEUAP-21," "NEUAP-22," "NEUAP-23," "NEUAP-24," "NEUAP-25," "NEUAP-26," "NEUAP-27," and "NEUAP-28." In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also includes a polypeptide comprising an amino acid sequence that differs by one or more conservative amino acid substitutions from an amino acid sequence selected from the group consisting of SEQ ID NO:1-27.

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of

- 5 SEQ ID NO:1-27 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

- 15 The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, 20 the method further comprises amplifying the polynucleotide prior to hybridization.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group 25 consisting of SEQ ID NO:28-54 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof.

- 30 The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing a polynucleotide of the

invention under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

5 The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

10 The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

15 The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

BRIEF DESCRIPTION OF THE FIGURES AND TABLES

20 Figures 1A and 1B show the amino acid sequence alignment between NEUAP-1 (2417014; SEQ ID NO:1) and a human neuronal thread protein, AD7c-NTP (GI 3002527; SEQ ID NO:55), produced using the multisequence alignment program of LASERGENE software (DNASTAR, Madison WI).

25 Figures 2A, 2B, and 2C show the amino acid sequence alignment between NEUAP-2 (2634931; SEQ ID NO:2) and a human glioma pathogenesis-related protein, GliPR (GI 847722; SEQ ID NO:56), produced using the multisequence alignment program of LASERGENE software.

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding NEUAP.

30 Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of NEUAP.

35 Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding NEUAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze NEUAP, along with applicable descriptions, references, and threshold parameters.

5

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing 10 particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a 15 reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be 20 used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

25 DEFINITIONS

"NEUAP" refers to the amino acid sequences of substantially purified NEUAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of 30 NEUAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of NEUAP either by directly interacting with NEUAP or by acting on components of the biological pathway in which NEUAP participates.

An "allelic variant" is an alternative form of the gene encoding NEUAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in

polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times 5 in a given sequence.

"Altered" nucleic acid sequences encoding NEUAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as NEUAP or a polypeptide with at least one functional characteristic of NEUAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe 10 of the polynucleotide encoding NEUAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding NEUAP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent NEUAP. Deliberate amino acid substitutions may be made on the basis of similarity in 15 polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of NEUAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. 20 Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally 25 occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well 30 known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of NEUAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of NEUAP either by directly interacting with NEUAP or by acting on components of the biological pathway in which

NEUAP participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind NEUAP polypeptides can be prepared using intact polypeptides or using 5 fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize 10 the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures 15 on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the 20 complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the 25 capability of the natural, recombinant, or synthetic NEUAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the 30 complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid

(PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.

- 5 Compositions comprising polynucleotide sequences encoding NEUAP or fragments of NEUAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).
- 10 "Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

15 "Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded 20 as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
25	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
30	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
35	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

5 A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative 10 polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of NEUAP or the polynucleotide encoding NEUAP which is 15 identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues 20 in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

25 A fragment of SEQ ID NO:28-54 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:28-54, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:28-54 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:28-54 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:28-54 and the region of 30 SEQ ID NO:28-54 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-27 is encoded by a fragment of SEQ ID NO:28-54. A fragment of SEQ ID NO:1-27 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-27. For example, a fragment of SEQ ID NO:1-27 is useful as an immunogenic peptide

for the development of antibodies that specifically recognize SEQ ID NO:1-27. The precise length of a fragment of SEQ ID NO:1-27 and the region of SEQ ID NO:1-27 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

5 The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to 10 one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target 15 sequence.

20 The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

25 Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 30 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms

is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

15 *Reward for match: 1*

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

20 *Word Size: 11*

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a

standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

5 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default
10 residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

15 *Matrix: BLOSUM62*

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

20 *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 25 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

30 "Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a

complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the 5 hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among 10 experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined 15 ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

20 High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking 25 reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative 30 of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_{ot} or R_{ot} analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid

support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

5 "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

10 The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate. The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of NEUAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of NEUAP.

15 The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

20 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

25 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

30 "Probe" refers to nucleic acid sequences encoding NEUAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target

DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for

example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence
5 that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, *supra*. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a
10 recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a
15 vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding NEUAP, or fragments thereof, or NEUAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

20 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide
25 containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

30 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,

microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human neuron-associated proteins (NEUAP), the polynucleotides encoding NEUAP, and the use of these compositions for the diagnosis, treatment, 5 or prevention of cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding NEUAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte 10 clones in which nucleic acids encoding each NEUAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each NEUAP and are useful as fragments in hybridization technologies.

15 The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows the identity of each polypeptide; and column 7 shows analytical methods and in some cases, 20 searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

As shown in Figures 1A and 1B, NEUAP-1 has chemical and structural similarity with a 25 human neuronal thread protein, AD7c-NTP (GI 3002527; SEQ ID NO:55). In particular, NEUAP-1 and AD7c-NTP share 24% identity, including a region of NEUAP-1 between residues S89 and Y127 in which the two proteins share 79% identity as well as two potential phosphorylation sites at S117 and S123.

MOTIFS, BLOCKS, and PFAM indicate that NEUAP-2 has an SCP-like extracellular protein 30 signature, common to plant PR-1 proteins, between approximately residues S4 and G173. The conserved His-Glu-His triad of PR family proteins is found in NEUAP-2 at residues H78, E109, and H128. As shown in Figures 2A, 2B, and 2C, NEUAP-2 has chemical and structural similarity with a human glioma pathogenesis-related protein, GliPR (GI 847722; SEQ ID NO:56). In particular, the two proteins share 27% identity, the His-Glu-His triad, and ten of the twelve cysteine residues found in NEUAP-2, including C163, known to be involved in disulfide bond formation in PR-1 proteins.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions

associated with nucleotide sequences encoding NEUAP. The first column of Table 3 lists the nucleotide SEQ ID NOS. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:28-54 and to distinguish between SEQ ID NO:28-54 and related polynucleotide sequences. The 5 polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express NEUAP as a fraction of total tissues expressing NEUAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing NEUAP as a fraction of total tissues expressing NEUAP. Of particular note is the expression of NDAP-2 in five neuronal tissues. Northern analysis shows the expression of NEUAP-1 in four tissues, three of which 10 are cancerous, including a neuronal teratocarcinoma. Of particular interest is the tissue-specific expression of SEQ ID NO:31 and SEQ ID NO:32. SEQ ID NO:31 is highly expressed and SEQ ID NO:32 is exclusively expressed in nervous tissue. Of particular interest is the expression of SEQ ID NO:42, SEQ ID NO:46. SEQ ID NO:47, SEQ ID NO: 48, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:56, and especially SEQ ID NO:51 in nervous tissues; and the expression of SEQ ID NO:42, SEQ 15 ID NO:46, SEQ ID NO:48, and SEQ ID NO:51 in tissues associated with neurological disorders. Column 5 lists the vectors used to subclone each cDNA library.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding NEUAP were isolated. Column 1 references the nucleotide SEQ ID NOS, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 20 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses NEUAP variants. A preferred NEUAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the NEUAP amino acid sequence, and which contains at least one functional or structural characteristic of NEUAP.

25 The invention also encompasses polynucleotides which encode NEUAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:28-54, which encodes NEUAP.

The invention also encompasses a variant of a polynucleotide sequence encoding NEUAP. In particular, such a variant polynucleotide sequence will have at least about 80%, or alternatively at 30 least about 90%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding NEUAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:28-54 which has at least about 80%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting

of SEQ ID NO:28-54. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of NEUAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding NEUAP, some bearing minimal 5 similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring NEUAP, and all such variations are to be considered 10 as being specifically disclosed.

Although nucleotide sequences which encode NEUAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring NEUAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding 15 NEUAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding NEUAP and its derivatives without altering the encoded amino acid 20 sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode NEUAP and NEUAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce 25 mutations into a sequence encoding NEUAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:28-54 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 30 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-

Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV),

- 5 PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short
10 Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding NEUAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed,

- 15 restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences
20 are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National
25 Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include

chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

5 In order to express a biologically active NEUAP, the nucleotide sequences encoding NEUAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in
10 polynucleotide sequences encoding NEUAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding NEUAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding NEUAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional
15 transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.
20 (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding NEUAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A
25 Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding NEUAP. These include, but are not limited to, microorganisms such as bacteria
30 transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze 5 the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process 10 from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode NEUAP may be cloned in recombinant DNA molecules that direct expression of 15 NEUAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express NEUAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter NEUAP-encoding sequences for a variety of purposes including, but 20 not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

25 In another embodiment, sequences encoding NEUAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, NEUAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., 30 Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of NEUAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid

sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

- Capillary electrophoresis systems which are commercially available may be used to analyze
- 5 the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process
- 10 from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

- In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode NEUAP may be cloned in recombinant DNA molecules that direct expression of
- 15 NEUAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express NEUAP.

- The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter NEUAP-encoding sequences for a variety of purposes including, but
- 20 not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

- 25 In another embodiment, sequences encoding NEUAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, NEUAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g.,
- 30 Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of NEUAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid

chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

5 In order to express a biologically active NEUAP, the nucleotide sequences encoding NEUAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in
10 polynucleotide sequences encoding NEUAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding NEUAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding NEUAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional
15 transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.
20 (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding NEUAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A
25 Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding NEUAP. These include, but are not limited to, microorganisms such as bacteria
30 transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding NEUAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding NEUAP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 5 plasmid (Life Technologies). Ligation of sequences encoding NEUAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. 10 Chem.* 264:5503-5509.) When large quantities of NEUAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of NEUAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of NEUAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH 15 promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of NEUAP. Transcription of sequences encoding NEUAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. 25 (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases 30 where an adenovirus is used as an expression vector, sequences encoding NEUAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses NEUAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma

virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of NEUAP in cell lines is preferred. For example, sequences encoding NEUAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) *Cell* 11:223-232; Lowy, I. et al. (1980) *Cell* 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci. USA* 77:3567-3570; Colbere-Garapin, F. et al. (1981) *J. Mol. Biol.* 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding NEUAP is inserted within a marker gene sequence, transformed cells containing

sequences encoding NEUAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding NEUAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

- 5 In general, host cells that contain the nucleic acid sequence encoding NEUAP and that express NEUAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.
- 10 Immunological methods for detecting and measuring the expression of NEUAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on NEUAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)
- 15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding NEUAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding NEUAP, or any fragments thereof, may be cloned into a vector 20 for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety 25 of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for 30 ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding NEUAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence

and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode NEUAP may be designed to contain signal sequences which direct secretion of NEUAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding NEUAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric NEUAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of NEUAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the NEUAP encoding sequence and the heterologous protein sequence, so that NEUAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled NEUAP may be achieved *in vitro* using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid

precursor, for example, ^{35}S -methionine.

Fragments of NEUAP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, *supra*, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be 5 achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of NEUAP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of NEUAP and neuron-associated proteins. In addition, the expression of NEUAP is closely 10 associated with nervous tissue, neurological disorders, cell proliferation including cancer, inflammation, and the immune response. Therefore, NEUAP appears to play a role in cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders. In the treatment of disorders associated with increased NEUAP expression or activity, it is desirable to decrease the expression or activity of NEUAP. In the 15 treatment of disorders associated with decreased NEUAP expression or activity, it is desirable to increase the expression or activity of NEUAP.

Therefore, in one embodiment, NEUAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of NEUAP. Examples of such disorders include, but are not limited to, a neurological 20 disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, 25 suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central 30 nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; seasonal affective disorder (SAD); akathesia, amnesia,

catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary 5 thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired 10 immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, 15 erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, 20 systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

In another embodiment, a vector capable of expressing NEUAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased 25 expression or activity of NEUAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified NEUAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of NEUAP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of NEUAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of NEUAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of NEUAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of NEUAP. Examples of such

disorders include, but are not limited to, those cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders described above. In one aspect, an antibody which specifically binds NEUAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express

5 NEUAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding NEUAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of NEUAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of NEUAP may be produced using methods which are generally known in the art. In particular, purified NEUAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind NEUAP. Antibodies to NEUAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with NEUAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to NEUAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of NEUAP

amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to NEUAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce NEUAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for NEUAP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between NEUAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering NEUAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for NEUAP. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of NEUAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.

5 The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple NEUAP epitopes, represents the average affinity, or avidity, of the antibodies for NEUAP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular NEUAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in

10 which the NEUAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of NEUAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

15

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of NEUAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding NEUAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding NEUAP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding NEUAP. Thus, complementary molecules or fragments may be used to modulate NEUAP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding NEUAP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used

to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding NEUAP. (See, e.g., Sambrook, *supra*; Ausubel, 1995, *supra*.)

Genes encoding NEUAP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding NEUAP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding NEUAP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding NEUAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques

for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding NEUAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutoxine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of NEUAP, antibodies to NEUAP, and mimetics, agonists, antagonists, or inhibitors of NEUAP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's

5 Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

10 Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, 15 hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar 20 solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of 25 gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

30 Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily

injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of 5 highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, 10 dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any 15 or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of NEUAP, such labeling would include amount, frequency, and method of administration.

20 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. 25 An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example 30 NEUAP or fragments thereof, antibodies of NEUAP, and agonists, antagonists or inhibitors of NEUAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Pharmaceutical compositions

which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, 5 the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the 10 subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 µg to 100,000 µg, up to a total dose of 15 about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

20 DIAGNOSTICS

In another embodiment, antibodies which specifically bind NEUAP may be used for the diagnosis of disorders characterized by expression of NEUAP, or in assays to monitor patients being treated with NEUAP or agonists, antagonists, or inhibitors of NEUAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. 25 Diagnostic assays for NEUAP include methods which utilize the antibody and a label to detect NEUAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

30 A variety of protocols for measuring NEUAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of NEUAP expression. Normal or standard values for NEUAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to NEUAP under conditions suitable for complex formation. The amount of standard complex

formation may be quantitated by various methods, such as photometric means. Quantities of NEUAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

- 5 In another embodiment of the invention, the polynucleotides encoding NEUAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of NEUAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess
10 expression of NEUAP, and to monitor regulation of NEUAP levels during therapeutic intervention.

- In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding NEUAP or closely related molecules may be used to identify nucleic acid sequences which encode NEUAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a
15 conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding NEUAP, allelic variants, or related sequences.

- Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the NEUAP encoding sequences. The hybridization probes of the subject
20 invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:28-54 or from genomic sequences including promoters, enhancers, and introns of the NEUAP gene.

- Means for producing specific hybridization probes for DNAs encoding NEUAP include the cloning of polynucleotide sequences encoding NEUAP or NEUAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may
25 be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

- Polynucleotide sequences encoding NEUAP may be used for the diagnosis of disorders
30 associated with expression of NEUAP. Examples of such disorders include, but are not limited to, a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other

demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; seasonal affective disorder (SAD); akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, bipolar disorder, dementia, depression, Down's syndrome, peripheral neuropathy, bipolar disorder, dementia, depression, Down's syndrome, peripheral neuropathy, and Tourette's disorder; a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma. The

polynucleotide sequences encoding NEUAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered NEUAP expression. Such qualitative or quantitative methods are well known in the art.

5 In a particular aspect, the nucleotide sequences encoding NEUAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding NEUAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a 10 standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding NEUAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

15 In order to provide a basis for the diagnosis of a disorder associated with expression of NEUAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding NEUAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from 20 normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, 25 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or 30 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding NEUAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding NEUAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding NEUAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of NEUAP include radiolabeling or biotinyling nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding NEUAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent *in situ* hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, *supra*,

pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding NEUAP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder.

- 5 The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In *situ* hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, 10 may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping 15 to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, NEUAP, its catalytic or immunogenic fragments, or 20 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between NEUAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds 25 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with NEUAP, or fragments thereof, and washed. Bound NEUAP is then detected by methods well known in the art. Purified NEUAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. 30 Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding NEUAP specifically compete with a test compound for binding NEUAP. In this manner, antibodies can be used to detect the presence of any peptide which shares

one or more antigenic determinants with NEUAP.

In additional embodiments, the nucleotide sequences which encode NEUAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, are hereby expressly incorporated by reference.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/124,687, U.S. Ser. No. 60/119,365, and U.S. Ser. No. [Attorney Docket No. PF-0637 US, filed December 11, 1998], are hereby expressly incorporated by reference.

20

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A⁺) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA

libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic 5 oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., 10 PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

15 Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. 20 Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 25 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSCAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput 30 instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene

families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:28-54. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and

5 amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel,

10 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as

15 exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within

20 a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding NEUAP occurred. Analysis involved the categorization of cDNA libraries by

25 organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories.

30 Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of NEUAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:28-54 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this

fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

5 Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR 10 was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 15 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

20 The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by 25 electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For 30 shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on

antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:28-54 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:28-54 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array

elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After 5 hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise 10 the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking 15 followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

VIII. Complementary Polynucleotides

Sequences complementary to the NEUAP-encoding sequences, or any parts thereof, are used 20 to detect, decrease, or inhibit expression of naturally occurring NEUAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of NEUAP. To 25 inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the NEUAP-encoding transcript.

IX. Expression of NEUAP

Expression and purification of NEUAP is achieved using bacterial or virus-based expression 30 systems. For expression of NEUAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).

Antibiotic resistant bacteria express NEUAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of NEUAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding NEUAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, NEUAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from NEUAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified NEUAP obtained by these methods can be used directly in the following activity assay.

X. Demonstration of NEUAP Activity

NEUAP may be detected by the immunoreactivity of tissues to monoclonal antibodies (MAb) raised against recombinant NEUAP. Mabs to recombinant NEUAP may be prepared by methods well known in the art, and used to detect the expression of NEUAP in tissues by western blot analysis. Western blot analysis is carried out as described by de la Monte et al. (1996) J. Neuropathol. Exp. Neurol. supra. Cytosolic protein extracts of tissues are prepared and electrophoresed in SDS-PAGE Laemmli gels, and immunoblotted using Mabs raised against NEUAP. Antibody binding is detected with horseradish peroxidase-conjugated secondary antibody (IgG), and enhanced chemiluminescence reagents (Amersham Corp, Arlington Heights, IL). The amount of MAb immunoreactivity measured is proportional to the activity of NEUAP in the tissue preparation.

Alternatively, NEUAP, or biologically active fragments thereof, are labeled with ¹²⁵I

Bolton-Hunter reagent (see, e.g., Bolton et al. (1973) Biochem. J. 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled NEUAP, washed, and any wells with labeled NEUAP complex are assayed. Data obtained using different concentrations of NEUAP are used to calculate values for the number, affinity, and association of NEUAP with the candidate molecules.

XI. Functional Assays

NEUAP function is assessed by expressing the sequences encoding NEUAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 µg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 µg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) *Flow Cytometry*, Oxford, New York NY.

The influence of NEUAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding NEUAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding NEUAP and other genes of interest can be analyzed by northern

analysis or microarray techniques.

XII. Production of NEUAP Specific Antibodies

NEUAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to 5 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the NEUAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well 10 described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-NEUAP activity by, for example, binding the peptide or NEUAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. 15

XIII. Purification of Naturally Occurring NEUAP Using Specific Antibodies

Naturally occurring or recombinant NEUAP is substantially purified by immunoaffinity 20 chromatography using antibodies specific for NEUAP. An immunoaffinity column is constructed by covalently coupling anti-NEUAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing NEUAP are passed over the immunoaffinity column, and the column is 25 washed under conditions that allow the preferential absorbance of NEUAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/NEUAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and NEUAP is collected.

XIV. Identification of Molecules Which Interact with NEUAP

NEUAP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter 30 reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled NEUAP, washed, and any wells with labeled NEUAP complex are assayed. Data obtained using different concentrations of NEUAP are used to calculate values for the number, affinity, and

association of NEUAP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	28	2417014	HNT3AZT01	2417014H1, 2417014F6, and 2417014T6 (HNT3AZT01)
2	29	2634931	BONTNOT01	1599164X11 (BLADNOT03), 1840865R6 (COLNNOT07), 2634931H1 (BONTNOT01), 3016948F6 (MUSCNOT07), SBDA02985F1, SBDA03153F1, and SBAA04561F1
3	30	110960	PITUNNOT01	110960F1, 110960H1, and 110960X31 (PITUNNOT01), 1413173F6 (BRAINCTR12), 2708730F6 (PONSAZT01)
4	31	380721	HYPONOBO1	380721H1 (HYPONOBO1), 530184R1 (BRAINNOT03), 4313795H1 (BRAFNNOT01)
5	32	829443	PROSTUT04	829443H1 and 829443T6 (PROSTUT04), 1356856F1 (LUNGNOT09), 1561879F1 (SPINNOT04), 2454553F6 (ENDANOT01), 5113377H1 (ENDITXT01), SBDA04734F1
6	33	1470058	PANCUT02	620887R6 (PGANNNOT01), 667364R6 (SGORNNOT01), 1001616R1 (BRSTNOT03), 1382686T1 (BRAITUT08), 3440580H2 (PENCNOT06), 4900807H1 (OVARDIT01)
7	34	1554947	BLADTUT04	444399R1 (MPHGNNOT03), 1554947H1 (BLADTUT04), 2552447H1 (LUNGUT06), 2776779H1 (PANCNOT15), 3140190H1 (SMCCNOT02), 3327533H1 (HEAONOT04), 4737377H1 (THYMNOR02)
8	35	1690245	PROSTUT10	380737R6 (HYPONOBO1), 459187R6 (KERANOT01), 882488R1 (THYRNNOT02), 1421177F1 (KIDNNOT09), 1690245F6 and 1690245H1 (PROSTUT10), 2880352H1 (UTRSTUT05)
9	36	1878262	LEUKNOT03	1878262F6 and 1878262H1 (LEUKNOT03), 3705684F6 (PENCNOT07)

Table 1 (Cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
10	37	2253519	OVARTUT01	917470R1 (BRSTNOT04), 1285941H1 (COLNNOT16), 1452424H1 (PENITUT01), 2101405H1 (BRAITUT02), 2253519H1, 2253519R6, and 2253519X308F2 (OVARTUT01), 2849605H1 (BRSTTUT13), 2941769F6 (PROSNOT28), 4540901H1 (THYRTMT01), 4699204F6 (BRALNCT01)
11	38	2888437	LUNGFFET04	550739H1 (BEPINOT01), 639134R6 and 1004296R1 (BRSTNOT03), 1456837H1 (COLNFFET02), 1576159F6 (LNODNOT03), 1813822F6 (SKINBIT01), 1965103R6 (BRSTNOT04), 2888437F6 and 2888437H1 (LUNGFFET04), 3041589T6 (BRSTNOT16), 3316465F6 (PROSBPT03), 3416354H1 (PTHYNOT04), 3987261F6 (UTRSTUT05), 4527360H1 (LYMBTXT01)
12	39	3201753	PENCNOT02	060572X51 (LUNGNOT01), 1417168H1 (BRAINOT12), 1514580F1 (PANCNTUT01), 1601609F6 (BLADNOT03), 1853144T6 (LUNGFFET03), 2551341H1 (LUNGTTUT06), 2967827F6 (SCORNOT04), 3201753F6 and 3201753H1 (PENCNOT02), 3435884F6 (PENCNOT05)
13	40	3800639	SPLNNOT12	152838R6 (FIBRAGT02), 820077H1 (KERANOT02), 1482425F1 (CORPNOT02), 1686313T6 (PROSNOT15), 1855749F6 (PROSNOT18), 2212060F6 (SINTFFET03), 2679094H1 (SINIUCT01), 2685279H1 (LONGNOT23), 2751789R6 (THP1AZS08), 3287040H1 (HEAONOT05), 3575146H1 (BRONNOT01), 3598393H1 (FIBPNOT01), 3798890H1 and 3800639H1 (SPLNNOT12), 4521233H1 (HNT2TXT01), 4988152F6 (LIVRTUT10), 5377369H1 and 5379308H1 (BRAXNOT01)
14	41	533825	BRAINOT03	533825H1 (BRAINOT03), 1661317F6 (BRSTNOT09), 3271477F6 (BRAINOT20), 3532613H1 (KIDNNNOT25), 4338159H1 (BRAUNOT02), SBEA00478F1, SBEA02751F1

Table 1 (Cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
15	42	1311833	COLNFET02	1311833F6 (COLNFET02), 1311833H1 (COLNFET02), 1311833T1 (COLNFET02), 1492314H1 (PROSNON01), 1742220H1 (HIPONON01), 2279875R6 (PROSNON01), 2279875T6 (PROSNON01)
16	43	1342819	COLNTUT03	231227F1 (SINTNOT02), 1319329F1 (BLADNOT04), 1342819H1 (COLNTUT03), 1381830F1 (BRAITUT08), 3244424F7 (BRAINOT19)
17	44	1871288	SKINBIT01	1871288F6 (SKINBIT01), 1871288H1 (SKINBIT01), 1891163F6 (BLADTUT07)
18	45	2587338	BRAITUT22	2587338F6 (BRAITUT22), 2587338H1 (BRAITUT22)
19	46	2821211	ADRETUT06	2666281T6 (ADRETUT06), 2821211H1 (ADRETUT06), 2821211T6 (ADRETUT06), 2821626H1 (ADRETUT06), 3973838F6 (ADRETUT06)
20	47	2824832	ADRETUT06	2137150F6 (ENDCNNOT01), 2137150T6 (ENDCNNOT01), 2824832H1 (ADRETUT06), SBLA01910F1, SBLA01493F1, SBLA02371F1, SBLA01241F1
21	48	3070147	UTRSNOR01	1399942F1 (BRAITUT08), 3070147F6 (UTRSNOR01), 3070147H1 (UTRSNOR01)
22	49	3271841	BRAINOT20	531341F1 (BRAINOT03), 531341R6 (BRAINOT03), 1368113R1 (SCORNON02), 3271841H1 (BRAINOT20), 4227380F6 (BRAMDIT01)
23	50	3537827	SEMVNOT04	1376729F1 (LUNGNOT10), 1472735R6 (LUNGUT03), 1995972T6 (BRSTTUT03), 2913592H1 (KIDNTUT15), 3174642F6 (UTRSTUT04), 3537827H1 (SEMVNOT04), 4261946F6 (BSCNDIT02), SBRA05006D1, SBRA01069D1
24	51	3729267	SMCCNON03	925471R1 (BRAINOT04), 988166R6 (LVENNOT03), 1303573F1 (PLACNOT02), 2176845F6 (ENDCNNOT03), 3729267H1 (SMCCNON03)

Table 1 (Cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
25	52	3768771	BRSTNOT24	550415R6 (BEPINOT01), 1700822F6 (BLADTUT05), 1732040F6 (BRSTTUT08), 2028053R6 (KERANOT02), 2579651F6 (KIDNTUT13), 2731787F6 (OVERTUT04), 3447610H1 (THYMNOT08), 3498679H1 (PROSTUT13), 3606095H1 (LUNGNOT30), 3685266F6 (HEAANOT01), 3768771H1 (BRSTNOT24)
26	53	4248993	BRADDIRO1	4248993F6 (BRADDIRO1), 4248993H1 (BRADDIRO1)
27	54	5402418	BRAHNOT01	270323F1 (HNT2NOT01), 950513T1 (FANCNOT05), 2083217F6 (UTRSNOT08), 2744356F6 (BRSTTUT14), 5402418H1 (BRAHNOT01)

Table 2

Polypeptide Seq ID No:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
1	198	S117, S51, S123	N49	M1-A27: Signal Peptide	AD7c-NTP (g3002527)	Motifs BLAST SPScan HMMER
2	463	T29, T50, T156, S195, S202, S299, T137, S218, S227, T323, S394	N114, N403, N409	M1-A27: Signal peptide Potential intramolecular disulfide-bridging site cysteine residues: C5, C74, C120, C126, C142, C147, C163, C183, C186, C192, C197, C283 SCP-like extracellular protein signature: S4-G173	GliPR Human glioma pathogenesis-related protein (g847722)	Motifs SPScan BLAST BLOCKS PFAM

Table 2 (Cont.)

Polypeptide Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
3	316	S283 S37 T42 S74 S92 T125 T216 S285 T313	N191	G184-T210, V226-I244, V106-V121 and Y289-N314 Transmembrane Regions; V264-E316	Neural Membrane Protein 35 (NMP35) (q3426268)	BLAST HMM BLOCKS
4	89	S56 T17 S33 S76		Syntaptophysin Signature; G224-M277 Peripherin Signature	Cyclic AMP-Regulated Phosphoprotein (ARPP-21) (q238781)	BLAST
5	273	S96 S273 T54 S136 T190 S205 S252 S258 T64 S142 S268		C107-C134 and C141-C176 EGF-Like Domain Signature; R130-D132 Cell Attachment Sequence; C152-C163 Aspartic Acid and Asparagine Hydroxylation Site; M1-G19 Signal Peptide	Multiple EGF Protein (MEGF6) (q3449294)	Motifs SPScan HMM PFAM

Table 2 (Cont.)

Polypeptide Seq ID No:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
6	263	S216 S47 S109 S125 T126 S216 S248 S29 T95 T240		R97-D99 Cell Attachment Sequence; M1-S29 Signal Peptide	Fe65L2 Protein (g2293387)	BLAST Motifs SPScan
7	165	S44 T56 S108 T111 S137			Brain Expressed (BRX) Protein (g2196874)	BLAST
8	424	T373 S131 T257 T275 S284 T303 T322 T360 T361 T421 S312 Y266	N129	L251-P280 WW/rsp5/WWP Domain Signature	Huntingtin Interacting Protein (g3319282)	BLAST Motifs PFAM
9	164	S71 T129 T133		M1-A34 Signal Peptide	Neuritin (g2062678)	BLAST SPScan HMM
10	796	T147 S285 S353 S442 T475 S476 S591 S767 T135 S319 S383 S442 S543 T738 S753 S775 T780 Y60 Y133	N590	S661-G664, S704-G707 and S706-G709 Glycosaminoglycan Attachment Site	Pecanex Protein (SW:P18490)	BLAST Motifs

Table 2 (Cont.)

Polypeptide Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
11	854	T249 S398 T757 S88 T159 S175 T265 S330 S340 S387 S398 T557 S582 T594 S614 T626 T677 S712 T800 S99 T377 S494 T507 T649 T668 S750 Y422 Y593	N48 N153 N369 N375 N492 N561 N697 N747 N798	S373-Y422 Neuraxin Signature; L358-A409 43 Kd Postsynaptic Protein Signature	CNS Expressed Protein	Motifs BLOCKS
12	856	S370 T475 S604 S69 S71 S73 S238 T253 S284 S296 T414 T475 S625 T705 T835 T20 S119 S263 T337 T341 S386 T390 S599 S633 S634 T690 Y118	N18 N199 N369 N389 N531 N568 N721	M1-P65, M136-N218, H269-E349, T415- D497, T511-1592, T648-G733 and S773- S856 PDZ Domain Signature; R819-D821 Cell Attachment Sequence; S144-G147 Glycosaminoglycan Attachment Site	Brain Expressed Multi-PDZ Protein (g2959979)	BLAST Motifs Pfam
13	361	S120 T122 T197 T296 S48 S223 T243	N189 N264	MNUDC Protein (g2654358)	BLAST Motifs	

Table 2 (Cont.)

Polypeptide Seq ID No:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
14	632	S48 S486 T549 S90 S91 S100 T159 S291 S292 T406 S431 S474 S574 S104 S107 T119 S124 S178 S191 S356 T397 Y440 Y499	N108 N157 N289 N384	PDZ domains: S178-E262; H285- Q367; V411-V496; D542-W627 Signal Peptide: M1-I18	LNXp70 (g3041881)	BLAST PFAM BLOCKS_PFAM SPScan MOTIFS
15	391	T77 S185 S203 S238 S36 T42 T63 S171 T191 T205 S223 T302 T334 S181 S220 S233	N324	Glycosaminoglycan attachment site: S85-G88 Protein Repeat Neurofilament: E123-K148; S111-P136 Transmembrane region: Y368-L388	heavy neurofilament subunit (g1841430)	BLOCKS_PRODO M BLAST MOTIFS HMM
16	490	S474 S90 T99 S105 S150 S269 S317 S335 S361 T26 S49 S87 T134 S238 S247 T255 T275 T329 T388 T401 T415 T454 S469 T476	N61 N189 N204 N359	Signal Peptide: M1-T19	neurofilament protein (g463250)	BLAST SPScan MOTIFS

Table 2 (Cont.)

Polypeptide Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
17	252	S116 S118 T155 T196 S219 S33 R81 S147 S164	N153	Glycosaminoglycan attachment site: S65-G68 Signal Peptide: M1-S33 Transmembrane region: I9-L27	bipolar disorder-associated protein (g2271473)	BLAST MOTIFS SPScan HMM
18	142	S3 S32 S36 T29	N106	Transmembrane region: L66-L84	ninjurin (g1644368)	BLAST HMM
19	67	T34			CNS-expressed protein (g862343)	BLAST
20	455	S39 T43 S104 T109 S185 S189 S204 S224 S226 S349 S365 T131 S358 S414	N58 N307	Acyl-CoA binding protein (DBI) signature: H41-F129	membrane-associated diazepam binding inhibitor MA-DBI (g244503)	PFAM BLOCKS PRINTS MOTIFS BLAST
21	252	S189 S54 S93 T119 Y242	N62 N127 N137 N143	Signal Peptide: M1-G22	neurexophilin (g508574)	BLAST SPScan

Table 2 (Cont.)

Polypeptide Seq ID No:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
22	149	S64 S40 S86 S10	N74	Transmembrane region: L125-L145	BM88 antigen; neuron-specific membrane protein (g557673)	BLAST HMM
23	204	S204 S16 T146 S157 T114	N6 N176	Transmembrane region: L66-A85 T114-W136	P24; neuron- specific membrane protein (g1890141)	BLAST HMM
24	367	S52 S55 T148 S181 T265 S303 T143 Y207		Glycosaminoglycan attachment site: S231-G234 Leucine-rich repeat: Y42-V88; K89-K134; E135-P180; S181-I228	leucine rich neuronal protein (g3135309)	PFAM BLOCKS BLAST MOTIFS
25	681	T70 T111 S155 S175 T206 S247 S375 S417 S502 T624 S633 T645 S653 S657 S66 T237 T349 S393 T539 S587 S647	N9 N254 N369 N474	Transmembrane region: C566-Y582	semaphorin (g854328)	BLAST HMM

Table 2 (Cont.)

Polypeptide Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods and Databases
26	137	T11 T77 S134		Microbodies C-terminal targeting signal: A135-F137	myelin-associated/oligodendrocyte basic protein	BLAST MOTIFS
27	117	N81			GEF-2; ganglioside expression factor-2 (g2104570)	BLAST MOTIFS

Table 3

Nucleotide SEQ ID No:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
28	110-154 434-478		Cancer (0.750)	pINCY
29	1083-1127 1407-1451		Cancer (0.590)	pINCY
30	71-145	Nervous (0.727) Urologic (0.068) Endocrine (0.045)	Cell Proliferation (0.455) Neurological (0.205) Inflammation (0.227)	PBLUESCRIPT
31	379-438	Nervous (1.000)	Cell Proliferation (0.222) Inflammation (0.222) Neurological (0.222)	PBLUESCRIPT
32	255-314	Reproductive (0.222) Cardiovascular (0.176) Nervous (0.157)	Cell Proliferation (0.620) Inflammation (0.315)	PSPORT1
33	898-972	Reproductive (0.319) Nervous (0.191) Developmental (0.106) Gastrointestinal (0.106)	Cell Proliferation (0.766) Inflammation (0.298)	pINCY
34	258-317	Gastrointestinal (0.179) Reproductive (0.179) Cardiovascular (0.143) Nervous (0.143) Hematopoietic/Immune (0.143)	Cell Proliferation (0.572) Inflammation (0.393)	pINCY

Table 3 (Cont.)

Nucleotide SEQ ID NO:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
35	184-243	Nervous (0.238) Reproductive (0.222) Gastrointestinal (0.127)	Cell Proliferation (0.603) Inflammation (0.254)	pINCY
36	306-380	Reproductive (0.500) Cardiovascular (0.250) Hematopoietic/Immune (0.250)	Cell Proliferation (0.750) Inflammation (0.250)	pINCY
37	88-147 433-507	Reproductive (0.355) Nervous (0.226) Musculoskeletal (0.129)	Cell Proliferation (0.677) Inflammation (0.129)	pSPORT1
38	83-142 1244-1318	Reproductive (0.230) Nervous (0.162) Cardiovascular (0.135)	Cell Proliferation (0.581) Inflammation (0.257)	pINCY
39	29-88 758-832	Nervous (0.281) Reproductive (0.246)	Cell Proliferation (0.491) Inflammation (0.228)	pINCY
40	435-494	Nervous (0.308) Reproductive (0.215) Hematopoietic/Immune (0.108)	Cell Proliferation (0.531) Inflammation (0.315) Neurological (0.100)	pINCY
41	1420-1482	Nervous (0.538) Reproductive (0.231) Urologic (0.077)	Cell Proliferation (0.462) Inflammation (0.346) Neurological (0.115)	pSPORT1
42	866-910	Reproductive (0.278) Developmental (0.222) Hematopoietic/Immune (0.167)	Cell Proliferation (0.611) Inflammation (0.389)	pINCY

Table 3 (Cont.)

Nucleotide SEQ ID No:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
43	948-992	Reproductive (0.287) Nervous (0.166) Cardiovascular (0.127) Hematopoietic/Immune (0.127)	Cell Proliferation (0.650) Inflammation (0.299)	pINCY
44	218-262	Reproductive (0.510) Gastrointestinal (0.143) Cardiovascular (0.102) Nervous (0.102)	Cell Proliferation (0.714) Inflammation (0.306)	pINCY
45	389-496	Nervous (0.267) Cardiovascular (0.200) Reproductive (0.200)	Cell Proliferation (0.533) Inflammation (0.333) Neurological (0.133)	pINCY
46	272-316	Nervous (0.667) Endocrine (0.167) Gastrointestinal (0.167)	Cell Proliferation (0.333) Inflammation (0.333)	pINCY
47	802-894	Developmental (0.267) Urologic (0.200) Endocrine (0.133) Reproductive (0.133)	Cell Proliferation (0.867) Inflammation (0.267)	pINCY
48	219-263	Reproductive (0.571) Cardiovascular (0.143) Nervous (0.143) Urologic (0.143)	Cell Proliferation (0.571) Inflammation (0.286)	pINCY

Table 3 (Cont.)

Nucleotide SEQ ID NO:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
49	280-369	Nervous (0.885) Cardiovascular (0.038) Developmental (0.038) Endocrine (0.038)	Cell Proliferation (0.308) Inflammation (0.346) Neurological (0.269)	PINCY
50	487-531	Nervous (0.338) Reproductive (0.294) Urologic (0.088)	Cell Proliferation (0.647) Inflammation (0.221)	PINCY
51	337-420	Reproductive (0.250) Gastrointestinal (0.156) Nervous (0.156)	Cell Proliferation (0.500) Inflammation (0.438)	PINCY
52	412-474 928-1017	Reproductive (0.255) Gastrointestinal (0.170) Nervous (0.170)	Cell Proliferation (0.617) Inflammation (0.383)	PINCY
53	109-150	Nervous (1.000)	Inflammation (1.000)	PINCY
54	198-242	Nervous (0.281) Reproductive (0.156) Gastrointestinal (0.138)	Cell Proliferation (0.463) Inflammation (0.394)	PINCY

Table 4

Nucleotide SEQ ID NO:	Library	Library Description
29	HNT3AZT01	Library was prepared from hNT precursor cells (at 80% confluence) treated for three days with 0.35 micromolar 5-aza-2'-deoxycytidine (a demethylating agent) in order to induce transcription of silent genes.
30	BONTNOT01	The library was constructed from normal bone connective tissue (periosteum) obtained from a 20-year-old Caucasian male during a hindquarter amputation. Pathology indicated partially necrotic and cystic osteoblastic grade 3 osteosarcoma (post chemotherapy) in the right lower limb. Patient history included osteogenesis imperfecta, bone infection of the lower limb, pathologic closed fracture, and non-union of fracture. Family history included osteogenesis imperfecta and closed fracture and diabetes with hyperosmolarity.
31	PITUNOT01	Library was constructed using RNA (Clontech, #6584-2, Lot 35278) obtained from the pituitary glands removed from a pool of 18 male and female Caucasian donors, 16 to 70 years old, who died from trauma.
32	HYPONOB01	Library was constructed using RNA (Clontech, #6579-2, Lot 3X843) isolated from the hypothalamus tissues of 51 male and female Caucasian donors, 16 to 75 years old.
33	PROSTUT04	Library was constructed using RNA isolated from prostate tumor tissue removed from a 57-year-old Caucasian male during radical prostatectomy, removal of both testes, and excision of regional lymph nodes. Pathology indicated adenocarcinoma (Gleason grade 3+3). Patient history included a benign neoplasm of the large bowel and type I diabetes. Family history included a malignant neoplasm of the prostate and type I diabetes.

Table 4 (Cont.)

Nucleotide SEQ ID NO:	Library	Library Description
34	PANCTUT02	Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease.
35	BLADTUT04	Library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Family history included type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction.
36	PROSTUT10	Library was constructed using RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3), and adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer and secondary bone cancer.
37	LEUKNOT03	Library was constructed using RNA isolated from white blood cells of a 27-year-old female with blood type A+.

Table 4 (Cont.)

Nucleotide SEQ ID NO:	Library	Library Description
38	OVARTUT01	Library was constructed using RNA isolated from ovarian tumor tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology indicated grade 2 mucinous cystadenocarcinoma involving the entire left ovary. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.
39	LUNGFET04	Library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 17 weeks' gestation from anencephalus.
40	PENCNOT02	Library was constructed using RNA isolated from penis right corpus cavernosum tissue removed from a male.
41	SPLNNNOT12	Library was constructed using RNA isolated from spleen tissue removed from a 65-year-old female. Pathology indicated the spleen was negative for metastasis, and the associated tumor tissue indicated well-differentiated neuroendocrine carcinoma (islet cell tumor) forming a dominant mass in the distal pancreas.
42	BRAINNOT03	Library was constructed using RNA isolated from brain tissue removed from a 26-year-old Caucasian male during cranioplasty and excision of a cerebral meningeal lesion. Pathology for the associated tumor tissue indicated a grade 4 oligoastrocytoma in the right fronto-parietal part of the brain.
43	COLNFET02	Library was constructed using RNA isolated from the colon tissue of a Caucasian female fetus, who died at 20 weeks' gestation.

Table 4 (Cont.)

Nucleotide SEQ ID NO:	Library	Library Description
44	COLNTUT03	Library was constructed using RNA isolated from colon tumor tissue obtained from the sigmoid colon of a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma. One lymph node contained metastasis with extranodal extension. Patient history included hyperlipidemia, cataract disorder, and dermatitis. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer.
45	SKINBIT01	Library was constructed using RNA isolated from diseased skin tissue of the left lower leg. Patient history included erythema nodosum of the left lower leg.
46	BRAITUT22	Library was constructed using RNA isolated from brain tumor tissue removed from the right frontal/parietal lobe of a 76-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a meningioma. Family history included senile dementia.
47	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
48	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
49	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.

Table 4 (Cont.)

50	UTRSNOR01	Library was constructed using RNA isolated from uterine endometrium tissue removed from a 29-year-old Caucasian female during a vaginal hysterectomy and cystocele repair. Pathology indicated the endometrium was secretory, and the cervix showed mild chronic cervicitis with focal squamous metaplasia. Pathology for the associated tumor tissue indicated intramural uterine leiomyoma. Patient history included hypothyroidism, pelvic floor relaxation, and paraplegia. Family history included benign hypertension, type II diabetes, and hyperlipidemia.
----	-----------	--

Table 4 (Cont.)

Nucleotide SEQ ID NO:	Library	Library Description
51	BRAINOT20	Library was constructed using RNA isolated from diseased brain tissue removed from the left temporal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology for the left temporal lobe, including the mesial temporal structures, indicated focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. The left frontal lobe showed a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This frontal lobe tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. GFAP was positive for astrocytes. Family history included brain cancer.
52	SEMVNOT04	Library was constructed using RNA isolated from seminal vesicle tissue removed from a 61-year-old Caucasian male during a radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma, Gleason grade 3+3. The patient presented with induration, hyperplasia of the prostate, and elevated prostate specific antigen. Patient history included renal failure, osteoarthritis, left renal artery stenosis, thrombocytopenia, hyperlipidemia, and hepatitis C (carrier). Family history included benign hypertension.
53	SMCCNON03	This normalized smooth muscle cell library was constructed from 7.56×10^6 independent clones from a smooth muscle tissue library. Starting RNA was made from smooth muscle cell tissue removed from the coronary artery of a 3-year-old Caucasian male. The normalization and hybridization conditions were adapted from Soares et al., (Proc. Natl. Acad. Sci. USA (1994) 91:9228-9232); Swaroop et al., (Nucleic Acids Research (1991) 19:1954-806); and Bonaldo et al., (Genome Research (1996) 6:791-806), using a significantly longer (48 hour) reannealing hybridization period.

Table 4 (Cont.)

Nucleotide SEQ ID NO:	Library	Library Description
54	BRSTNOT24	Library was constructed using RNA isolated from diseased breast tissue removed from a 46-year-old Caucasian female during bilateral subcutaneous mastectomy. Pathology indicated nonproliferative fibrocystic disease bilaterally. Family history included breast cancer, benign hypertension, and atherosclerotic coronary artery disease.
55	BRADDIRO1	Library was constructed using RNA isolated from diseased choroid plexus tissue of the lateral ventricle, removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema.
56	BRAHNOT01	Library was constructed using RNA isolated from posterior hippocampus tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarcts of the cerebral neocortex. Microscopically, the cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. In addition, scattered throughout the cerebral cortex, there were multiple small microscopic areas of cavitation with surrounding gliosis. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	Mismatch <50%
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) <i>J. Mol. Biol.</i> 215:403-410; Altschul, S.F. et al. (1997) <i>Nucleic Acids Res.</i> 25: 3389-3402.	<i>ESTs:</i> Probability value= 1.0E-8 or less <i>Full Length sequences:</i> Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, fastx, tfasta, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) <i>Proc. Natl. Acad Sci.</i> 85:2444-2448; Pearson, W.R. (1990) <i>Methods Enzymol.</i> 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) <i>Adv. Appl. Math.</i> 2:482-489.	<i>ESTs:</i> fasta E value=1.0E-6 <i>Assembled ESTs:</i> fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value= 1.0E-8 or less <i>Full Length sequences:</i> fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, <i>Nucl. Acid Res.</i> , 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) <i>Methods Enzymol.</i> 266:88-105; and Atwood, T.K. et al. (1997) <i>J. Chem. Inf. Comput. Sci.</i> 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) <i>J. Mol. Biol.</i> , 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) <i>Nucleic Acids Res.</i> 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score > GCG-specified "HIGH" value for that particular Prosite motif. Generally, score = 1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score = 120 or greater; Match length = 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score = 3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.
- 5 2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
- 10 3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
- 15 4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
- 15 6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
- 20 7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
- 25 8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
- 30 9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof.
10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
5
13. A host cell comprising the expression vector of claim 12.
14. A method for producing a polypeptide, the method comprising the steps of:
 - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
15
16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
20
18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.
25
20. A method for treating or preventing a disorder associated with increased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

1/5

1 **M A** - - - - - - - - - **G S P S R A A G R R L Q L P** - - - - - - - - - 2417014
 1 **M E F S L L P R L L P R L P** **G S S D S** GI 3002527

17 - **L L C L F L Q** - - - - - - - - - 2417014

31 **P A S A S P V A G I T G M C T H A R L I L Y F F L V E M E F** GT 3002527

24 - - - **G A T A V L F A V F** - - - - - - - - - - - - - - - **V R Y N H K T** 2417014
 61 **L H V G Q A G L E L P T S D D P S V S A S Q S A R Y R T G H** GT 3002527

41 **D A A L** - - - - - - - - - - - - - - - - - - - **W H** - - - - - - - - - 2417014
 91 **H A R L C L A N F C G R N R V S L M C P S W S P E L K Q S T** GI 3002527

47 - - - - - - **R S N H S N A D N E F Y F R Y** - - **P K E S H S** 2417014
 121 **C L S L P K C W D Y R R A A V P G I L F I L F R H R C P T** GT 3002527

68 **V A Q A G V Q R R N L G S L Q P S P P R** - - - - - - - - - - - - - - - 2417014
 151 **L T Q D E V Q W C D H S S L Q P S T P E I K H P P A S S Q** GI 3002527

88 - - - - - - - - - - - - **W** - - - - - - - - - - - - - - - 2417014
 181 **V A G T K D M H H Y T W L I F I F I F N F L R Q S I N S V T** GT 3002527

FIGURE 1A

2/5

95 Q A G V Q W H N L G S P Q P I L P P G F K R F S C L S L S S 2417014
 211 Q A G V Q W R N L G S L Q P I L P P G F K L F S C P S L L S S GI 3002527

125 W D Y S - - - L E S V F P L I A E - - - - - - - - - - - - - 2417014
 241 W D Y R R P P R L A N F F V F L V E M G F T M F A R L I L I GI 3002527

139 - - - - - - - - - G Q R S A T S Q A M H Q L - - - - - - - - - F G 2417014
 271 S G P C D L P A S A S Q S A G I T G V S H H A R L I F N F C GI 3002527

154 L F V T L M F A S V G G G - - - - L G G L - - - - - - L L 2417014
 301 L F E M E S H S V T Q A G V Q W P N L Q P O L P P G L K GI 3002527

173 K L P F L D S P P - - - R L P A - - - - - - - - - L R G P 2417014
 331 R F S C L S L P S S W D Y G H L P P H P A N F C I F I R G G GI 3002527

190 - S S L A G A W R A
 361 V S P Y L S G W S Q T P D L R

FIGURE 1B

3/5

1 M H G S C S F L M L L P L L L V A T T G P V G A L T D 2634931
 M - - - - - - - - - - - - - - - - V S F V S N Y S H T A N I L P D I E N GI 847722

31 [E] E - K R L M V E L H N L Y R A Q V S P T A S D M L H M R W 2634931
 21 [E] D F T K D C V R I H N K F R S E V K P T A S D M L Y M T W GI 847722

60 D E E L A A F A K A Y A R Q C V W G H N K E R G R R G E N L 2634931
 51 D P A L A Q I A K A W A S N C Q F S H N T - R L K P P H K L GI 847722

90 - - - F A I T D E G M - - - D V P L - - - - A M E E W H H 2634931
 80 H P N F T S I L G E N I W T G S V P I F S V S S A I T N W Y D GI 847722

109 E R E H Y N L S A A T C S P G Q M C G H Y T Q V V W A K T E 2634931
 110 E I Q D Y N F K T R I C K - - K V C G H Y T Q V V W A D S Y GI 847722

139 R I G C G S H F C E K L O G V E E - T N I E L L V C N Y E P 2634931
 138 K V G C A V Q F C P K V S G F D A L S N G A H F I C N Y G P GI 847722

168 P G N V K G K R P Y Q E G T P C S Q C P S G Y H C K N S L C 2634931
 168 G G N Y P T - W P Y K R G A T C S A C P N N D K C I D N L C GI 847722

FIGURE 2A

4/5

198	E P I G S P E D A Q D L P Y L V T E A P S F R A T E A S D S	2634931
197	- - - - -	V N D S E T GI 847722
228	R K M G T P S S L A T G I P A F L V T E V S G S L A T K A L	2634931
203	K - - - - -	GI 847722
258	P A V E T Q A P T S L A T K D P P S M A T E A P P C V T T E	2634931
204	- - - - -	S N GI 847722
288	V P S I L A A H S L P S L D E E P V T F P K S T H V P I P K	2634931
206	V T T M L - - - - -	Y I R L A H I S T GI 847722
318	S A D K V T D K T K V P S R S P E N S L D P K M S L T G A R	2634931
219		GI 847722
348	E L L P H A Q E E A E A E L P P S S E V L A S V F P A O	2634931
219		GI 847722

FIGURE 2B

5/5

378	D K P G E L Q A T L D H T G H T S S K S L P N F P N T S A T	2634931
219		GI 847722
408	A N A T G G R A L A L Q S S L P G A E G P D K P S V V S G L	2634931
219		GI 847722
438	N S G P G H V W G P L L G L L P P L V L A G I F	2634931
219		GI 847722

FIGURE 2C

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
TANG, Y. Tom
YUE, Henry
BAUGHN, Mariah R.
HILLMAN, Jennifer L.
LAL, Preeti
AU-YOUNG, Janice
YANG, Junming
LU, Dyung Aina M.
AZIMZAI, Yalda

<120> NEURON-ASSOCIATED PROTEINS

<130> PF-0637 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/210,083; unassigned; 60/119,365; 60/124,687

<151> 1998-12-11; 1998-12-11; 1999-02-09; 1999-03-16

<160> 56

<170> PERL Program

<210> 1

<211> 198

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2417014CD1

<400> 1
Met Ala Gly Ser Pro Ser Arg Ala Ala Gly Arg Arg Leu Gln Leu
1 5 10 15
Pro Leu Leu Cys Leu Phe Leu Gln Gly Ala Thr Ala Val Leu Phe
20 25 30
Ala Val Phe Val Arg Tyr Asn His Lys Thr Asp Ala Ala Leu Trp
35 40 45
His Arg Ser Asn His Ser Asn Ala Asp Asn Glu Phe Tyr Phe Arg
50 55 60
Tyr Pro Lys Glu Ser His Ser Val Ala Gln Ala Gly Val Gln Arg
65 70 75
Arg Asn Leu Gly Ser Leu Gln Pro Ser Pro Pro Arg Trp Ser Phe
80 85 90
Ala Leu Val Ala Gln Ala Gly Val Gln Trp His Asn Leu Gly Ser
95 100 105
Pro Gln Pro Leu Pro Pro Gly Phe Lys Arg Phe Ser Cys Leu Ser
110 115 120
Leu Leu Ser Ser Trp Asp Tyr Ser Leu Glu Ser Val Phe Pro Leu

	125		130		135
Ile Ala Glu Gly Gln Arg Ser Ala Thr Ser Gln Ala Met His Gln					
	140		145		150
Leu Phe Gly Leu Phe Val Thr Leu Met Phe Ala Ser Val Gly Gly					
	155		160		165
Gly Leu Gly Gly Leu Leu Leu Lys Leu Pro Phe Leu Asp Ser Pro					
	170		175		180
Pro Arg Leu Pro Ala Leu Arg Gly Pro Ser Ser Leu Ala Gly Ala					
	185		190		195
Trp Arg Ala					

<210> 2

<211> 463

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2634931CD1

<400> 2

Met	His	Gly	Ser	Cys	Ser	Phe	Leu	Met	Leu	Leu	Leu	Pro	Leu	Leu
1				5				10					15	
Leu	Leu	Leu	Val	Ala	Thr	Thr	Gly	Pro	Val	Gly	Ala	Leu	Thr	Asp
					20				25				30	
Glu	Glu	Lys	Arg	Leu	Met	Val	Glu	Leu	His	Asn	Leu	Tyr	Arg	Ala
				35					40				45	
Gln	Val	Ser	Pro	Thr	Ala	Ser	Asp	Met	Leu	His	Met	Arg	Trp	Asp
				50				55					60	
Glu	Glu	Leu	Ala	Ala	Phe	Ala	Lys	Ala	Tyr	Ala	Arg	Gln	Cys	Val
				65				70					75	
Trp	Gly	His	Asn	Lys	Glu	Arg	Gly	Arg	Arg	Gly	Glu	Asn	Leu	Phe
				80				85					90	
Ala	Ile	Thr	Asp	Glu	Gly	Met	Asp	Val	Pro	Leu	Ala	Met	Glu	Glu
				95				100					105	
Trp	His	His	Glu	Arg	Glu	His	Tyr	Asn	Leu	Ser	Ala	Ala	Thr	Cys
				110				115					120	
Ser	Pro	Gly	Gln	Met	Cys	Gly	His	Tyr	Thr	Gln	Val	Val	Trp	Ala
				125				130					135	
Lys	Thr	Glu	Arg	Ile	Gly	Cys	Gly	Ser	His	Phe	Cys	Glu	Lys	Leu
				140				145					150	
Gln	Gly	Val	Glu	Glu	Thr	Asn	Ile	Glu	Leu	Leu	Val	Cys	Asn	Tyr
				155				160					165	
Glu	Pro	Pro	Gly	Asn	Val	Lys	Gly	Lys	Arg	Pro	Tyr	Gln	Glu	Gly
				170				175					180	
Thr	Pro	Cys	Ser	Gln	Cys	Pro	Ser	Gly	Tyr	His	Cys	Lys	Asn	Ser
				185				190					195	
Leu	Cys	Glu	Pro	Ile	Gly	Ser	Pro	Glu	Asp	Ala	Gln	Asp	Leu	Pro
				200				205					210	
Tyr	Leu	Val	Thr	Glu	Ala	Pro	Ser	Phe	Arg	Ala	Thr	Glu	Ala	Ser
				215				220					225	
Asp	Ser	Arg	Lys	Met	Gly	Thr	Pro	Ser	Ser	Leu	Ala	Thr	Gly	Ile
				230				235					240	
Pro	Ala	Phe	Leu	Val	Thr	Glu	Val	Ser	Gly	Ser	Leu	Ala	Thr	Lys

245	250	255
Ala Leu Pro Ala Val Glu Thr Gln Ala Pro Thr Ser Leu Ala Thr		
260	265	270
Lys Asp Pro Pro Ser Met Ala Thr Glu Ala Pro Pro Cys Val Thr		
275	280	285
Thr Glu Val Pro Ser Ile Leu Ala Ala His Ser Leu Pro Ser Leu		
290	295	300
Asp Glu Glu Pro Val Thr Phe Pro Lys Ser Thr His Val Pro Ile		
305	310	315
Pro Lys Ser Ala Asp Lys Val Thr Asp Lys Thr Lys Val Pro Ser		
320	325	330
Arg Ser Pro Glu Asn Ser Leu Asp Pro Lys Met Ser Leu Thr Gly		
335	340	345
Ala Arg Glu Leu Leu Pro His Ala Gln Glu Glu Ala Glu Ala Glu		
350	355	360
Ala Glu Leu Pro Pro Ser Ser Glu Val Leu Ala Ser Val Phe Pro		
365	370	375
Ala Gln Asp Lys Pro Gly Glu Leu Gln Ala Thr Leu Asp His Thr		
380	385	390
Gly His Thr Ser Ser Lys Ser Leu Pro Asn Phe Pro Asn Thr Ser		
395	400	405
Ala Thr Ala Asn Ala Thr Gly Gly Arg Ala Leu Ala Leu Gln Ser		
410	415	420
Ser Leu Pro Gly Ala Glu Gly Pro Asp Lys Pro Ser Val Val Ser		
425	430	435
Gly Leu Asn Ser Gly Pro Gly His Val Trp Gly Pro Leu Leu Gly		
440	445	450
Leu Leu Leu Leu Pro Pro Leu Val Leu Ala Gly Ile Phe		
455	460	

<210> 3
<211> 316
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 110960CD1

<400> 3
Met Thr Gln Gly Lys Leu Ser Val Ala Asn Lys Ala Pro Gly Thr
1 5 10 15
Glu Gly Gln Gln Gln Val His Gly Glu Lys Lys Glu Ala Pro Ala
20 25 30
Val Pro Ser Ala Pro Pro Ser Tyr Glu Glu Ala Thr Ser Gly Glu
35 40 45
Gly Met Lys Ala Gly Ala Phe Pro Pro Ala Pro Thr Ala Val Pro
50 55 60
Leu His Pro Ser Trp Ala Tyr Val Asp Pro Ser Ser Ser Ser Ser
65 70 75
Tyr Asp Asn Gly Phe Pro Thr Gly Asp His Glu Leu Phe Thr Thr
80 85 90
Phe Ser Trp Asp Asp Gln Lys Val Arg Arg Val Phe Val Arg Lys

95	100	105
Val Tyr Thr Ile Leu Leu Ile Gln Leu	Leu Val Thr Leu Ala	Val
110	115	120
Val Ala Leu Phe Thr Phe Cys Asp Pro	Val Lys Asp Tyr Val	Gln
125	130	135
Ala Asn Pro Gly Trp Tyr Trp Ala Ser	Tyr Ala Val Phe Phe	Ala
140	145	150
Thr Tyr Leu Thr Leu Ala Cys Cys Ser	Gly Pro Arg Arg His	Phe
155	160	165
Pro Trp Asn Leu Ile Leu Leu Thr Val	Phe Thr Leu Ser Met	Ala
170	175	180
Tyr Leu Thr Gly Met Leu Ser Ser Tyr	Tyr Asn Thr Thr Ser	Val
185	190	195
Leu Leu Cys Leu Gly Ile Thr Ala Leu	Val Cys Leu Ser Val	Thr
200	205	210
Val Phe Ser Phe Gln Thr Lys Phe Asp	Phe Thr Ser Cys Gln	Gly
215	220	225
Val Leu Phe Val Leu Leu Met Thr Leu	Phe Ser Gly Leu	Ile
230	235	240
Leu Ala Ile Leu Leu Pro Phe Gln Tyr	Val Pro Trp Leu His	Ala
245	250	255
Val Tyr Ala Ala Leu Gly Ala Gly Val	Phe Thr Leu Phe Leu	Ala
260	265	270
Leu Asp Thr Gln Leu Leu Met Gly Asn	Arg Arg His Ser Leu	Ser
275	280	285
Pro Glu Glu Tyr Ile Phe Gly Ala Leu	Asn Ile Tyr Leu Asp	Ile
290	295	300
Ile Tyr Ile Phe Thr Phe Leu Gln	Leu Phe Gly Thr Asn	Arg
305	310	315
Glu		

<210> 4
<211> 89
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 380721CD1

<400> 4
Met Ser Glu Gln Gly Asp Leu Asn Gln Ala Ile Ala Glu Glu Gly
1 5 10 15
Gly Thr Glu Gln Glu Thr Ala Thr Pro Glu Asn Gly Ile Val Lys
20 25 30
Ser Glu Ser Leu Asp Glu Glu Glu Lys Leu Glu Leu Gln Arg Arg
35 40 45
Leu Glu Ala Gln Asn Gln Glu Arg Arg Lys Ser Lys Ser Gly Ala
50 55 60
Gly Lys Gly Lys Leu Thr Arg Ser Leu Ala Val Cys Glu Glu Ser
65 70 75
Ser Ala Arg Pro Gly Gly Glu Ser Leu Gln Gly Gln Thr Leu
80 85

<210> 5
<211> 273
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 829443CD1

<400> 5
Met Arg Gly Ser Gln Glu Val Leu Leu Met Trp Leu Leu Val Leu
1 5 10 15
Ala Val Gly Gly Thr Glu His Ala Tyr Arg Pro Gly Arg Arg Val
20 25 30
Cys Ala Val Arg Ala His Gly Asp Pro Val Ser Glu Ser Phe Val
35 40 45
Gln Arg Val Tyr Gln Pro Phe Leu Thr Thr Cys Asp Gly His Arg
50 55 60
Ala Cys Ser Thr Tyr Arg Thr Ile Tyr Arg Thr Ala Tyr Arg Arg
65 70 75
Ser Pro Gly Leu Ala Pro Ala Arg Pro Arg Tyr Ala Cys Cys Pro
80 85 90
Gly Trp Lys Arg Thr Ser Gly Leu Pro Gly Ala Cys Gly Ala Ala
95 100 105
Ile Cys Gln Pro Pro Cys Arg Asn Gly Gly Ser Cys Val Gln Pro
110 115 120
Gly Arg Cys Arg Cys Pro Ala Gly Trp Arg Gly Asp Thr Cys Gln
125 130 135
Ser Asp Val Asp Glu Cys Ser Ala Arg Arg Gly Gly Cys Pro Gln
140 145 150
Arg Cys Val Asn Thr Ala Gly Ser Tyr Trp Cys Gln Cys Trp Glu
155 160 165
Gly His Ser Leu Ser Ala Asp Gly Thr Leu Cys Val Pro Lys Gly
170 175 180
Gly Pro Pro Arg Val Ala Pro Asn Pro Thr Gly Val Asp Ser Ala
185 190 195
Met Lys Glu Glu Val Gln Arg Leu Gln Ser Arg Val Asp Leu Leu
200 205 210
Glu Glu Lys Leu Gln Leu Val Leu Ala Pro Leu His Ser Leu Ala
215 220 225
Ser Gln Ala Leu Glu His Gly Leu Pro Asp Pro Gly Ser Leu Leu
230 235 240
Val His Ser Phe Gln Gln Leu Gly Arg Ile Asp Ser Leu Ser Glu
245 250 255
Gln Ile Ser Phe Leu Glu Glu Gln Leu Gly Ser Cys Ser Cys Lys
260 265 270
Lys Asp Ser

<210> 6
<211> 263
<212> PRT
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1470058CD1

<400> 6

Met	Leu	Lys	Cys	His	Val	Phe	Arg	Cys	Asp	Val	Pro	Ala	Lys	Ala
1				5					10					15
Ile	Ala	Ser	Ala	Leu	His	Gly	Leu	Cys	Ala	Gln	Ile	Leu	Ser	Glu
				20					25					30
Arg	Val	Glu	Val	Ser	Gly	Asp	Ala	Ser	Cys	Cys	Ser	Pro	Asp	Pro
				35					40					45
Ile	Ser	Pro	Glu	Asp	Leu	Pro	Arg	Gln	Val	Glu	Leu	Leu	Asp	Ala
				50					55					60
Val	Ser	Gln	Ala	Ala	Gln	Lys	Tyr	Glu	Ala	Leu	Tyr	Met	Gly	Thr
				65					70					75
Leu	Pro	Val	Thr	Lys	Ala	Met	Gly	Met	Asp	Val	Leu	Asn	Glu	Ala
				80					85					90
Ile	Gly	Thr	Leu	Thr	Ala	Arg	Gly	Asp	Arg	Asn	Ala	Trp	Val	Pro
				95					100					105
Thr	Met	Leu	Ser	Val	Ser	Asp	Ser	Leu	Met	Thr	Ala	His	Pro	Ile
				110					115					120
Gln	Ala	Glu	Ala	Ser	Thr	Glu	Glu	Pro	Leu	Trp	Gln	Cys	Pro	
				125					130					135
Val	Arg	Leu	Val	Thr	Phe	Ile	Gly	Val	Gly	Arg	Asp	Pro	His	Thr
				140					145					150
Phe	Gly	Leu	Ile	Ala	Asp	Leu	Gly	Arg	Gln	Ser	Phe	Gln	Cys	Ala
				155					160					165
Ala	Phe	Trp	Cys	Gln	Pro	His	Ala	Gly	Gly	Leu	Ser	Glu	Ala	Val
				170					175					180
Gln	Ala	Ala	Cys	Met	Val	Gln	Tyr	Gln	Lys	Cys	Leu	Val	Ala	Ser
				185					190					195
Ala	Ala	Arg	Gly	Lys	Ala	Trp	Gly	Ala	Gln	Ala	Arg	Ala	Arg	Leu
				200					205					210
Arg	Leu	Lys	Arg	Thr	Ser	Ser	Met	Asp	Ser	Pro	Gly	Gly	Pro	Leu
				215					220					225
Pro	Leu	Pro	Leu	Leu	Lys	Gly	Gly	Val	Gly	Gly	Ala	Gly	Ala	Thr
				230					235					240
Pro	Arg	Lys	Arg	Gly	Val	Phe	Ser	Phe	Leu	Asp	Ala	Phe	Arg	Leu
				245					250					255
Lys	Pro	Ser	Leu	Leu	His	Met	Pro							
				260										

<210> 7

<211> 165

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1554947CD1

<400> 7

Met	Ala	Asp	Phe	Asp	Glu	Ile	Tyr	Glu	Glu	Glu	Asp	Glu	Glu
1				5					10				15
Arg	Ala	Leu	Glu	Glu	Gln	Leu	Leu	Lys	Tyr	Ser	Pro	Asp	Pro
													Val

20	25	30
Val Val Arg Gly Ser Gly His Val Thr Val Phe Gly Leu Ser Asn		
35	40	45
Lys Phe Glu Ser Glu Phe Pro Ser Ser Leu Thr Gly Lys Val Ala		
50	55	60
Pro Glu Glu Phe Lys Ala Ser Ile Asn Arg Val Asn Ser Cys Leu		
65	70	75
Lys Lys Asn Leu Pro Val Asn Val Arg Trp Leu Leu Cys Gly Cys		
80	85	90
Leu Cys Cys Cys Thr Leu Gly Cys Ser Met Trp Pro Val Ile		
95	100	105
Cys Leu Ser Lys Arg Thr Arg Arg Ser Ile Glu Lys Leu Leu Glu		
110	115	120
Trp Glu Asn Asn Arg Leu Tyr His Lys Leu Cys Leu His Trp Arg		
125	130	135
Leu Ser Lys Arg Lys Cys Glu Thr Asn Asn Met Met Glu Tyr Val		
140	145	150
Ile Leu Ile Glu Phe Leu Pro Lys Thr Pro Ile Phe Arg Pro Asp		
155	160	165

<210> 8

<211> 424

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1690245CD1

<400> 8

Met Gln Asn Leu Gly Met Thr Ser Pro Leu Pro Tyr Asp Ser Leu		
1	5	10
Gly Tyr Asn Ala Pro His His Pro Phe Ala Gly Tyr Pro Pro Gly		
20	25	30
Tyr Pro Met Gln Ala Tyr Val Asp Pro Ser Asn Pro Asn Ala Gly		
35	40	45
Lys Val Leu Leu Pro Thr Pro Ser Met Asp Pro Val Cys Ser Pro		
50	55	60
Ala Pro Tyr Asp His Ala Gln Pro Leu Val Gly His Ser Thr Glu		
65	70	75
Pro Leu Ser Ala Pro Pro Pro Val Pro Val Val Pro His Val Ala		
80	85	90
Ala Pro Val Glu Val Ser Ser Ser Gln Tyr Val Ala Gln Ser Asp		
95	100	105
Gly Val Val His Gln Asp Ser Ser Val Ala Val Leu Pro Val Pro		
110	115	120
Ala Pro Gly Pro Val Gln Gly Gln Asn Tyr Ser Val Trp Asp Ser		
125	130	135
Asn Gln Gln Ser Val Ser Val Gln Gln Tyr Ser Pro Ala Gln		
140	145	150
Ser Gln Ala Thr Ile Tyr Tyr Gln Gly Gln Thr Cys Pro Thr Val		
155	160	165
Tyr Gly Val Thr Ser Pro Tyr Ser Gln Thr Thr Pro Pro Ile Val		
170	175	180

Gln Ser Tyr Ala Gln Pro Ser Leu Gln Tyr Ile Gln Gly Gln Gln
 185 190 195
 Ile Phe Thr Ala His Pro Gln Gly Val Val Val Gln Pro Ala Ala
 200 205 210
 Ala Val Thr Thr Ile Val Ala Pro Gly Gln Pro Gln Pro Leu Gln
 215 220 225
 Pro Ser Glu Met Val Val Thr Asn Asn Leu Leu Asp Leu Pro Pro
 230 235 240
 Pro Ser Pro Pro Lys Pro Lys Thr Ile Val Leu Pro Pro Asn Trp
 245 250 255
 Lys Thr Ala Arg Asp Pro Glu Gly Lys Ile Tyr Tyr Tyr His Val
 260 265 270
 Ile Thr Arg Gln Thr Gln Trp Asp Pro Pro Thr Trp Glu Ser Pro
 275 280 285
 Gly Asp Asp Ala Ser Leu Glu His Glu Ala Glu Met Asp Leu Gly
 290 295 300
 Thr Pro Thr Tyr Asp Glu Asn Pro Met Lys Ala Ser Lys Lys Pro
 305 310 315
 Lys Thr Ala Glu Ala Asp Thr Ser Ser Glu Leu Ala Lys Lys Ser
 320 325 330
 Lys Glu Val Phe Arg Lys Glu Met Ser Gln Phe Ile Val Gln Cys
 335 340 345
 Leu Asn Pro Tyr Arg Lys Pro Asp Cys Lys Val Gly Arg Ile Thr
 350 355 360
 Thr Thr Glu Asp Phe Lys His Leu Ala Arg Lys Leu Thr His Gly
 365 370 375
 Val Met Asn Lys Glu Leu Lys Tyr Cys Lys Asn Pro Glu Asp Leu
 380 385 390
 Glu Cys Asn Glu Asn Val Lys His Lys Thr Lys Glu Tyr Ile Lys
 395 400 405
 Lys Tyr Met Gln Lys Phe Gly Ala Val Tyr Lys Pro Lys Glu Asp
 410 415 420
 Thr Glu Leu Glu

<210> 9
 <211> 164
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1878262CD1

<400> 9
 Met Arg Cys Cys Arg Arg Arg Cys Cys Cys Arg Gln Pro Pro His
 1 5 10 15
 Ala Leu Arg Pro Leu Leu Leu Pro Leu Val Leu Leu Pro Pro
 20 25 30
 Leu Ala Ala Ala Ala Ala Gly Pro Asn Arg Cys Asp Thr Ile Tyr
 35 40 45
 Gln Gly Phe Ala Glu Cys Leu Ile Arg Leu Gly Asp Ser Met Gly
 50 55 60
 Arg Gly Gly Glu Leu Glu Thr Ile Cys Arg Ser Trp Asn Asp Phe

	65	70	75
His Ala Cys Ala Ser Gln Val Leu Ser Gly Cys Pro Glu Glu Ala			
80	85	90	
Ala Ala Val Trp Glu Ser Leu Gln Gln Glu Ala Arg Gln Ala Pro			
95	100	105	
Arg Pro Asn Asn Leu His Thr Leu Cys Gly Ala Pro Val His Val			
110	115	120	
Arg Glu Arg Gly Thr Gly Ser Lys Thr Asn Gln Glu Thr Leu Arg			
125	130	135	
Ala Thr Ala Pro Ala Leu Pro Met Ala Pro Ala Pro Pro Leu Leu			
140	145	150	
Ala Ala Ala Leu Ala Leu Ala Tyr Leu Leu Arg Pro Leu Ala			
155	160		

<210> 10
<211> 796
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2253519CD1

	<400> 10		
Met Thr Val Ala Gly Leu Lys Leu Leu Arg Ser Ala Phe Cys Cys			
1	5	10	15
Pro Pro Gln Gln Tyr Leu Thr Leu Ala Phe Thr Val Leu Leu Phe			
20	25	30	
His Phe Asp Tyr Pro Arg Leu Ser Gln Gly Phe Leu Leu Asp Tyr			
35	40	45	
Phe Leu Met Ser Leu Leu Cys Ser Lys Leu Trp Asp Leu Leu Tyr			
50	55	60	
Lys Leu Arg Phe Val Leu Thr Tyr Ile Ala Pro Trp Gln Ile Thr			
65	70	75	
Trp Gly Ser Ala Phe His Ala Phe Ala Gln Pro Phe Ala Val Pro			
80	85	90	
His Ser Ala Met Leu Phe Val Gln Ala Leu Leu Ser Gly Leu Phe			
95	100	105	
Ser Thr Pro Leu Asn Pro Leu Leu Gly Ser Ala Val Phe Ile Met			
110	115	120	
Ser Tyr Ala Arg Pro Leu Lys Phe Trp Glu Arg Asp Tyr Asn Thr			
125	130	135	
Lys Arg Val Asp His Ser Asn Thr Arg Leu Val Thr Gln Leu Asp			
140	145	150	
Arg Asn Pro Gly Ala Asp Asp Asn Asn Leu Asn Ser Ile Phe Tyr			
155	160	165	
Glu His Leu Thr Arg Ser Leu Gln His Thr Leu Cys Gly Asp Leu			
170	175	180	
Val Leu Gly Arg Trp Gly Asn Tyr Gly Pro Gly Asp Cys Phe Val			
185	190	195	
Leu Ala Ser Asp Tyr Leu Asn Ala Leu Val His Leu Ile Glu Val			
200	205	210	
Gly Asn Gly Leu Val Thr Phe Gln Leu Arg Gly Leu Glu Phe Arg			
215	220	225	

Gly Thr Tyr Cys Gln Gln Arg Glu Val Glu Ala Ile Thr Glu Gly
 230 235 240
 Val Glu Glu Asp Glu Gly Cys Cys Cys Cys Glu Pro Gly His Leu
 245 250 255
 Pro Arg Val Leu Ser Phe Asn Ala Ala Phe Gly Gln Arg Trp Leu
 260 265 270
 Ala Trp Glu Val Thr Ala Ser Lys Tyr Val Leu Glu Gly Tyr Ser
 275 280 285
 Ile Ser Asp Asn Asn Ala Ala Ser Met Leu Gln Val Phe Asp Leu
 290 295 300
 Arg Lys Ile Leu Ile Thr Tyr Tyr Val Lys Ser Ile Ile Tyr Tyr
 305 310 315
 Val Ser Arg Ser Pro Lys Leu Glu Val Trp Leu Ser His Glu Gly
 320 325 330
 Ile Thr Ala Ala Leu Arg Pro Val Arg Val Pro Gly Tyr Ala Asp
 335 340 345
 Ser Asp Pro Thr Phe Ser Leu Ser Val Asp Glu Asp Tyr Asp Leu
 350 355 360
 Arg Leu Ser Gly Leu Ser Leu Pro Ser Phe Cys Ala Val His Leu
 365 370 375
 Glu Trp Ile Gln Tyr Cys Ala Ser Arg Arg Thr Arg Pro Val Asp
 380 385 390
 Gln Asp Trp Asn Ser Pro Leu Val Thr Leu Cys Phe Gly Leu Cys
 395 400 405
 Val Leu Gly Arg Arg Ala Leu Gly Thr Ala Ser His Ser Met Ser
 410 415 420
 Ala Ser Leu Glu Pro Phe Leu Tyr Gly Leu His Ala Leu Phe Lys
 425 430 435
 Gly Asp Phe Arg Ile Thr Ser Pro Arg Asp Glu Trp Val Phe Ala
 440 445 450
 Asp Met Asp Leu Leu His Arg Val Val Ala Pro Gly Val Arg Met
 455 460 465
 Ala Leu Lys Leu His Gln Asp His Phe Thr Ser Pro Asp Glu Tyr
 470 475 480
 Glu Glu Pro Ala Ala Leu Tyr Asp Ala Ile Ala Ala Asn Glu Glu
 485 490 495
 Arg Leu Val Ile Ser His Glu Gly Asp Pro Ala Trp Arg Ser Ala
 500 505 510
 Ile Leu Ser Asn Thr Pro Ser Leu Leu Ala Leu Arg His Val Leu
 515 520 525
 Asp Asp Ala Ser Asp Glu Tyr Lys Ile Ile Met Leu Asn Arg Arg
 530 535 540
 His Leu Ser Phe Arg Val Ile Lys Val Asn Arg Glu Cys Val Arg
 545 550 555
 Gly Leu Trp Ala Gly Gln Gln Gln Glu Leu Val Phe Leu Arg Asn
 560 565 570
 Arg Asn Pro Glu Arg Gly Ser Ile Gln Asn Ala Lys Gln Ala Leu
 575 580 585
 Arg Asn Met Ile Asn Ser Ser Cys Asp Gln Pro Leu Gly Tyr Pro
 590 595 600
 Ile Tyr Val Ser Pro Leu Thr Thr Ser Leu Ala Gly Ser His Pro
 605 610 615
 Gln Leu Arg Ala Leu Trp Gly Gly Pro Ile Ser Leu Gly Ala Ile
 620 625 630
 Ala His Trp Leu Leu Arg Thr Trp Glu Arg Leu His Lys Gly Cys

635	640	645
Gly Ala Gly Cys Asn Ser Gly Gly Asn Val Asp Asp Ser Asp	Cys	
650	655	660
Ser Gly Gly Gly Gly Leu Thr Ser Leu Ser Asn Asn Pro Pro	Val	
665	670	675
Ala His Pro Thr Pro Glu Asn Thr Ala Gly Asn Gly Asp Gln Pro		
680	685	690
Leu Pro Pro Gly Pro Gly Trp Gly Pro Arg Ser Ser Leu Ser Gly		
695	700	705
Ser Gly Asp Gly Arg Pro Pro Pro Leu Leu Gln Trp Pro Pro Pro		
710	715	720
Arg Leu Pro Gly Pro Pro Pro Ala Ser Pro Ile Pro Thr Glu Gly		
725	730	735
Pro Arg Thr Ser Arg Pro Pro Gly Pro Gly Leu Leu Ser Ser Glu		
740	745	750
Gly Pro Ser Gly Lys Trp Ser Leu Gly Gly Arg Lys Gly Leu Gly		
755	760	765
Gly Ser Asp Gly Glu Pro Ala Ser Gly Ser Pro Lys Gly Gly Thr		
770	775	780
Pro Lys Ser Gln Val Arg His Leu Trp Glu Gly Trp Val Pro Glu		
785	790	795
Gly		

<210> 11
<211> 854
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2888437CD1

<400> 11		
Met Lys Cys Leu Tyr Tyr Leu Tyr Ala Ser Leu Asp Pro Asn Ala		
1 5 10 15		
Val Lys Ala Leu Asn Glu Met Trp Lys Cys Gln Asn Met Leu Arg		
20 25 30		
Ile His Val Arg Glu Leu Leu Asp Leu His Lys Gln Pro Thr Ser		
35 40 45		
Glu Ala Asn Cys Ser Ala Met Phe Gly Lys Leu Met Thr Ile Ala		
50 55 60		
Lys Asn Leu Pro Asp Pro Gly Lys Ala Gln Asp Phe Val Lys Lys		
65 70 75		
Phe Asn Gln Val Leu Gly Asp Asp Glu Lys Leu Arg Ser Gln Leu		
80 85 90		
Glu Leu Leu Ile Ser Pro Thr Cys Ser Cys Lys Gln Ala Asp Ile		
95 100 105		
Cys Val Arg Glu Ile Ala Arg Lys Leu Ala Asn Pro Lys Gln Pro		
110 115 120		
Thr Asn Pro Phe Leu Glu Met Val Lys Phe Leu Leu Glu Arg Ile		
125 130 135		
Ala Pro Val His Ile Asp Ser Glu Ala Ile Ser Ala Leu Val Lys		
140 145 150		

Leu Met Asn Lys Ser Ile Glu Gly Thr Ala Asp Asp Glu Glu Glu
 155 160 165
 Gly Val Ser Pro Asp Thr Ala Ile Arg Ser Gly Leu Glu Leu Leu
 170 175 180
 Lys Val Leu Ser Phe Thr His Pro Thr Ser Phe His Ser Ala Glu
 185 190 195
 Thr Tyr Glu Ser Leu Leu Gln Cys Leu Arg Met Glu Asp Asp Lys
 200 205 210
 Val Ala Glu Ala Ala Ile Gln Ile Phe Arg Asn Thr Gly His Lys
 215 220 225
 Ile Glu Thr Asp Leu Pro Gln Ile Arg Ser Thr Leu Ile Pro Ile
 230 235 240
 Leu His Gln Lys Ala Lys Arg Gly Thr Pro His Gln Ala Lys Gln
 245 250 255
 Ala Val His Cys Ile His Ala Ile Phe Thr Asn Lys Glu Val Gln
 260 265 270
 Leu Ala Gln Ile Phe Glu Pro Leu Ser Arg Ser Leu Asn Ala Asp
 275 280 285
 Val Pro Glu Gln Leu Ile Thr Pro Leu Val Ser Leu Gly His Ile
 290 295 300
 Ser Met Leu Ala Pro Asp Gln Phe Ala Ser Pro Met Lys Ser Val
 305 310 315
 Val Ala Asn Phe Ile Val Lys Asp Leu Leu Met Asn Asp Arg Ser
 320 325 330
 Thr Gly Glu Lys Asn Gly Lys Leu Trp Ser Pro Asp Glu Glu Val
 335 340 345
 Ser Pro Glu Val Leu Ala Lys Val Gln Ala Ile Lys Leu Leu Val
 350 355 360
 Arg Trp Leu Leu Gly Met Lys Asn Asn Gln Ser Lys Ser Ala Asn
 365 370 375
 Ser Thr Leu Arg Leu Leu Ser Ala Met Leu Val Ser Glu Gly Asp
 380 385 390
 Leu Thr Glu Gln Lys Arg Ile Ser Lys Ser Asp Met Ser Arg Leu
 395 400 405
 Arg Leu Ala Ala Gly Ser Ala Ile Met Lys Leu Ala Gln Glu Pro
 410 415 420
 Cys Tyr His Glu Ile Ile Thr Pro Glu Gln Phe Gln Leu Cys Ala
 425 430 435
 Leu Val Ile Asn Asp Glu Cys Tyr Gln Val Arg Gln Ile Phe Ala
 440 445 450
 Gln Lys Leu His Lys Ala Leu Val Lys Leu Leu Pro Leu Glu
 455 460 465
 Tyr Met Ala Ile Phe Ala Leu Cys Ala Lys Asp Pro Val Lys Glu
 470 475 480
 Arg Arg Ala His Ala Arg Gln Cys Leu Leu Lys Asn Ile Ser Ile
 485 490 495
 Arg Arg Glu Tyr Ile Lys Gln Asn Pro Met Ala Thr Glu Lys Leu
 500 505 510
 Leu Ser Leu Leu Pro Glu Tyr Val Val Pro Tyr Met Ile His Leu
 515 520 525
 Leu Ala His Asp Pro Asp Phe Thr Arg Ser Gln Asp Val Asp Gln
 530 535 540
 Leu Arg Asp Ile Lys Glu Cys Leu Trp Phe Met Leu Glu Val Leu
 545 550 555
 Met Thr Lys Asn Glu Asn Asn Ser His Ala Phe Met Lys Lys Met

560	565	570
Ala Glu Asn Ile Lys Leu Thr Arg Asp Ala Gln Ser Pro Asp	Glu	
575	580	585
Ser Lys Thr Asn Glu Lys Leu Tyr Thr Val Cys Asp Val Ala Leu		
590	595	600
Cys Val Ile Asn Ser Lys Ser Ala Leu Cys Asn Ala Asp Ser Pro		
605	610	615
Lys Asp Pro Val Leu Pro Met Lys Phe Phe Thr Gln Pro Glu Lys		
620	625	630
Asp Phe Cys Asn Asp Lys Ser Tyr Ile Ser Glu Glu Thr Arg Val		
635	640	645
Leu Leu Leu Thr Gly Lys Pro Lys Pro Ala Gly Val Leu Gly Ala		
650	655	660
Val Asn Lys Pro Leu Ser Ala Thr Gly Arg Lys Pro Tyr Val Arg		
665	670	675
Ser Thr Gly Thr Glu Thr Gly Ser Asn Ile Asn Val Asn Ser Glu		
680	685	690
Leu Asn Pro Ser Thr Gly Asn Arg Ser Arg Glu Gln Ser Ser Glu		
695	700	705
Ala Ala Glu Thr Gly Val Ser Glu Asn Glu Glu Asn Pro Val Arg		
710	715	720
Ile Ile Ser Val Thr Pro Val Lys Asn Ile Asp Pro Val Lys Asn		
725	730	735
Lys Glu Ile Asn Ser Asp Gln Ala Thr Gln Gly Asn Ile Ser Ser		
740	745	750
Asp Arg Gly Lys Lys Arg Thr Val Thr Ala Ala Gly Ala Glu Asn		
755	760	765
Ile Gln Gln Lys Thr Asp Glu Lys Val Asp Glu Ser Gly Pro Pro		
770	775	780
Ala Pro Ser Lys Pro Arg Arg Gly Arg Arg Pro Lys Ser Glu Ser		
785	790	795
Gln Gly Asn Ala Thr Lys Asn Asp Asp Leu Asn Lys Pro Ile Asn		
800	805	810
Lys Gly Arg Lys Arg Ala Ala Val Gly Gln Glu Ser Pro Gly Gly		
815	820	825
Leu Glu Ala Gly Asn Ala Lys Ala Pro Lys Leu Gln Asp Leu Ala		
830	835	840
Lys Lys Ala Ala Pro Ala Glu Arg Gln Ile Asp Leu Gln Arg		
845	850	

<210> 12
<211> 856
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3201753CD1

<400> 12
Met Arg Gly Ile Phe Ile Lys His Val Leu Glu Asp Ser Pro Ala
1 5 10 15
Gly Lys Asn Gly Thr Leu Lys Pro Gly Asp Arg Ile Val Glu Val
20 25 30

Asp Gly Met Asp Leu Arg Asp Ala Ser His Glu Gln Ala Val Glu
 35 40 45
 Ala Ile Arg Lys Ala Gly Asn Pro Val Val Phe Met Val Gln Ser
 50 55 60
 Ile Ile Asn Arg Pro Arg Ala Pro Ser Gln Ser Glu Ser Glu Pro
 65 70 75
 Glu Lys Ala Pro Leu Cys Ser Val Pro Pro Pro Pro Ser Ala
 80 85 90
 Phe Ala Glu Met Gly Ser Asp His Thr Gln Ser Ser Ala Ser Lys
 95 100 105
 Ile Ser Gln Asp Val Asp Lys Glu Asp Glu Phe Gly Tyr Ser Trp
 110 115 120
 Lys Asn Ile Arg Glu Arg Tyr Gly Thr Leu Thr Gly Glu Leu His
 125 130 135
 Met Ile Glu Leu Glu Lys Gly His Ser Gly Leu Gly Leu Ser Leu
 140 145 150
 Ala Gly Asn Lys Asp Arg Ser Arg Met Ser Val Phe Ile Val Gly
 155 160 165
 Ile Asp Pro Asn Gly Ala Ala Gly Lys Asp Gly Arg Leu Gln Ile
 170 175 180
 Ala Asp Glu Leu Leu Glu Ile Asn Gly Gln Ile Leu Tyr Gly Arg
 185 190 195
 Ser His Gln Asn Ala Ser Ser Ile Ile Lys Cys Ala Pro Ser Lys
 200 205 210
 Val Lys Ile Ile Phe Ile Arg Asn Lys Asp Ala Val Asn Gln Met
 215 220 225
 Ala Val Cys Pro Gly Asn Ala Val Glu Pro Leu Pro Ser Asn Ser
 230 235 240
 Glu Asn Leu Gln Asn Lys Glu Thr Glu Pro Thr Val Thr Thr Ser
 245 250 255
 Asp Ala Ala Val Asp Leu Ser Ser Phe Lys Asn Val Gln His Leu
 260 265 270
 Glu Leu Pro Lys Asp Gln Gly Gly Leu Gly Ile Ala Ile Ser Glu
 275 280 285
 Glu Asp Thr Leu Ser Gly Val Ile Ile Lys Ser Leu Thr Glu His
 290 295 300
 Gly Val Ala Ala Thr Asp Gly Arg Leu Lys Val Gly Asp Gln Ile
 305 310 315
 Leu Ala Val Asp Asp Glu Ile Val Val Gly Tyr Pro Ile Glu Lys
 320 325 330
 Phe Ile Ser Leu Lys Thr Ala Lys Met Thr Val Lys Leu Thr
 335 340 345
 Ile His Ala Glu Asn Pro Asp Ser Gln Ala Val Pro Ser Ala Ala
 350 355 360
 Gly Ala Ala Ser Gly Glu Lys Lys Asn Ser Ser Gln Ser Leu Met
 365 370 375
 Val Pro Gln Ser Gly Ser Pro Glu Pro Glu Ser Ile Arg Asn Thr
 380 385 390
 Ser Arg Ser Ser Thr Pro Ala Ile Phe Ala Ser Asp Pro Ala Thr
 395 400 405
 Cys Pro Ile Ile Pro Gly Cys Glu Thr Thr Ile Glu Ile Ser Lys
 410 415 420
 Gly Arg Thr Gly Leu Gly Leu Ser Ile Val Gly Gly Ser Asp Thr
 425 430 435
 Leu Leu Gly Ala Ile Ile His Glu Val Tyr Glu Glu Gly Ala

440	445	450
Ala Cys Lys Asp Gly Arg Leu Trp Ala	Gly Asp Gln Ile Leu	Glu
455	460	465
Val Asn Gly Ile Asp Leu Arg Lys Ala	Thr His Asp Glu Ala	Ile
470	475	480
Asn Val Leu Arg Gln Thr Pro Gln Arg	Val Arg Leu Thr Leu	Tyr
485	490	495
Arg Asp Glu Ala Pro Tyr Lys Glu	Glu Val Cys Asp Thr	Leu
500	505	510
Thr Ile Glu Leu Gln Lys Lys Pro Gly	Lys Gly Leu Gly Leu	Ser
515	520	525
Ile Val Gly Lys Arg Asn Asp Thr Gly	Val Phe Val Ser Asp	Ile
530	535	540
Val Lys Gly Gly Ile Ala Asp Ala Asp	Gly Arg Leu Met Gln	Gly
545	550	555
Asp Gln Ile Leu Met Val Asn Gly Glu	Asp Val Arg Asn Ala	Thr
560	565	570
Gln Glu Ala Val Ala Ala Leu Leu Lys	Cys Ser Leu Gly Thr	Val
575	580	585
Thr Leu Glu Val Gly Arg Ile Lys Ala	Gly Pro Phe His Ser	Glu
590	595	600
Arg Arg Pro Ser Gln Ser Ser Gln Val	Ser Glu Gly Ser Leu	Ser
605	610	615
Ser Phe Thr Phe Pro Leu Ser Gly Ser	Ser Thr Ser Glu Ser	Leu
620	625	630
Glu Ser Ser Ser Lys Lys Asn Ala Leu	Ala Ser Glu Ile Gln	Gly
635	640	645
Leu Arg Thr Val Glu Met Lys Lys Gly	Pro Thr Asp Ser Leu	Gly
650	655	660
Ile Ser Ile Ala Gly Gly Val Gly Ser	Pro Leu Gly Asp Val	Pro
665	670	675
Ile Phe Ile Ala Met Met His Pro Thr	Gly Val Ala Ala Gln	Thr
680	685	690
Gln Lys Leu Arg Val Gly Asp Arg Ile	Val Thr Ile Cys Gly	Thr
695	700	705
Ser Thr Glu Gly Met Thr His Thr Gln	Ala Val Asn Leu Lys	
710	715	720
Asn Ala Ser Gly Ser Ile Glu Met Gln	Val Val Ala Gly Gly	Asp
725	730	735
Val Ser Val Val Thr Gly His Gln Gln	Glu Pro Ala Ser Ser	Ser
740	745	750
Leu Ser Phe Thr Gly Leu Thr Ser Ser	Ser Ile Phe Gln Asp	Asp
755	760	765
Leu Gly Pro Pro Gln Cys Lys Ser Ile	Thr Leu Glu Arg Gly	Pro
770	775	780
Asp Gly Leu Gly Phe Ser Ile Val Gly	Gly Tyr Gly Ser Pro	His
785	790	795
Gly Asp Leu Pro Ile Tyr Val Lys Thr	Val Phe Ala Lys Gly	Ala
800	805	810
Ala Ser Glu Asp Gly Arg Leu Lys Arg	Gly Asp Gln Ile Ile	Ala
815	820	825
Val Asn Gly Gln Ser Leu Glu Gly Val	Thr His Glu Glu Ala	Val
830	835	840

Ala Ile Leu Lys Arg Thr Lys Gly Thr Val Thr Leu Met Val Leu
845 850 855

Ser

<210> 13
<211> 361
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3800639CD1

<400> 13
Met Glu Thr Gly Ala Ala Glu Leu Tyr Asp Gln Ala Leu Leu Gly
1 5 10 15
Ile Leu Gln His Val Gly Asn Val Gln Asp Phe Leu Arg Val Leu
20 25 30
Phe Gly Phe Leu Tyr Arg Lys Thr Asp Phe Tyr Arg Leu Leu Arg
35 40 45
His Pro Ser Asp Arg Met Gly Phe Pro Pro Gly Ala Ala Gln Ala
50 55 60
Leu Val Leu Gln Val Phe Lys Thr Phe Asp His Met Ala Arg Gln
65 70 75
Asp Asp Glu Lys Arg Arg Gln Glu Leu Glu Glu Lys Ile Arg Arg
80 85 90
Lys Glu Glu Glu Ala Lys Thr Val Ser Ala Ala Ala Ala Glu
95 100 105
Lys Glu Pro Val Pro Val Pro Gln Glu Ile Glu Ile Asp Ser
110 115 120
Thr Thr Glu Leu Asp Gly His Gln Glu Val Glu Lys Val Gln Pro
125 130 135
Pro Gly Pro Val Lys Glu Met Ala His Gly Ser Gln Glu Ala Glu
140 145 150
Ala Pro Gly Ala Val Ala Gly Ala Ala Glu Val Pro Arg Glu Pro
155 160 165
Pro Ile Leu Pro Arg Ile Gln Glu Gln Phe Gln Lys Asn Pro Asp
170 175 180
Ser Tyr Asn Gly Ala Val Arg Glu Asn Tyr Thr Trp Ser Gln Asp
185 190 195
Tyr Thr Asp Leu Glu Val Arg Val Pro Val Pro Lys His Val Val
200 205 210
Lys Gly Lys Gln Val Ser Val Ala Leu Ser Ser Ser Ser Ile Arg
215 220 225
Val Ala Met Leu Glu Glu Asn Gly Glu Arg Val Leu Met Glu Gly
230 235 240
Lys Leu Thr His Lys Ile Asn Thr Glu Ser Ser Leu Trp Ser Leu
245 250 255
Glu Pro Gly Lys Cys Val Leu Val Asn Leu Ser Lys Val Gly Glu
260 265 270
Tyr Trp Trp Asn Ala Ile Leu Glu Gly Glu Glu Pro Ile Asp Ile
275 280 285
Asp Lys Ile Asn Lys Glu Arg Ser Met Ala Thr Val Asp Glu Glu
290 295 300

Glu Gln Ala Val Leu Asp Arg Leu Thr Phe Asp Tyr His Gln Lys		
305	310	315
Leu Gln Gly Lys Pro Gln Ser His Glu Leu Lys Val His Glu Met		
320	325	330
Leu Lys Lys Gly Trp Asp Ala Glu Gly Ser Pro Phe Arg Gly Gln		
335	340	345
Arg Phe Asp Pro Ala Met Phe Asn Ile Ser Pro Gly Ala Val Gln		
350	355	360

Phe

<210> 14

<211> 632

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 533825CD1

<400> 14

Met Lys Ala Leu Leu Leu Val Leu Pro Trp Leu Ser Pro Ala			
1	5	10	15
Asn Tyr Ile Asp Asn Val Gly Asn Leu His Phe Leu Tyr Ser Glu			
20	25	30	
Leu Cys Lys Gly Ala Ser His Tyr Gly Leu Thr Lys Asp Arg Lys			
35	40	45	
Arg Arg Ser Gln Asp Gly Cys Pro Asp Gly Cys Ala Ser Leu Thr			
50	55	60	
Ala Thr Ala Pro Ser Pro Glu Val Ser Ala Ala Ala Thr Ile Ser			
65	70	75	
Leu Met Thr Asp Glu Pro Gly Leu Asp Asn Pro Ala Tyr Val Ser			
80	85	90	
Ser Ala Glu Asp Gly Gln Pro Ala Ile Ser Pro Val Asp Ser Gly			
95	100	105	
Arg Ser Asn Arg Thr Arg Ala Arg Pro Phe Glu Arg Ser Thr Ile			
110	115	120	
Arg Ser Arg Ser Phe Lys Lys Ile Asn Arg Ala Leu Ser Val Leu			
125	130	135	
Arg Arg Thr Lys Ser Gly Ser Ala Val Ala Asn His Ala Asp Gln			
140	145	150	
Gly Arg Glu Asn Ser Glu Asn Ile Thr Ala Pro Glu Val Phe Pro			
155	160	165	
Arg Leu Tyr His Leu Ile Pro Asp Gly Glu Ile Thr Ser Ile Lys			
170	175	180	
Ile Asn Arg Val Asp Pro Ser Glu Ser Leu Ser Ile Arg Leu Val			
185	190	195	
Gly Gly Ser Glu Thr Pro Leu Val His Ile Ile Ile Gln His Ile			
200	205	210	
Tyr Arg Asp Gly Val Ile Ala Arg Asp Gly Arg Leu Leu Pro Gly			
215	220	225	
Asp Ile Ile Leu Lys Val Asn Gly Met Asp Ile Ser Asn Val Pro			
230	235	240	
His Asn Tyr Ala Val Arg Leu Leu Arg Gln Pro Cys Gln Val Leu			
245	250	255	

Trp Leu Thr Val Met Arg Glu Gln Lys Phe Arg Ser Arg Asn Asn
 260 265 270
 Gly Gln Ala Pro Asp Ala Tyr Arg Pro Arg Asp Asp Ser Phe His
 275 280 285
 Val Ile Leu Asn Lys Ser Ser Pro Glu Glu Gln Leu Gly Ile Lys
 290 295 300
 Leu Val Arg Lys Val Asp Glu Pro Gly Val Phe Ile Phe Asn Val
 305 310 315
 Leu Asp Gly Gly Val Ala Tyr Arg His Gly Gln Leu Glu Glu Asn
 320 325 330
 Asp Arg Val Leu Ala Ile Asn Gly His Asp Leu Arg Tyr Gly Ser
 335 340 345
 Pro Glu Ser Ala Ala His Leu Ile Gln Ala Ser Glu Arg Arg Val
 350 355 360
 His Leu Val Val Ser Arg Gln Val Arg Gln Arg Ser Pro Asp Ile
 365 370 375
 Phe Gln Glu Ala Gly Trp Asn Ser Asn Gly Ser Trp Ser Pro Gly
 380 385 390
 Pro Gly Glu Arg Ser Asn Thr Pro Lys Pro Leu His Pro Thr Ile
 395 400 405
 Thr Cys His Glu Lys Val Val Asn Ile Gln Lys Asp Pro Gly Glu
 410 415 420
 Ser Leu Gly Met Ala Val Ala Gly Gly Ala Ser His Arg Glu Trp
 425 430 435
 Asp Leu Pro Ile Tyr Val Ile Ser Val Glu Pro Gly Gly Val Ile
 440 445 450
 Ser Arg Asp Gly Arg Ile Lys Thr Gly Asp Ile Leu Leu Asn Val
 455 460 465
 Asp Gly Val Glu Leu Thr Glu Val Ser Arg Ser Glu Ala Val Ala
 470 475 480
 Leu Leu Lys Arg Thr Ser Ser Ser Ile Val Leu Lys Ala Leu Glu
 485 490 495
 Val Lys Glu Tyr Glu Pro Gln Glu Asp Cys Ser Ser Pro Ala Ala
 500 505 510
 Leu Asp Ser Asn His Asn Met Ala Pro Pro Ser Asp Trp Ser Pro
 515 520 525
 Ser Trp Val Met Trp Leu Glu Leu Pro Arg Cys Leu Tyr Asn Cys
 530 535 540
 Lys Asp Ile Val Leu Arg Arg Asn Thr Ala Gly Ser Leu Gly Phe
 545 550 555
 Cys Ile Val Gly Gly Tyr Glu Glu Tyr Asn Gly Asn Lys Pro Phe
 560 565 570
 Phe Ile Lys Ser Ile Val Glu Gly Thr Pro Ala Tyr Asn Asp Gly
 575 580 585
 Arg Ile Arg Cys Gly Asp Ile Leu Leu Ala Val Asn Gly Arg Ser
 590 595 600
 Thr Ser Gly Met Ile His Ala Cys Leu Ala Arg Leu Leu Lys Glu
 605 610 615
 Leu Lys Gly Arg Ile Thr Leu Thr Ile Val Ser Trp Pro Gly Thr
 620 625 630
 Phe Leu

<210> 15
<211> 391
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 1311833CD1

<400> 15
Met Lys Met Lys Ile Gln Lys Lys Glu Lys Gln Leu Ser Asn Leu
1 5 10 15
Lys Val Leu Asn His Ser Pro Met Ser Asp Ala Ser Val Asn Phe
20 25 30
Asp Tyr Lys Ser Pro Ser Pro Phe Asp Cys Ser Thr Asp Gln Glu
35 40 45
Glu Lys Ile Glu Asp Val Ala Ser His Cys Leu Pro Gln Lys Asp
50 55 60
Leu Tyr Thr Ala Glu Glu Ala Ala Thr Leu Phe Pro Arg Lys
65 70 75
Met Thr Ser His Asn Gly Met Glu Asp Ser Gly Gly Gly Thr
80 85 90
Gly Val Lys Lys Lys Arg Lys Lys Glu Pro Gly Asp Gln Glu
95 100 105
Gly Ala Ala Lys Gly Ser Lys Asp Arg Glu Pro Lys Pro Lys Arg
110 115 120
Lys Arg Glu Pro Lys Glu Pro Lys Glu Pro Arg Lys Ala Lys Glu
125 130 135
Pro Lys Lys Ala Lys Glu His Lys Glu Pro Lys Gln Lys Asp Gly
140 145 150
Ala Lys Lys Ala Arg Lys Pro Arg Glu Ala Ser Gly Thr Lys Glu
155 160 165
Ala Lys Glu Lys Arg Ser Cys Thr Asp Ser Ala Ala Arg Thr Lys
170 175 180
Ser Arg Lys Ala Ser Lys Glu Gln Gly Pro Thr Pro Val Glu Lys
185 190 195
Lys Lys Lys Gly Lys Arg Lys Ser Glu Thr Thr Val Glu Ser Leu
200 205 210
Glu Leu Asp Gln Gly Leu Thr Asn Pro Ser Leu Arg Ser Pro Glu
215 220 225
Glu Ser Thr Glu Ser Thr Asp Ser Gln Lys Arg Arg Ser Gly Arg
230 235 240
Gln Val Lys Arg Arg Lys Tyr Asn Glu Asp Leu Asp Phe Lys Val
245 250 255
Val Asp Asp Asp Gly Glu Thr Ile Ala Val Leu Gly Ala Gly Arg
260 265 270
Thr Ser Ala Leu Ser Ala Ser Thr Leu Ala Trp Gln Ala Glu Glu
275 280 285
Pro Pro Glu Asp Asp Ala Asn Ile Ile Glu Lys Ile Leu Ala Ser
290 295 300
Lys Thr Val Gln Glu Val His Pro Gly Glu Pro Pro Phe Asp Leu
305 310 315
Glu Leu Phe Tyr Val Lys Tyr Arg Asn Phe Ser Tyr Leu His Cys
320 325 330
Lys Trp Ala Thr Met Glu Glu Leu Glu Lys Asp Pro Arg Ile Ala

335	340	345
Gln Lys Ile Lys Arg Phe Arg Asn Lys Gln Ala Gln Met Lys His		
350	355	360
Ile Phe Thr Glu Val Lys Gln Tyr Leu Leu Thr His Leu Thr Ala		
365	370	375
Ala Phe Leu Ala Ala Val Asn Thr Val Phe Thr Phe Leu Ser Pro		
380	385	390

Ser

<210> 16
<211> 490
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 1342819CD1

<400> 16

Met Glu Asp Ser Ala Ser Ala Ser Leu Ser Ser Ala Ala Ala Thr		
1	5	10
Gly Thr Ser Thr Ser Thr Pro Ala Ala Pro Thr Ala Arg Lys Gln		
20	25	30
Leu Asp Lys Glu Gln Val Arg Lys Ala Val Asp Ala Leu Leu Thr		
35	40	45
His Cys Lys Ser Arg Lys Asn Asn Tyr Gly Leu Leu Leu Asn Glu		
50	55	60
Asn Glu Ser Leu Phe Leu Met Val Val Leu Trp Lys Ile Pro Ser		
65	70	75
Lys Glu Leu Arg Val Arg Leu Thr Leu Pro His Ser Ile Arg Ser		
80	85	90
Asp Ser Glu Asp Ile Cys Leu Phe Thr Lys Asp Glu Pro Asn Ser		
95	100	105
Thr Pro Glu Lys Thr Glu Gln Phe Tyr Arg Lys Leu Leu Asn Lys		
110	115	120
His Gly Ile Lys Thr Val Ser Gln Ile Ile Ser Leu Gln Thr Leu		
125	130	135
Lys Lys Glu Tyr Lys Ser Tyr Glu Ala Lys Leu Arg Leu Leu Ser		
140	145	150
Ser Phe Asp Phe Phe Leu Thr Asp Ala Arg Ile Arg Arg Leu Leu		
155	160	165
Pro Ser Leu Ile Gly Arg His Phe Tyr Gln Arg Lys Lys Val Pro		
170	175	180
Val Ser Val Asn Leu Leu Ser Lys Asn Leu Ser Arg Glu Ile Asn		
185	190	195
Asp Cys Ile Gly Gly Thr Val Leu Asn Ile Ser Lys Ser Gly Ser		
200	205	210
Cys Ser Ala Ile Arg Ile Gly His Val Gly Met Gln Ile Glu His		
215	220	225
Ile Ile Glu Asn Ile Val Ala Val Thr Lys Gly Leu Ser Glu Lys		
230	235	240
Leu Pro Glu Lys Trp Glu Ser Val Lys Leu Leu Phe Val Lys Thr		
245	250	255
Glu Lys Ser Ala Ala Leu Pro Ile Phe Ser Ser Phe Val Ser Asn		

260	265	270
Trp Asp Glu Ala Thr Lys Arg Ser Leu	Leu Asn Lys Lys Lys Lys	Lys
275	280	285
Glu Ala Arg Arg Lys Arg Arg Glu Arg	Asn Phe Glu Lys Gln Lys	
290	295	300
Glu Arg Lys Lys Lys Arg Gln Gln Ala Arg	Lys Thr Ala Ser Val	
305	310	315
Leu Ser Lys Asp Asp Val Ala Pro Glu	Ser Gly Asp Thr Thr Val	
320	325	330
Lys Lys Pro Glu Ser Lys Lys Glu Gln	Thr Pro Glu His Gly Lys	
335	340	345
Lys Lys Arg Gly Arg Gly Lys Ala Gln	Val Lys Ala Thr Asn Glu	
350	355	360
Ser Glu Asp Glu Ile Pro Gln Leu Val	Pro Ile Gly Lys Lys Thr	
365	370	375
Pro Ala Asn Glu Lys Val Glu Ile Gln	Lys His Ala Thr Gly Lys	
380	385	390
Lys Ser Pro Ala Lys Ser Pro Asn Pro	Ser Thr Pro Arg Gly Lys	
395	400	405
Lys Arg Lys Ala Leu Pro Ala Ser Glu	Thr Pro Lys Ala Ala Glu	
410	415	420
Ser Glu Thr Pro Gly Lys Ser Pro Glu	Lys Lys Pro Lys Ile Lys	
425	430	435
Glu Glu Ala Val Lys Glu Lys Ser Pro	Ser Leu Gly Lys Lys Asp	
440	445	450
Ala Arg Gln Thr Pro Lys Lys Pro Glu	Ala Lys Phe Phe Thr Thr	
455	460	465
Pro Ser Lys Ser Val Arg Lys Ala Ser	His Thr Pro Lys Lys Trp	
470	475	480
Pro Lys Lys Pro Lys Val Pro Gln Ser	Thr	
485	490	

<210> 17
<211> 252
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 1871288CD1

<400> 17		
Met Ala Glu Leu Glu Phe Val Gln Ile Ile Ile Val Val		
1 5 10 15		
Met Met Val Met Val Val Val Ile Thr Cys Leu Leu Ser His Tyr		
20 25 30		
Lys Leu Ser Ala Arg Ser Phe Ile Ser Arg His Ser Gln Gly Arg		
35 40 45		
Arg Arg Glu Asp Ala Leu Ser Ser Glu Gly Cys Leu Trp Pro Ser		
50 55 60		
Glu Ser Thr Val Ser Gly Asn Gly Ile Pro Glu Pro Gln Val Tyr		
65 70 75		
Ala Pro Pro Arg Pro Thr Asp Arg Leu Ala Val Pro Pro Phe Ala		
80 85 90		

Gln	Arg	Glu	Arg	Phe	His	Arg	Phe	Gln	Pro	Thr	Tyr	Pro	Tyr	Leu
95								100						105
Gln	His	Glu	Ile	Asp	Leu	Pro	Pro	Thr	Ile	Ser	Leu	Ser	Asp	Gly
		110							115					120
Glu	Glu	Pro	Pro	Pro	Tyr	Gln	Gly	Pro	Cys	Thr	Leu	Gln	Leu	Arg
		125							130					135
Asp	Pro	Glu	Gln	Gln	Leu	Glu	Leu	Asn	Arg	Glu	Ser	Val	Arg	Ala
		140							145					150
Pro	Pro	Asn	Arg	Thr	Ile	Phe	Asp	Ser	Asp	Leu	Met	Asp	Ser	Ala
		155							160					165
Arg	Leu	Gly	Gly	Pro	Cys	Pro	Pro	Ser	Ser	Asn	Ser	Gly	Ile	Ser
		170							175					180
Ala	Thr	Cys	Tyr	Gly	Ser	Gly	Gly	Arg	Met	Glu	Gly	Pro	Pro	Pro
		185							190					195
Thr	Tyr	Ser	Glu	Val	Ile	Gly	His	Tyr	Pro	Gly	Ser	Ser	Phe	Gln
		200							205					210
His	Gln	Gln	Ser	Ser	Gly	Pro	Pro	Ser	Leu	Leu	Glu	Gly	Thr	Arg
		215							220					225
Leu	His	His	Thr	His	Ile	Ala	Pro	Leu	Glu	Ser	Ala	Ala	Ile	Trp
		230							235					240
Ser	Lys	Glu	Lys	Asp	Lys	Gln	Lys	Gly	His	Pro	Leu			
		245							250					

<210> 18

<211> 142

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2587338CD1

<400> 18

Met	Glu	Ser	Ala	Arg	Glu	Asn	Ile	Asp	Leu	Gln	Pro	Gly	Ser	Ser
1					5				10					15
Asp	Pro	Arg	Ser	Gln	Pro	Ile	Asn	Leu	Asn	His	Tyr	Ala	Thr	Lys
					20				25					30
Lys	Ser	Val	Ala	Glu	Ser	Met	Leu	Asp	Val	Ala	Leu	Phe	Met	Ser
					35				40					45
Asn	Ala	Met	Arg	Leu	Lys	Ala	Val	Leu	Glu	Gln	Gly	Pro	Ser	Ser
					50				55					60
His	Tyr	Tyr	Thr	Leu	Val	Thr	Leu	Ile	Ser	Leu	Ser	Leu	Leu	
					65				70					75
Leu	Gln	Val	Val	Ile	Gly	Val	Leu	Leu	Val	Val	Ile	Ala	Arg	Leu
					80				85					90
Asn	Leu	Asn	Glu	Val	Glu	Lys	Gln	Trp	Arg	Leu	Asn	Gln	Leu	Asn
					95				100					105
Asn	Gly	Ser	His	Ile	Leu	Val	Phe	Phe	Thr	Val	Val	Ile	Asn	Gly
					110				115					120
Phe	Ile	Thr	Gly	Phe	Gly	Ala	His	Lys	Thr	Arg	Val	Leu	Ala	Cys
					125				130					135
Gln	Asp	Ser	Arg	Asn	Pro	Leu								
					140									

<210> 19
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2821211CD1

<400> 19
Met Glu Ile Ile Glu Asn Ser Phe His Ile Asn Gly Leu Lys Ile
1 5 10 15
Asn Gln Arg Thr Leu Cys Val His Val Cys Ile Ser Ala His Arg
20 25 30
Asn Ile Tyr Thr Tyr Val Asp Tyr Ile His Val Cys Ile Tyr Val
35 40 45
Tyr Ile Tyr Ile His Leu Tyr Lys Cys Ile Tyr Thr Tyr Thr Tyr
50 55 60
Asn Val Cys Met Cys Ile Tyr
65

<210> 20
<211> 455
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2824832CD1

<400> 20
Met Phe Gln Phe His Ala Gly Ser Trp Glu Ser Trp Cys Cys Cys
1 5 10 15
Cys Leu Ile Pro Ala Asp Arg Pro Trp Asp Arg Gly Gln His Trp
20 25 30
Gln Leu Glu Met Ala Asp Thr Arg Ser Val His Glu Thr Arg Phe
35 40 45
Glu Ala Ala Val Lys Val Ile Gln Ser Leu Pro Lys Asn Gly Ser
50 55 60
Phe Gln Pro Thr Asn Glu Met Met Leu Lys Phe Tyr Ser Phe Tyr
65 70 75
Lys Gln Ala Thr Glu Gly Pro Cys Lys Leu Ser Arg Pro Gly Phe
80 85 90
Trp Asp Pro Ile Gly Arg Tyr Lys Trp Asp Ala Trp Ser Ser Leu
95 100 105
Gly Asp Met Thr Lys Glu Glu Ala Met Ile Ala Tyr Val Glu Glu
110 115 120
Met Lys Lys Ile Ile Glu Thr Met Pro Met Thr Glu Lys Val Glu
125 130 135
Glu Leu Leu Arg Val Ile Gly Pro Phe Tyr Glu Ile Val Glu Asp
140 145 150
Lys Lys Ser Gly Arg Ser Ser Asp Ile Thr Ser Asp Leu Gly Asn

<210> 21
<211> 252
<212> PRT
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 3070147CD1

<400> 21
Met Gln Leu Thr Arg Cys Cys Phe Val Phe Leu Val Gln Gly Ser
1 5 10 15

Leu Tyr Leu Val Ile Cys Gly Gln Asp Asp Gly Pro Pro Gly Ser
 20 25 30
 Glu Asp Pro Glu Arg Asp Asp His Glu Gly Gln Pro Arg Pro Arg
 35 40 45
 Val Pro Arg Lys Arg Gly His Ile Ser Pro Lys Ser Arg Pro Met
 50 55 60
 Ala Asn Ser Thr Leu Leu Gly Leu Leu Ala Pro Thr Gly Glu Ala
 65 70 75
 Trp Gly Ile Leu Gly Gln Pro Pro Asn Arg Pro Asn His Ser Pro
 80 85 90
 Pro Pro Ser Ala Lys Val Lys Ile Phe Gly Trp Gly Asp Phe
 95 100 105
 Tyr Ser Asn Ile Lys Thr Val Ala Leu Asn Leu Leu Val Thr Gly
 110 115 120
 Lys Ile Val Asp His Gly Asn Gly Thr Phe Ser Val His Phe Gln
 125 130 135
 His Asn Ala Thr Gly Gln Gly Asn Ile Ser Ile Ser Leu Val Pro
 140 145 150
 Pro Ser Lys Ala Val Glu Phe His Gln Glu Gln Gln Ile Phe Ile
 155 160 165
 Glu Ala Lys Ala Ser Lys Ile Phe Asn Cys Arg Met Glu Trp Glu
 170 175 180
 Lys Val Glu Arg Gly Arg Arg Thr Ser Leu Cys Thr His Asp Pro
 185 190 195
 Ala Lys Ile Cys Ser Arg Asp His Ala Gln Ser Ser Ala Thr Trp
 200 205 210
 Ser Cys Ser Gln Pro Phe Lys Val Val Cys Val Tyr Ile Ala Phe
 215 220 225
 Tyr Ser Thr Asp Tyr Arg Leu Val Gln Lys Val Cys Pro Asp Tyr
 230 235 240
 Asn Tyr His Ser Asp Thr Pro Tyr Tyr Pro Ser Gly
 245 250

<210> 22
 <211> 149
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3271841CD1

<400> 22
 Met Glu Ser Arg Gly Lys Ser Ala Ser Ser Pro Lys Pro Asp Thr
 1 5 10 15
 Lys Val Pro Gln Val Thr Thr Glu Ala Lys Val Pro Pro Ala Ala
 20 25 30
 Asp Gly Lys Ala Pro Leu Thr Lys Pro Ser Lys Lys Glu Ala Pro
 35 40 45
 Ala Glu Lys Gln Gln Pro Pro Ala Ala Pro Thr Thr Ala Pro Ala
 50 55 60
 Lys Lys Thr Ser Ala Lys Ala Asp Pro Ala Leu Leu Asn Asn His
 65 70 75
 Ser Asn Leu Lys Pro Ala Pro Thr Val Pro Ser Ser Pro Asp Ala

80	85	90
Thr Pro Glu Pro Lys Gly Pro Gly Asp	Gly Ala Glu Glu Asp	Glu
95	100	105
Ala Ala Ser Gly Gly Pro Gly Gly Arg	Gly Pro Trp Ser Cys	Glu
110	115	120
Asn Phe Asn Pro Leu Leu Val Ala Gly	Gly Val Ala Val Ala Ala	
125	130	135
Ile Ala Leu Ile Leu Gly Val Ala Phe	Leu Val Arg Lys Lys	
140	145	

<210> 23
<211> 204
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3537827CD1

<400> 23

Met Met Pro Ser Cys Asn Arg Ser Cys Ser Cys Ser Arg Gly Pro			
1	5	10	15
Ser Val Glu Asp Gly Lys Trp Tyr Gly Val Arg Ser Tyr Leu His			
20	25	30	
Leu Phe Tyr Glu Asp Cys Ala Gly Thr Ala Leu Ser Asp Asp Pro			
35	40	45	
Glu Gly Pro Pro Val Leu Cys Pro Arg Arg Pro Trp Pro Ser Leu			
50	55	60	
Cys Trp Lys Ile Ser Leu Ser Ser Gly Thr Leu Leu Leu Leu			
65	70	75	
Gly Val Ala Ala Leu Thr Thr Gly Tyr Ala Val Pro Pro Lys Leu			
80	85	90	
Glu Gly Ile Gly Glu Gly Glu Phe Leu Val Leu Asp Gln Arg Ala			
95	100	105	
Ala Asp Tyr Asn Gln Ala Leu Gly Thr Cys Arg Leu Ala Gly Thr			
110	115	120	
Ala Leu Cys Val Ala Ala Gly Val Leu Leu Ala Ile Cys Leu Phe			
125	130	135	
Trp Ala Met Ile Gly Trp Leu Ser Gln Asp Thr Lys Ala Glu Pro			
140	145	150	
Leu Asp Pro Glu Ala Asp Ser His Val Glu Val Phe Gly Asp Glu			
155	160	165	
Pro Glu Gln Gln Leu Ser Pro Ile Phe Arg Asn Ala Ser Gly Gln			
170	175	180	
Ser Trp Phe Ser Pro Pro Ala Ser Pro Phe Gly Gln Ser Ser Val			
185	190	195	
Gln Thr Ile Gln Pro Lys Arg Asp Ser			
200			

<210> 24
<211> 367
<212> PRT
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3729267CD1

<400> 24

Met Ala Ser Glu Leu Cys Lys Thr Ile Ser Val Ala Arg Leu Glu
1 5 10 15
Lys His Lys Asn Leu Phe Leu Asn Tyr Arg Asn Leu His His Phe
20 25 30
Pro Leu Glu Leu Leu Lys Asp Glu Gly Leu Gln Tyr Leu Glu Arg
35 40 45
Leu Tyr Met Lys Arg Asn Ser Leu Thr Ser Leu Pro Glu Asn Leu
50 55 60
Ala Gln Lys Leu Pro Asn Leu Val Glu Leu Tyr Leu His Ser Asn
65 70 75
Asn Ile Val Val Val Pro Glu Ala Ile Gly Ser Leu Val Lys Leu
80 85 90
Gln Cys Leu Asp Leu Ser Asp Asn Ala Leu Glu Ile Val Cys Pro
95 100 105
Glu Ile Gly Arg Leu Arg Ala Leu Arg His Leu Arg Leu Ala Asn
110 115 120
Asn Gln Leu Gln Phe Leu Pro Pro Glu Val Gly Asp Leu Lys Glu
125 130 135
Leu Gln Thr Leu Asp Ile Ser Thr Asn Arg Leu Leu Thr Leu Pro
140 145 150
Glu Arg Leu His Met Cys Leu Ser Leu Gln Tyr Leu Thr Val Asp
155 160 165
Arg Asn Arg Leu Trp Tyr Val Pro Arg His Leu Cys Gln Leu Pro
170 175 180
Ser Leu Asn Glu Leu Ser Met Ala Gly Asn Arg Leu Ala Phe Leu
185 190 195
Pro Leu Asp Leu Gly Arg Ser Arg Glu Leu Gln Tyr Val Tyr Val
200 205 210
Asp Asn Asn Ile His Leu Lys Gly Leu Pro Ser Tyr Leu Tyr Asn
215 220 225
Lys Val Ile Gly Cys Ser Gly Cys Gly Ala Pro Ile Gln Val Ser
230 235 240
Glu Val Lys Leu Leu Ser Phe Ser Ser Gly Gln Arg Thr Val Phe
245 250 255
Leu Pro Ala Glu Val Lys Ala Ile Gly Thr Glu His Asp His Val
260 265 270
Leu Pro Leu Gln Glu Leu Ala Met Arg Gly Leu Tyr His Thr Tyr
275 280 285
His Ser Leu Leu Lys Asp Leu Asn Phe Leu Ser Pro Ile Ser Leu
290 295 300
Pro Arg Ser Leu Leu Glu Leu Leu His Cys Pro Leu Gly His Cys
305 310 315
His Arg Cys Ser Glu Pro Met Phe Thr Ile Val Tyr Pro Lys Leu
320 325 330
Phe Pro Leu Arg Glu Thr Pro Met Ala Gly Leu His Gln Trp Lys
335 340 345
Thr Thr Val Ser Phe Val Ala Tyr Cys Cys Ser Thr Gln Cys Leu
350 355 360
Gln Thr Phe Asp Leu Leu Ser
365

<210> 25
<211> 681
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3768771CD1

<400> 25

Met Cys Thr Tyr Ile Asn Met Glu Asn Phe Thr Leu Ala Arg Asp
1 5 10 15
Glu Lys Gly Asn Val Leu Leu Glu Asp Gly Lys Gly Arg Cys Pro
20 25 30
Phe Asp Pro Asn Phe Lys Ser Thr Ala Leu Val Val Asp Gly Glu
35 40 45
Leu Tyr Thr Gly Thr Val Ser Ser Phe Gln Gly Asn Asp Pro Ala
50 55 60
Ile Ser Arg Ser Gln Ser Leu Arg Pro Thr Lys Thr Glu Ser Ser
65 70 75
Leu Asn Trp Leu Gln Asp Pro Ala Phe Val Ala Ser Ala Tyr Ile
80 85 90
Pro Glu Ser Leu Gly Ser Leu Gln Gly Asp Asp Asp Lys Ile Tyr
95 100 105
Phe Phe Phe Ser Glu Thr Gly Gln Glu Phe Glu Phe Phe Glu Asn
110 115 120
Thr Ile Val Ser Arg Ile Ala Arg Ile Cys Lys Gly Asp Glu Gly
125 130 135
Gly Glu Arg Val Leu Gln Gln Arg Trp Thr Ser Phe Leu Lys Ala
140 145 150
Gln Leu Leu Cys Ser Arg Pro Asp Asp Gly Phe Pro Phe Asn Val
155 160 165
Leu Gln Asp Val Phe Thr Leu Ser Pro Ser Pro Gln Asp Trp Arg
170 175 180
Asp Thr Leu Phe Tyr Gly Val Phe Thr Ser Gln Trp His Arg Gly
185 190 195
Thr Thr Glu Gly Ser Ala Val Cys Val Phe Thr Met Lys Asp Val
200 205 210
Gln Arg Val Phe Ser Gly Leu Tyr Lys Glu Val Asn Arg Glu Thr
215 220 225
Gln Gln Trp Tyr Thr Val Thr His Pro Val Pro Thr Pro Arg Pro
230 235 240
Gly Ala Cys Ile Thr Asn Ser Ala Arg Glu Arg Lys Ile Asn Ser
245 250 255
Ser Leu Gln Leu Pro Asp Arg Val Leu Asn Phe Leu Lys Asp His
260 265 270
Phe Leu Met Asp Gly Gln Val Arg Ser Arg Met Leu Leu Leu Gln
275 280 285
Pro Gln Ala Arg Tyr Gln Arg Val Ala Val His Arg Val Pro Gly
290 295 300
Leu His His Thr Tyr Asp Val Leu Phe Leu Gly Thr Gly Asp Gly
305 310 315

Arg	Leu	His	Lys	Ala	Val	Ser	Val	Gly	Pro	Arg	Val	His	Ile	Ile
														330
				320				325						
Glu	Glu	Leu	Gln	Ile	Phe	Ser	Ser	Gly	Gln	Pro	Val	Gln	Asn	Leu
														345
				335				340						
Leu	Leu	Asp	Thr	His	Arg	Gly	Leu	Leu	Tyr	Ala	Ala	Ser	His	Ser
														360
				350				355						
Gly	Val	Val	Gln	Val	Pro	Met	Ala	Asn	Cys	Ser	Leu	Tyr	Arg	Ser
														375
				365				370						
Cys	Gly	Asp	Cys	Leu	Leu	Ala	Arg	Asp	Pro	Tyr	Cys	Ala	Trp	Ser
														390
				380				385						
Gly	Ser	Ser	Cys	Lys	His	Val	Ser	Leu	Tyr	Gln	Pro	Gln	Leu	Ala
														405
				395				400						
Thr	Arg	Pro	Trp	Ile	Gln	Asp	Ile	Glu	Gly	Ala	Ser	Ala	Lys	Asp
														420
				410				415						
Leu	Cys	Ser	Ala	Ser	Ser	Val	Val	Ser	Pro	Ser	Phe	Val	Pro	Thr
														435
				425				430						
Gly	Glu	Lys	Pro	Cys	Glu	Gln	Val	Gln	Phe	Gln	Pro	Asn	Thr	Val
														450
				440				445						
Asn	Thr	Leu	Ala	Cys	Pro	Leu	Leu	Ser	Asn	Leu	Ala	Thr	Arg	Leu
														465
				455				460						
Trp	Leu	Arg	Asn	Gly	Ala	Pro	Val	Asn	Ala	Ser	Ala	Ser	Cys	His
														480
				470				475						
Val	Leu	Pro	Thr	Gly	Asp	Leu	Leu	Leu	Val	Gly	Thr	Gln	Gln	Leu
														495
				485				490						
Gly	Glu	Phe	Gln	Cys	Trp	Ser	Leu	Glu	Glu	Gly	Phe	Gln	Gln	Leu
														510
				500				505						
Val	Ala	Ser	Tyr	Cys	Pro	Glu	Val	Val	Glu	Asp	Gly	Val	Ala	Asp
														525
				515				520						
Gln	Thr	Asp	Glu	Gly	Gly	Ser	Val	Pro	Val	Ile	Ile	Ser	Thr	Ser
														540
				530				535						
Arg	Val	Ser	Ala	Pro	Ala	Gly	Gly	Lys	Ala	Ser	Trp	Gly	Ala	Asp
														555
				545				550						
Arg	Ser	Tyr	Trp	Lys	Glu	Phe	Leu	Val	Met	Cys	Thr	Leu	Phe	Val
														570
				560				565						
Leu	Ala	Val	Leu	Leu	Pro	Val	Leu	Phe	Leu	Leu	Tyr	Arg	His	Arg
														585
				575				580						
Asn	Ser	Met	Lys	Val	Phe	Leu	Lys	Gln	Gly	Glu	Cys	Ala	Ser	Val
														600
				590				595						
His	Pro	Lys	Thr	Cys	Pro	Val	Val	Leu	Pro	Pro	Glu	Thr	Arg	Pro
														615
				605				610						
Leu	Asn	Gly	Leu	Gly	Pro	Pro	Ser	Thr	Pro	Leu	Asp	His	Arg	Gly
														630
				620				625						
Tyr	Gln	Ser	Leu	Ser	Asp	Ser	Pro	Pro	Gly	Ser	Arg	Val	Phe	Thr
														645
				635				640						
Glu	Ser	Glu	Lys	Arg	Pro	Leu	Ser	Ile	Gln	Asp	Ser	Phe	Val	Glu
														660
				650				655						
Val	Ser	Pro	Val	Cys	Pro	Arg	Pro	Arg	Val	Arg	Leu	Gly	Ser	Glu
														675
				665				670						
Ile	Arg	Asp	Ser	Val	Val									
				680										

<210> 26

<211> 137

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 4248993CD1

<400> 26

Met	Gly	Arg	Lys	Leu	Asp	Leu	Ser	Gly	Leu	Thr	Asp	Asp	Glu	Thr
1				5					10				15	
Glu	His	Val	Leu	Gln	Val	Val	Gln	Arg	Asp	Phe	Asn	Leu	Arg	Lys
				20					25				30	
Lys	Glu	Glu	Glu	Arg	Leu	Ser	Glu	Leu	Lys	Gln	Lys	Leu	Asp	Glu
				35					40				45	
Glu	Gly	Ser	Lys	Cys	Ser	Ile	Leu	Ser	Lys	His	Gln	Gln	Phe	Val
				50					55				60	
Glu	His	Cys	Cys	Met	Arg	Cys	Cys	Ser	Pro	Phe	Thr	Phe	Leu	Val
				65					70				75	
Asn	Thr	Lys	Arg	Gln	Cys	Gly	Asp	Cys	Lys	Phe	Asn	Val	Cys	Lys
				80					85				90	
Ser	Cys	Cys	Ser	Tyr	Gln	Lys	His	Glu	Lys	Ala	Trp	Val	Cys	Cys
				95					100				105	
Val	Cys	Gln	Gln	Ala	Arg	Leu	Leu	Arg	Ala	Gln	Ser	Leu	Glu	Trp
				110					115				120	
Phe	Tyr	Asn	Asn	Val	Lys	Ser	Arg	Phe	Lys	Arg	Phe	Gly	Ser	Ala
				125					130				135	
Arg	Phe													

<210> 27

<211> 117

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 5402418CD1

<400> 27

Met	Lys	Phe	Gln	Tyr	Lys	Glu	Asp	His	Pro	Phe	Glu	Tyr	Arg	Lys
1				5					10				15	
Lys	Glu	Gly	Glu	Lys	Ile	Arg	Lys	Lys	Tyr	Pro	Asp	Arg	Val	Pro
				20					25				30	
Val	Ile	Val	Glu	Lys	Ala	Pro	Lys	Ala	Arg	Val	Pro	Asp	Leu	Asp
				35					40				45	
Lys	Arg	Lys	Tyr	Leu	Val	Pro	Ser	Asp	Leu	Thr	Val	Gly	Gln	Phe
				50					55				60	
Tyr	Phe	Leu	Ile	Arg	Lys	Arg	Ile	His	Leu	Arg	Pro	Glu	Asp	Ala
				65					70				75	
Leu	Phe	Phe	Phe	Val	Asn	Asn	Thr	Ile	Pro	Pro	Thr	Ser	Ala	Thr
				80					85				90	

Met Gly Gln Leu Tyr Glu Asp Asn His Glu Glu Asp Tyr Phe Leu
 95 100 105
 Tyr Val Ala Tyr Ser Asp Glu Ser Val Tyr Gly Lys
 110 115

```
<210> 28  
<211> 1058  
<212> DNA  
<213> Homo sapiens
```

<220>
<221> misc_feature
<223> Incyte ID No.: 2417014CB1

<210> 29
<211> 2235
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 2634931CB1

gatgggacga ggagctggcc gccttcgcca aggctacgc acggcagtgc gtgtggggcc 600
 acaacaagga ggcggggcgc cgccggcaga atctgttgc catcacagac gagggcatgg 660
 acgtgccgtt ggccatggag gatgtggacc acgagcgtga gcactacaac ctcagcgccg 720
 ccacctgcag cccaggccag atgtgcggcc actacacgc ggtggatgg gccaagacag 780
 agaggatcg ctgtggttcc cacttctgtg aagaagctcca gggtgtttag gagaccaaca 840
 tcgaattact ggtgtcaac tatgagcctc cggggAACGT gaaggggaaa cggccctacc 900
 aggaggggac tccgtctcc caatgtccct ctggctacca ctgcaagaac tccctctgtg 960
 aaccatcg aagccccgaa gatgtcagg attgcctta cctggtaact gaggccccat 1020
 cttccggc gactgaagca tcagactcta ggaaaatggg tactccttct tcccttagcaa 1080
 cggggattcc ggctttcttg gtaacagagg tctcaggctc cctggcaacc aaggctctgc 1140
 ctgctgtgaa aaccaggcc ccaacttctt tagcaacgaa agaccgccc tccatggcaa 1200
 cagaggctcc accctgcgtt acaactgagg tcccttccat tttggcagct cacagcctgc 1260
 ctccttggaa tgaggagcca gttacctcc ccaaatacgac ccatgttctt atcccaaaat 1320
 cagcagacaa agtacacgac aaaacaaaag tgccctctag gagcccagag aactctctgg 1380
 aaaaaagat gtccctgaca ggggcaaggg agtcttacc ccatgcccag gaggaggctg 1440
 aggctgagggc tgagttgcct cttccagtg aggtcttggc ctcagttttt ccagcccagg 1500
 acaagccagg tgagctgcgtt gccacactgg accacacggg gcacacactcc tccaagtccc 1560
 tgcccaattt cccaaatacc tctgcccaccg ctaatgcccac ggggtggcgt gccctggctc 1620
 tgcagtcgtc cttgccagggt gcagaggccc ctgacaagcc tagcgtctgt tcagggctga 1680
 actcgggccc tggcatgtg tggggccctc tcctggact actgctctg cctcctctgg 1740
 tggggctgg aatcttctga aggggatacc actcaaaggg tgaagaggta agctgtcctc 1800
 ctgtcatctt cccacccctg tccccagccc ctaaaacaaga tacttcttgg ttaaggccct 1860
 ccggaaaggaa aaggctacgg ggcattgtcc tcatacacacc atccatctg gaggcacaag 1920
 gcctggctgg ctgcgtc agggggccgc ctgaggactg cacacgggc ccacacctct 1980
 cctccccctc ctcctgtgtt cctgggggtt ggaggattt agggagctca ctgccttacct 2040
 ggccctggggc tgcgtccca cacagcatgt gcgtctccc tgagtgcctg ttagctggg 2100
 gatggggatt cttagggca gatgaaggac aagccccact ggagtgggt tcttgagtg 2160
 ggggaggcag ggacgaggga agggaaagcaa ctcctgacte tccaataaaa acctgtccaa 2220
 cctgtgaaaa aaaaaa 2235

<210> 30
 <211> 1559
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 110960CB1

<400> 30
 cccaggcccc gcccctcttcc ccccccggc cgtatggtacg cgccggctcg cctggccccc 60
 ctgcagtggaa tgggtgttgc acccacgcgg aggaagggaa agacgcaggc aggctgcgg 120
 taaccaagcg gccacccggg cctcaggacc cccttccccg agagacggca ccatgaccca 180
 gggaaagctc tccgtggcta acaaggcccc tgggaccgg gggcagcagc aggtgcattgg 240
 cgagaagaag gaggctccag cagtgccttc agccccaccc tcctatgagg aagccaccc 300
 tggggagggg atgaaggcag gggccttccc cccagcccc acagcgggtc ctctccaccc 360
 tagctggcc tatgtggacc ccagcagcag ctccagctat gacaacgggtt tccccacccgg 420
 agaccatgag ctcttcacca ctttcagctg ggatgaccag aaagttcgta gagttttgt 480
 cagaaaaggcc tacaccatcc tgctgattca gctgtgggt accttggctg tcgtggctct 540
 cttaactttc tgtgaccctg tcaaggacta tgtccaggcc aaccacggct ggtactggc 600
 atccatgtgtt gtttttttgg caacctaccc gaccctggct tgctgttctg gaccaggag 660
 gcattttcccc tggaaacctga ttctcctgac cgtttaacc ctgtccatgg cctacctcac 720
 tgggatgctg tccagctact acaacaccac ctccgtgtcg ctgtgcctgg gcatcacggc 780
 cttgtctgc ctctcagtc cctgttccag aagttcgact tcacctcctg 840

ccagggcgtg ctttcggtgc ttctcatgac tcttttcttc agcggactca tcctggccat 900
 ctccttaccc ttccaatatg tgccctggct ccatgcagtt tatgcagcac tggagcggg 960
 tgtatttaca ttgttcctgg cacttgacac ccagttgtcg atggtaacc gacgcaactc 1020
 gctgagccct gaggagtata ttttggac cctcaacatt tacctagaca tcatctatat 1080
 cttcaccttc ttctgcagc ttttggcac taaccgagaa tgaggagccc tcctgcccc 1140
 accgtcctcc agagaatgcg cccctctgg ttccctgtcc ctcccctgcg ctctgcgag 1200
 accagatata aaacttagctg ccaacccagc ctgtggccag gtcaactgtct accccccagccc 1260
 agcccagccc tctggcgctt gtacatacgc catggggacc ctgaggaact gaggccacgt 1320
 caatccctgt gccgccccat tcgcccgtt catcttccaa actgggacgg tcaggctga 1380
 aggctcctct gggtttgggg gtccaaaggga caaggaggag aagcctagca ggatttcaga 1440
 tgcaggagag agacccaggg aagcccgca gagccctgag ccccaactgca attctcctag 1500
 ggctgcacat catgtggctt agggacactg tctgcatcca gtctgtgtct cctgtcttc 1559

<210> 31
 <211> 876
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 380721CB1

<400> 31
 cccacgcgtc cgccccacgcg tccgattttt catctttttt caggttgacg atgtgtcaca 60
 ctgtgttaagg gaatcgcatg gagatgggca ttccgaactg ttaatgggga catgggactc 120
 cagttgtctc tgatcaactg tgtggatttt cctggcgtag aacgacagaa gccgctagta 180
 agtcgccaag acctacagca ggaattctgc accaaagggc ataaaatctt gtatttaa 240
 tttgcacatctg ggagaatgtc tgagcaagga gacctaatac aggcaatagc agaggaagga 300
 gggactgagc aggagacggc cactccagag aacggcattt taaaatcaga aagtctggat 360
 gaagaggaga aactggaact gcagaggcg ctggaggctc agaatcaaga aagaagaaaa 420
 tccaaatgtcag gaggcggaaa aggtaaactg actcgcatgc ttgctgtctg tgaggaatct 480
 tctgcacagac caggagggtga aagtcttcag ggtcagactc tctgaaaact gcataatngga 540
 agggatttca aaagggttag gttaaaaatg aaattaaaag taggnacagt agtgctgaat 600
 tttccctcaaa ggctctctt tgataaggct gaaccaaata taatcccaag aatactctt 660
 cttcccttgt tggagatgtc ttacctctca gctccccaaa atgcacttgca ctataagaaa 720
 cacaattgtct ggttcatata aacttaggaa atagtgaata aggtgcattt aactttggag 780
 aaatactttt atggctttgg tggagatttc tcaataactgc caaagttgtc cagaaatcga 840
 tctgagctga tggctgctt tagttcatat tatcat 876

<210> 32
 <211> 1521
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 829443CB1

<400> 32
 caagctggcc ctgcacggct gcaagggagg ctctgtgga caggccaggc aggtggccct 60
 caggaggtgc ctccaggcgcc ccagtggcc tgaggccca gcaagggtca gggccatct 120
 ccagtcccag gacacagcag cggccaccat ggccacgcct ggctccagc agcatcagca 180
 gccccccagga cgggggaggc acaggtggcc cccaccaccc ggaggagcag ctctgcccc 240

tgtccgggggg	atgactgatt	ctcctccgccc	aggccaccca	gaggagaagg	ccaccggcc	300
tggaggcaca	ggccatgagg	ggctctcagg	aggtgctgt	gatgtggctt	ctgggtttgg	360
cagtggcg	cacagagcac	gcctaccggc	ccggccgtag	ggtgtgtgt	gtccgggctc	420
acggggaccc	tgtctccgag	tgcgtgtgc	agcgtgtgt	ccagcccttc	ctcaccacct	480
gcgacgggca	cggggcctgc	agcacccatt	gaaccatcta	taggaccggc	taccggccca	540
gccctgggct	ggccccctgccc	aggcctcgct	acgcgtgt	ccccggctgg	aagaggacca	600
gcgggcttcc	tggggcctgt	ggagcagcaa	tatgccagcc	gcatggccgg	aacggaggga	660
gctgtgttcca	gcctggccgc	tgccgcgtcc	ctgcaggatg	gccccgtgac	acttgcctgt	720
cagatgtgga	tgaatgcagt	gctaggaggg	ggggctgtcc	ccagcgtgtc	gtcaacacccg	780
ccggcagttt	ctgggtgccag	tgttggggagg	ggcacagecc	gtctgcagac	ggtacactt	840
gtgtgccccaa	gggagggccc	cccagggtgg	cccccaaccc	gacaggagtg	gacagtgc当地	900
tgaaggaaaga	agtgcagagg	ctgcagttca	gggtggaccc	gctggaggag	aagctgcagc	960
tgggtctggc	cccaactgcac	agcctggcc	cgcaggcact	ggagcatggg	ctccggacc	1020
ccggcagctt	cctgggtgcac	tccttccagc	agctcgcccg	catcgactcc	ctgagcgagc	1080
agatttcctt	cctggaggag	cagctgggt	cctgctccctg	caagaaagac	tcgtgactgc	1140
ccagcgcccc	aggctggact	gagccctca	ccggccctcg	cagccccat	gccccctgccc	1200
aacatgtgg	gggtccagaa	gccacccctgg	ggtgactgag	cggaaggcca	gcaaggccct	1260
tccttccttt	ccttcctcccc	ttcttcggg	ggctccccag	accctggcat	ggatgggt	1320
gggatcttct	ctgtgaatcc	accctggct	accccccaccc	tggctacccc	aacggcatcc	1380
caaggccagg	ttggccctca	gctgagggaa	ggtacgagct	ccctgctgg	gcctgggacc	1440
catggcaca	gccaggcagc	ccggaggctg	ggtggggccct	cagtggggc	tgctgcctga	1500
cccccagcac	aataaaaaatg	t				1521

<210> 33

<211> 1349

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte ID No.: 1470058CB1

<400> 33

```

aggctgggct gattcccttc tgtgctcccc catgcttccc gaacagtgc aggtgagtg 60
aaaccaggta tcctgagccc catccctgat gtcctactc catccctgct atatccctag 120
cctgactttc cagccctctg caggctctg cctctaacc a gttctaccc cagccccatc 180
tctgccccctg cttaggactt cgcttttgtg gcaagtgaca aagatacg tctgatcg 240
tgccatgtgt ttgcgtgtga tgtccctgcc aaggccattt ccagtgcctt acatgggott 300
tgtgcccaga tcttgcaga gcgagtagag gtcagtgggt atgccttgc ctgctcccc 360
gaccatctt ctcctgaaga cctgcccacgg caagtggagc tgctgatgc gtaagccaa 420
gctgtcaga agtacgaggc actgtatatg gggacactgc cagtcaccaa gccatgggc 480
atggatgtgc tgaacgaggc cattggtaacc ctcaccgcca ggggggaccc gaatgcctgg 540
gtccccacca tgcgtcgtgt gtctgactt ctcatgactg cacatcccat tcaggcagag 600
gccagtacag aggaggagcc attgtggcag tgccctgtgc gccttgcac atttatttgt 660
gttggcccgcg acccacacac ctttggccctc atcgctgacc tggggcgtca gagttccag 720
tgcgcaggct tctggtgcca gccccatgca gggggactct ctgaagctgt gcaggctgcc 780
tgtatggttc agtaccagaa gtgtctgtg gcctctgcag ctcgaggcaaa gccttgggt 840
gcccaggccc gtggccgcct gcggtcaag cgaccagct ccatggattt cccaggaggt 900
ccccctgcccc tccccctgct caaaggaggg gtggcggtg caggggcaac ccctcgaaag 960
cggggtgtct tctttttct tgcgtcctt cgcgtaaac cctctctgct ccatatgccc 1020
taaacttata tgggaaggct ggggaagtag gtcgtgggtc catgcctaaac tctgtaccgt 1080
tttattcctc aaggctata gcctgtcaact ctttgaagcc ttctctgcct gtcctccga 1140
tccttgcaca cgcgtctattt attgccccat ttattgtta tacggatgac tggggaggc 1200
tgcaccacaa cgtaggaccc tggctccccctt ttccctgggt ccttgcgttc ttggccccc 1260

```

tccaaacctg gacagttggc tctacctcg taacacttta tagcaaaatc agtgcaaata 1320
 aaaatccctc agtgacctca aaaaaaaaaa 1349

<210> 34
 <211> 1338
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1554947CB1

<400> 34
 ggctgttgct gtggtttccct gagttgctgc tgctgcggcg gcggcagcgg cgtctgtgct 60
 tgtggagggtg tcggcctctg ggccggatgtt gacattgtgt tttgttatt gctgatggta 120
 atggcggcgg cggtggcgcc gacggtccag accccatccc ctctgttagcc ggagccgaga 180
 cagccgacag cgaactccgc ggctctggag ccggcggcag cggcgaetcc cctcagcctc 240
 cgccgcctcg cccgcccgtta ccccgccgca aaccggggta gtcaggccct ttgggcaggg 300
 gagctcggag gtcaggatg gcgatttcg acgaaatcta tgaggaagag gaggacgagg 360
 agcggggccct ggaggagcag ctgctcaagt actcgccgga cccgggtggc gtccgcggct 420
 cccgtcacgt caccgtatcc ggactgagca acaaatttga atctgaattt ccttcttcat 480
 taactggaaa agtagctctt gaagaattta aagccagcat caacagagtt aacagttgtc 540
 ttaagaagaa ctttcctgtt aatgtacgtt ggctactttg tggctgcctt tggtgtgtc 600
 gcacatttagg ttgcagtatg tggccagttt tttgcctcag taaaagaaca cgaagatcga 660
 ttgagaagtt attagaatgg gaaaacaata gtttatacca caagctgtgc ttgcatttgg 720
 gactgagcaa aaggaaatgt gaaacgaata acatgatgga atatgtcattt ctcatagaat 780
 ttttacccaa gacaccgatt tttcgaccag attagcattt actttatttt tagagacttt 840
 ccaagtatgt tgcctttcca atggcgtt gttttgtgt ctccctgggttg tgacataaca 900
 ttgggttctac agaatcggtt ggtttttttt ttgtttttgt tttttttttt tttttaaata 960
 accgcattttt ctaagtgtgc atttttgtca atctttgcaaa cagttatttc atacagatgt 1020
 ttaatactta agttattgtg ctctttctg ttatgtattt tgattttcaa ggattacttt 1080
 tttgtattat caaaaaaaaa catttgaact tagcataaaaa agtggccagc cttttttattt 1140
 ttgtcaccaa ggtacacaca gtcctttatt tataaattcc ttaacagaga aaaacacctt 1200
 tgtaaggctc aacttaccta ttccagcaag cacactttt ctgtcatttt ttctttctt 1260
 tcaaatttga tattgtcattt attttaaaat agtaagtgtt cttaatagt cttttggac 1320
 ctaacataacc ctttctca 1338

<210> 35
 <211> 2120
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1690245CB1

<400> 35
 tccctctcac caccctcttc tgccttatgag cggggaaacaa aaaggccaga tgacagatat 60
 gatacaccaa cttctaaaaa gaaagtacga attaaagacc gcaataaaact ttctacagag 120
 gaacgcccga agttgttga gcaagaggtg gctcaacggg aggctcagaa adaacagcaa 180
 cagatgcaga acctggaaat gacatcacca ctgccttatg actcttttgg ttataatgcc 240
 ccgcatttcc ctttgcgtgg ttacccacca gtttatecca tgcaggccca tggatccc 300
 agcaacccta atgctggaaa ggtgttcctg cccacaccca gcatggaccc agtgtgttct 360

cctgctcctt atgatcatgc tcagcccttg gtgggacatt ctacagaacc ctttctgcc 420
cctccaccag taccagtggt gccacatgtg gcagctcctg tggaaatttc cagttcccag 480
tatgtggccc agagtatgg tgttagtacac caagactcca gcgttctgt cttgccatg 540
cggcccccg gcccaggtaa gggacagaat tataatgtttt gggattcaaa ccaacagtct 600
gtcagtgtac agcagcaga ctcttcgtca cagtctcaag caaccatata ttatcaagga 660
cagacatgtc caacagtcta tggtgtgaca tcaccttatt cacagacaac tccaccaatt 720
gtacagagtt atgcccagcc aagtcttcag tatatccagg ggcaacagat tttcacagct 780
catccacaag gagtggttgt acagccagcc gcagcagtga ctacaatagt tgcaccagg 840
cagcctcagc cttgcagcc atctgaaatg gttgtgacaa ataatctttt ggtctccg 900
ccccctctc ctcccaaacc aaaaaccatt gtcttaccc ccaactggaa gacagctcg 960
gatccagaag ggaagattta ttactaccat gtgatcaca ggcagactca gtgggatcct 1020
cctacttggg aaagcccagg agatgtatgc agccttgagc atgaagctga gatggacctg 1080
ggaactccaa catatgtatga aaaccccatg aaggcctcga aaaagcccaa gacagcagaa 1140
gcagacacctt ccagtgaact agcaaagaaa agcaaagaag tattcagaaa agagatgtcc 1200
cagttcatcg tccagtgcct gaacccttac cggaaacactg actgcaaagt gggagaatt 1260
accacaactg aagactttaa acatctggct cgcaagctga ctcacgggt gatgaataag 1320
gagctgaagt actgtaaagaa tcctgaggac ctggagtgtca atgagaatgt gaaacacaaa 1380
accaaggagt abattaagaa gtacatgcag aagtttgggg ctgtttacaa acccaaagag 1440
gacactgaat ttagtgtact gttggccag ggtgggagga tgggtggtca ggtaaagacag 1500
actctaggaa gaggaaatcc tggggcctt tctgtcccac ccctgtcagc actgtgtctac 1560
ttagtataca tcaccctggg gaattcaacc ctgcagatgt caactgttca ggcacaaaaat 1620
gaactccatc tacaagtgtat tacctagttg tgagctgttgc gcatgtggtt agaagccatc 1680
agaggtgcaaa ggcttagaa aagaccctgg ccagacactga ctccactt aaacctgggt 1740
cttctccttg gcggtgctgt cagcgcacag acccatgcgc atccccaccc acaacccttt 1800
accctgtatga tctgtattat attttaatgt atatgtgaat atattgaaaa taatttggtt 1860
tttctgggtt ttgtttgggt ttctgttttgc cttttagcct ctacatgtca ggatcacagg 1920
aagactttgt aaggacagtt taagttctcc tgcaagggtt aatttggttt catgtaaata 1980
ttccaaagca ggctgccttg tggtttggc cagccctgtg ctatgttgc aagattgatt 2040
tactgcttaa aatcacttta ctttatccaa ttttactga actttttatg taaaaaaaaa 2100
aaatcaattt aaaaaaaaaaa 2120

<210> 36
<211> 642
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte' ID No.: 1878262CB1

<400> 36
ctcctgcact aggctcttag ccagggatga tgcgtcgcc cgcgcgcgc tgctgtgcc 60
ggcaaccacc ccatgcccgt agggcggtgc ttgtgtgtcc cctgttcctt ttacccccc 120
tggcagcaggc tgacggggc ccaaaccat gtgacaccat ataccaggc ttgcggagt 180
gtctcatccg ctggggggac agcatggcc gggggggc gctggagacc atctgcagg 240
cttggaatga ctccccatgcc tgtgcctctc aggtccctgtc aggtgtccg gaggaggcag 300
ctgcagtgtg ggaatcacta cagcaagaag ctcggccaggc ccccccgtccg aataacttgc 360
acactctgtg cggtggcccg gtgcattttc gggagcgccg cacaggctcc aaaacccaacc 420
aggagacgct gggggctaca gcgcctgcac tccccatggc ccctgcggcc caactgtgg 480
cggtgtctct ggtctctggcc tacctcctga ggctctggc ctagtttgtt gggttggta 540
gcagcgccccg tacctccaggc cctgtctgg cggtggttgtt ccaggtctg cagagcgccag 600
cagggctttt cattaaaggt atttatattt gaaaaaaaaaa aa 642

<210> 37
<211> 2536
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2253519CB1

<400> 37
gccgtggc tcaacgcct cacgggtggac gcccacacag tcgtcagcca cccggacaag 60
tactgcttct actgcccggc gctgctgatg accgtggctg ggctgaagct gctgcgctca 120
gcctctgct gccccccaca gcagtacctg acgttggctt tcaccgtcct gctcttccac 180
tttgactacc cgccgccttc ccagggcttt ctgcttgcact acttccctcat gtccctgctt 240
tgcagcaagc tggggactt gctgtacaag ctgcgttccg tgctgaccta catcgcccc 300
tggcagatca cctggggctc ggctttccac gcttttccc agccgttgc cgtgccacac 360
tcggccatgc tggcgttcca ggccctgctc tcggggctct tctccacgccc tctcaaccca 420
ctgctaggca gtggcgtctt catcatgtcc tacgctggc ccctcaagtt ctgggagcgc 480
gactacaaca ctaaacgtgt ggatcattcc aacacccggc tggtcacaca gctggacagg 540
aaccctggcg ctgatgacaa caacctcaac tccatcttct atgagcactt gacacgttgc 600
ctgcagcaca cactgtgtgg ggacctggc ctggggcgct ggggcaacta tggccctggt 660
gactgttcg tcctggcctc tgactacctc aacgccttgg tgcacccat cgagggttggc 720
aatggcctcg tcaccttcca gctgcgtggc cttgagttcc ggggcactta ctgcccagcag 780
cgcgagggtgg aggctatcac cgagggtgtg gaggaggacg agggctgttgc ctgctgtgaa 840
cctggccacc tgccacgggt cctgtcccttc aatgctgcct ttgggcagcg ctggctggct 900
tgggaggtaa cagccagcaa gtacgtgtg gagggctata gcattagtga caataatgct 960
gcctccatgc tgcaggtttt cgacccctgc aagatcctca tcacctacta tgtcaagagc 1020
atcatctact acgtgagccg ctcaccaaag ctggaggtgt ggctcagcca tgagggcattc 1080
acggcagccc tgaggcctgt ggggtgccc ggctatgccc actcggatcc caccccttcg 1140
ctgagtgtgg atgaggacta tgacccctgc ctgtctggc ttcgcgtgcc ctccctttgt 1200
gctgtgcacc tcgagtggat ccagttccgc gcctccggc gcaccaggcc cgtggaccag 1260
gattggaaact ccccgcttggt cacgctgtgt tttggcctgt gtgtgctggg cggccgggccc 1320
ctggggacag cctctcacag catgtctgca agcctggage cttccctcta cggcctgcac 1380
gccctgttca agggggattt tcgcatcacc tccccacgtg acgagttggg ctttgcgcac 1440
atggacctgc ttcacccgtt tggcgttccgat ggggttgcga tggccctcaa gtttaccatc 1500
gaccacttca cgtccccaga tgaatatgag gagccagcag ccctatacaga tgcatttgcg 1560
gccaacgagg agcggcttgtt catctcacat gagggtgacc cagcatggcg cagcgcacate 1620
ctcagcaaca cggccctccct gctggcgctg cgccatgtcc tggatgatgc ctccgcacgag 1680
tacaagatca tcatgctcaa cccggcgccac ctcagcttcc gagtcatcaa ggtgaaccgg 1740
gagtgcgtgc gcccgttgtt gggggggcag cagcaggagc tgggtttctt gggcaaccgc 1800
aaccccgagg gtggcagcat ccagaacgcc aagcaggcgc ttgcacat gatcaactcc 1860
tcctgtgacc agccgctggg ctacccatc tacgtgtcgc ctctcaccac ctgcgtggct 1920
ggcagccacc cccagctacg ggactgtgg ggtggccca tcagcctggg tgccattgcc 1980
caactggctcc tgcgcacctg ggagaggctt cacaagggtt gtggcgcggc ctgcaatagt 2040
ggcgaaaacg tggatgattt agactgttagt gggggcggtg gcctgacccctc ctccagcaat 2100
aaccccccccg tggcacacccc cacacctgag aacacggcag gcaatggtga ccaacccctc 2160
ccaccaggcc ctggctgggg gcccggctt ccctctgtt gctctgggtt gggcgcccc 2220
ccaccccttc tgcagtgcc tccccctcg tccctggac caccccttc atcgcctatc 2280
cccacagagg gtccccggac ctcacggccc cctggccgg gtctccttag tttctgaggc 2340
cccagtggaa agtggagccct gggggccgg aaggggctgg gaggatctga cggggagcc 2400
gcctcaggga gccccaaagg agtacccccc aaatctcagg taaggcacct gtgggagggt 2460
tggtcccag aaggctaagg cctgctcacc cgcacccctc tcccccttc cccaggcgcc 2520
tctagaccc tgcctc 2536

<210> 38
<211> 3957
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2888437CB1

<400> 38
ggaaagctgca gagaaaagtca gctggataaa ggacaaaactt ctgcataattt attatcagaa 60
cagcattgac gacaaaactgt tggttagagaa aatctttgc cagtatcttgc tccccccacaa 120
cctggaaaca gaagagagaa tgaaatgc ttatattactt tatgcttagtt tggatccaaa 180
tgctgtaaaaa gctctcaacg aaatgtggaa gtgtcagaac atgcttcgga tccatgtacg 240
cgaactattt gatttgcaca agcagcctac atcagaggct aactgttctg ccatgtttgg 300
aaaactgtatg accatagcaa agaatttgc tgaccccccggg aaagcacaag attttgtgaa 360
gaaatttaac cagggttctcg gcgtatgtga gaaaacttcgg tctcagttgg agttattaat 420
tagcccaacc tggcttgc aacaagcaga tattttgtgt agagaaatag cccggaaact 480
tgcaaattt aagcaaccaa caaatccccc tttagagatg gtcaaatttc tgttggaaag 540
aatcgcacct gtgcacattt attcagaagc cataagtgc ctagtggaaat tgatgaataa 600
gtcaatagag gggacagcag atgatgaaga ggagggtgt agtccagata cagctatccg 660
ttcaggactt gaaccttcta aggttctgc ttttacacat cctacccgt tccactctgc 720
agagacatat gagtccttgc tacagtgcct aagaatggag gatgacaagg tagcagaagc 780
tgcatttcaaa atttttagaa atacagggtca caaaatagaa acagacccccc cccagataacg 840
atcgacccctt atccccattt tacatcaaaa agcaaaagagg ggtactccac accaagcaaa 900
acaggctgtg cactgtatac acgccatatt cacaatataaa gaagtccagc ttgcacagat 960
ttttgagcca ctcaagttagga gtctgaatgc tgatgtgcca gaacaactt taactccatt 1020
agtttcattt ggcacacattt ctatgttagc accagatcag tttgcttccc caatgaaatc 1080
tgcatttgc aatttttattt tgaaagatct gctaatttgc gacagggtca caggtgaaaa 1140
gaatggaaaa ctgtggctc cagatgaaga gttttccccc gaagtacttag caaaggta 1200
ggcaattttttaa ctctggtaa ggtggctgtt ggttatgaaa aacaaccagt ctaaatctgc 1260
caattcaacc ctccggttat tattcagcgat gttggtttagt gagggtgacc tgacagagca 1320
aaagaggatc agtaaatctg atatgtctcg ctgcgattt gctgctggta gtgccataat 1380
gaagcttgc tggaaaccc ttttaccatga aatttttacc ccagaacagt ttcaatctgc 1440
tgcacttgc attaatgtatg agtgttacca agtaaggcag atatttgc tggaaatc 1500
taaggcactt gtgaagttac tgctccattt ggagtatatg gogatcttgc cttgtgtgc 1560
caaagatctt gtgaaggaga gaagagcaca cgcacgacaa ttttacttga aaaatatcag 1620
tatacgccagg gaatacattt agcagaatcc tatggctact gagaatttattt tattacttgc 1680
gcctgaatattt gtagttccat acatgattca cctgcttagcc catgatcccg attttaca 1740
atcacaagat gttgtatcgc ttctgtat ctttgc ttttgc ttttgc ttttgc ttttgc 1800
tttaatgaca aagaatgaaa acaatagcc tggctttatg aagaagatgg cagagaacat 1860
caagtttaacc agagatgccc agtctccaga tgaatccaa acaatgtaaa aactgtatac 1920
agtatgtatg gtggctctt caatgaaattt ttttacacaa ctttgc ttttgc ttttgc ttttgc 1980
acccaaaggac ccagtctcccg aagagacaag agtacttgc ttaacaggaa agccaaaggc 2040
cgataagatc tatatttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2100
tgctggatgtt cttaggtgc taaataagcc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2160
tagaagactt ggcactgaga ctggaaatc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2220
aacccggaaat cgatcaaggg aacagatc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2280
tgaagagaac ctgtgtggaa attaatttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2340
gaataagaaat attaatcgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2400
gaaaagaaca gtaacagcag ctgggtgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2460
agatgaatcg ggacccccc ccccttccaa acccaggaga ggacgtcgac ccaagtctgc 2520
atctcaggcc aatgtatc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2580
gagagctgca gtgggtcagg agagccctgg gggtttggaa gcaggtatc ccaaggcacc 2640
caaaactqcaaa gatttagccca aaaaaggcagc acccaggaga aqacaaatttgc acttacaaatc 2700

gtaaaaatgc atttgcaaag ggagaaaaatg aaggccaaac agaagcagggc tccagcttct 2760
 gcaaaaactt ggattcacaa atgtccctga acagaaaaatg aagetcaacg cagaccgtgt 2820
 gtgtctgaa gtgagctca gaacacacac tctctgcctt gaaaactaaa gagactatta 2880
 cttccctttc acatgaccac aagtccctcg atggaaatgt acagcagaaa ctcttgagag 2940
 agaggctaaa agcaactctg ttctccccct tccccttagac ttttcttacg aqaagtcaat 3000
 aattaagcaa attgcttaac acttggttcc agttctgccc tatctggagt ttaaatgcgt 3060
 aatacaccat taatttccac gctgcagttt ttatTTaaa gaaagtaca a agatgtcttt 3120
 acactgacac tgaaaattca tccatTTtag agccaggaat tcccatgtta cacagggaaa 3180
 aatagaagtc tactgaatta atTTTTaaa agaaaagaga tcagattaaa tatttctttg 3240
 ttttcttggaaaacttt tatgtataat tctttctgccc tgccacttt tctgcaaaaaa 3300
 tgagatgtac agatttccgt tccctgctat gaaaagtgtat gtggtagcaa ttttataaat 3360
 gttgcttctt gatTTTATC agagtggaaa aattaaaattt attgatttgc aagttagtaaa 3420
 cagttcatat tttgatttcc cctcatttttata gtttatata atttgcata aatgtacata 3480
 ttgtgttttggaaaactttt tttcataaag catatcaatt taaaatgggtt ttactcctg tgattatgtt 3540
 ggaatatttgc gaaTTTaaa ggagtaaaga ctgtccagca ttgggtttta taatgtttgt 3600
 caccagattt ttatTAATG aaaaaaaaaatc aattttaaa aaatagttgg a ctttggcag 3660
 ctTTTaaAGGA aagtggagg tggTTTtagga ttgctatcaa tttttagcat tggctatttt 3720
 ggaatataagt gtttgcTTT tggctatgg tctgggctca tttttaggtt ttttttagaa 3780
 aactgttgca tcaatataattt atgTTTCTTG gcattttca gcataggtaa tggcact 3840
 ttatgtgtac acataatcat attaagttt tttgcataaaa ataaatgcctt ctatgtca 3900
 tggcagtctt ttaatTTTT ttatcatatg ctttcttgc aattttttca tgtaaaa 3957

<210> 39
 <211> 3188
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3201753CB1

<400> 39
 ggggagtcgg ctaagcaatg gagaagtgtat gaggggcatt ttcatcaaac atgttctgg 60
 agatagtcca gctggcaaaa atggaacctt gaaacctggat gatagaatcg tggaggtgg 120
 tggaaatggac ctcagagatg caagccatga acaagctgtg gaagccattc gggaaagcagg 180
 caaccctgtt gttttatgg tacagagcat tataaacaga ccaagggcac ccagtcagtc 240
 agagtcagag ccagagaagg ctccattgtg cagtgtgccc ccaccccccctt cttcagccctt 300
 tgccgaaatg ggtagtgtatc acacacagtc atctgcaagc aaaatctcac aagatgtgg 360
 caaaagggat gagTTTgggtt acagctggaa aaatatcaga gagcgttatg gaaCCCTAAC 420
 aggccagactg catatgatttgc aactggagaa aggtcatatgt gttttggccc taagtcttgc 480
 tggaaacaaa gaccgatcca ggtatgtatgtt cttcatatgtt gggattgtatc caaatggagc 540
 tgcaggaaaa gatggatcgat tgcaatttgc agatgatgtt ctatgtatca atggcagat 600
 tttatatggaa agaagtccatc agaatgcctc atcaatcattt aaatgtgccctt cttctaaagt 660
 gaaaataattt tttatcagaat aataaagatgc agtgaatcatg atggccgtat gtcctggaaa 720
 tgcagtagaa cttttgcctt ctaactcaga aaatcttcaa aataaggaga cagagccaaac 780
 tgTTTactact tctgtatgcag ctgtggaccc tggatccatc taaaatgtgc aacatctgg 840
 gcttcccaag gatcagggggg gtttgggtat tgctatcagc gaagaagata cactcagtgg 900
 agtcatcata aagagcttac cagagcatgg ggttagcagcc acggatggac gactcaaagt 960
 cggagatcg atactggctg tagatgtatgaa aattttttttt gtttaccccta ttggaaaagtt 1020
 tattagcctt ctgaagacacg caaagatgac agtaaaactt accatccatg ctgagaatcc 1080
 agatcccac gctgttccctt cagcagctgg tgcagccagt ggagaaaaaaa agaacagctc 1140
 ccagtctctg atggcccac agtctggctc cccagaaccg gatgtccatcc gaaatacaag 1200
 cagatcatca acaccagcaa tttttgcTTT tggatccatc acctgccccca ttatccctgg 1260
 ctgcgaaaca accatcgaga tttccaaagg gcaacaggg ctggccctga gcatcgatgg 1320

gggttcagac acgctgctgg gtgccattat tatccatgaa gtttatgaag aaggagcagc 1380
 atgtaaaat gaaagactct gggctggaga tcagatctt gaggtgaatg gaatttgactt 1440
 gagaaaaggcc acacatgatg aagcaatcaa tgtcctgaga cagacgccac agagagtgcg 1500
 cctgacactc tacagagatg aggcccata caaagaggag gaagtgtgt acaccctcac 1560
 tattgagctg cagaagaagc cgggaaaagg cctaggatta agtattgtt gtaaaagaaa 1620
 cgatactgga gtatttgtt cagacattgt caaaggagga attgcagatg ccgatggaa 1680
 actgatgcag ggagaccaga tattaatggt gaatggggaa gacgttcgta atgcccacca 1740
 agaagcggtt gccgcttgc taaagtgtt cctaggcaca gtaaccttgg aagttggaa 1800
 aatcaaagct ggtccattcc attcagagag gaggccatct caaagcagcc aggtgagtga 1860
 aggccagctg tcacatcttca cttttccact ctctggatcc agtacatctg agtcaactgga 1920
 aagtagctca aagaagaatg cattggcatc taaaatacag ggattaagaa cagtcgaaat 1980
 gaaaaaggcc cctactgact cactggaaat cagcatcgct ggaggagtag gcagcccact 2040
 tggtgatgtg cctatatttta ttgcaatgtat gcacccaaact ggagtgcag cacagaccca 2100
 aaaactcaga gttgggata ggattgtcac catctgtggc acatccactg agggcatgac 2160
 tcacacccaa gcagtttaacc tactgaaaaa tgcatctggc tccattgaaa tgcaggtgg 2220
 tgcggagga gacgtgatgtg tggcacagg tcacagcag gagcctgcaa gttccagtt 2280
 ttcttcact gggctgacgt caagcagtat atttcaggat gattnaggac ctccctcaatg 2340
 taagtctatt acactagagc gaggaccaga tggcttaggc ttcaatgatg ttggaggata 2400
 tggcagccct catggagact taccatatttta tggtaaaaca gtgtttgcaa agggagcagc 2460
 ctctgaagac ggacgtctga aaaggggcga tcagatcatt gctgtcaatg ggcagagtct 2520
 agaaggagtc accatgaaag aagctgttgc catccttaaa cggacaaaag gcactgtcac 2580
 tttgatggtt ctctcttgc ttggctgcca gaattgaacc aacccaaaccc ctagctcacc 2640
 tcctactgt aagagaatgc actggctctg acaatttta tgctgtgtt agccgggtct 2700
 tcaaaaactgt agggggggaaa taacacttaa gtttctttt ctcatactaga aatgctttcc 2760
 ttactgacaa ctaacatca ttttctttt cttcttgcatttttgaact taaaagagaag 2820
 gaatattttgt gtaggtgaat ctctttta tttgtggaga tatctaattt tttgtgtca 2880
 catggcaag aattattaca tgctaagctg gtttagtataa agaaagataa ttctaaagct 2940
 aaccaaagaa aatggcttca gtaagtttagg atgaaaaatg aaaatataaa ataaagaaga 3000
 aaatctcgaa gagttaaaaa aaaatgcctc aatttggcaa tctacccctt ctcacccaccc 3060
 caaactaaaaa aaagaaaaaa aggtttctt atgaaaatct taaaaaatac tgcgttattt 3120
 ttaaaaattt caacagtatt ataaaaacat tgcatactccc cacctctaattt atgcataat 3180
 attttcc 3188

<210> 40
 <211> 3551
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3800639CB1

<400> 40
 tgtctgaggg ggcgtgtgt gtgtgaagcg tacctaggc gggaggcgac atggagacag 60
 gggcgcccgaa gctgtatgac caggccctt tggcatttc gcagcacgtg ggcaacgtcc 120
 aggatttctt ggcgttctc ttggcttcc tctaccgcaaa gacagacttc tatcgcttgc 180
 tgcgccaccc atcggaccgc atggcttcc cgccccgggc cgccgcaggcc ttgggtgtgc 240
 aggtatttcaa aaccttttgcac cacatggccc gtcaggatga tgagaagaga aggcaggaac 300
 ttgaagagaa aatcagaaga aaggaagagg aagaggccaa gactgtgtca gctgtgcag 360
 ctgagaagga gccagttccca gttccagttcc agggaaataga gattgactcc accacagaat 420
 tggatgggca tcaggaagta gagaagatgc agctccagg ccctgtgaag gaaatggccc 480
 atggttcaca ggaggcagaa gctccaggag cagttgtgg tgctgtgaa gtccttaggg 540
 aaccaccaat tcttcccagg attcaggagc agtccagaa aaatcccac agttacaatg 600
 tgctgtccg agagaactac acctggtcac aggactatac tgacctggag gtcagggtgc 660

cagtacccaa gcacgtggtg aaggaaaagc aggtctca gtgcaccc 720
ttcggtggc catgctggag gaaaatgggg agcgctcgtt catggaaagg aagtcaccc 780
acaagatcaa cactgagagt tctctctgg aactcgagcc cgggaagtgc gttttggta 840
acctgagcaa ggtgggcgag tattgtgg acgccatct ggaggagagaa gagcccatcg 900
acattgacaa gatcaacaag gagcgttcca tggccaccgt ggatgaggag gaacaggcgg 960
tggggacag gcttacctt gactaccacc agaagctgca gggcaagccca cagagccatg 1020
agctgaaagt ccatgagatg ctgaaagg ggtggatgc tgaaggttct cccttcccgag 1080
gccagcgatt cgaccctgccc atgttcaaca tctccccggg ggctgtgcag ttttaatgac 1140
cagaaggaaa gggaaaccctc gccggggggg aggccagagcc ttatctcggtt ctgccttct 1200
tggctccctg cattccaggg acttgcttgtt cttgtttacc ctagccatc tttctttca 1260
agggtgaacc aggcccttcca ccctgacccctt gcatctccag actgttccag agaagggtcg 1320
gggcagctg ctatgtggtg gccgcgtgtt ctgacactga gtgaagggtt tttgaaatgca 1380
ggagaggata tcccagcaaa ttgggatcac atgtttttgtt ctccacagca accagccact 1440
gcaggcagca tgtctttccccc cccctgtct ctgcttgcgtt tggtttgac gctatttgc 1500
ttgcatgtct tctggggggg atgtggagtt gttgtggac tctcaggcga actgaagtca 1560
ttgaagtgta tgaagctctg tgcttgcatttccccc agggcaagca aggaatggctt gtcctgtgagg 1620
ctgctctggg aaactccctt ccccttgacc tcttttggaga gcattcacgtt ggtcttctt 1680
ctcatcccttataaatgtt ctttgcctgc ctcagccctca tggtcagagc agtggagact 1740
ggagccctgt ttgcacgttccccc tagttgttccccc gagaagactt aggttctggg ctcaggtcca 1800
gatgcagcgg ggattctgtt ctctgactgtt ggccacccctt ctttgggttct ttttgcctt 1860
aaccaggccc gggccaccacg catggcatgc tggcttggc tccocataag adgtccttct 1920
tgggtgcacg gtgtcaaagt gtggggcaggaa gtggagactt ggtgccttca ggaggagacc 1980
acagcatgtc catcagctca gcagagctcg acagccacaa gtccctgagaa gctttgacct 2040
tgaagggtt ctggggagagg aggaatttctt gcatggggcg tgaaggcaca ctgtccccc 2100
acaactgaac cagaagagag tgaagactcc cctcttccca tccctctgtgc caggtgcct 2160
actgtgttcc ttggaaactt tggcccaatc ttttgcatttccccc tccaggactt ggtcaactg 2220
tcaggacccc caagccatag ccctgagcca tggctgttca ctgactccag ccaaggtgca 2280
aagacgagat tatgagacag gtcctcaggc ctgtgttcca agtactcaca ggggctctgg 2340
gtgcccattcg cccggagttt gtttgcatttgc ccaccggcac tggcttccca cdtgtctgtc 2400
aagctcagag catggataag ccacacagca gggcagtgc ccctggcacc atgcacggcc 2460
agcaagaatc aaggcccgca gatgctaaga gggcctatttgc tggggaaag gttcccccgtc 2520
ctgcacactc tctatggata cttgggttgc tggggcttccccc ttggagagta agtttgtggt 2580
ttgtttctgg ttacagtgg tggctgacac cccttgcatttgc aaagcattcc tggaaagtct 2640
tctgtggtc caaacatgtt gtcggatca tcaaggaga gcaaaaggcc ctagataacc 2700
cctttgaaat gtggagactt ttttgcatttgc ttttgcatttgc tgagctgggtt aagccctct 2760
aaagagatct cgaccctggg gagcagaatttctt gtttgcatttgc atgagggggtt ctgagaaaga 2820
cttgcatttttttgcatttgc agtttgcatttgc attgagggttcc taggatttgc adaccactgt 2880
cccacaagag ctttgcatttgc taatgaaagg aggttgcatttgc tgggtgttca cctcttctt 2940
ctatagttcc cgagttggcc cccattgcatttgc ccccccaccctt gtgggttagtcc tttccagaagt 3000
gatgcagtgg ttttgcatttgc cttacacccatttgc ttttgcatttgc attttgcatttgc agtcaatttgc 3060
ttccatgggtt actagtgtttt gtttgcatttgc attttgcatttgc ttttgcatttgc tttctccca 3120
ctccctgtccc tggctttaata aacagcaaaac caatatcttgc gaaatgttccccc ttggggatag 3180
tattgggtat tggcccccatttgc gcaaggaaacag ccacttgcatttgc tgggtttccccc tgccacactg 3240
cggtgcttgg ttttgcatttgc gtttgcatttgc ttttgcatttgc ttttgcatttgc gggccacgt 3300
gtctgggtgg ttttgcatttgc ccctgagccca ccacccttgc ttttgcatttgc ttttgcatttgc tttccagagct 3360
ggcacaccctt gtttgcatttgc ttttgcatttgc cacaacacccatttgc gtttgcatttgc cagccactaa 3420
gtcccaccatcg ttttgcatttgc agggaaaggcc gtttgcatttgc ttttgcatttgc cagggcccgaa 3480
ggagagtgag ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 3540
attggatattt a

<210> 41
<211> 2308
<212> DNA
<213> *Homo sapiens*

<220>
 <221> misc_feature
 <223> Incyte ID No.: 533825CB1

<400> 41

```

cgccaaaccgt ggtggctcct tgcgttccata catcctctca tctgagaatc agagagcata 60
atcttcttac gggcccgtga tttattaaacg tggcttaatc tgaaggttct cagtcaaatt 120
ctttgtgatc tactgattgt gggggcatgg caagggttgc ttaaaggagc ttggctgggt 180
tggggcccttg tagctgacag aagggtggca gggagaaggc agcacactgc tcggagaatg 240
aaggcgcttc tggctgggt ctgccttgg ctcagtcctg ctaactacat tgacaatgtg 300
ggcaacctgc acttcctgtta ttcaactc tgtaaagggtg cttccacta cggcctgacc 360
aaagatagga agaggcgctc acaagatggc tgccagacg gctgtgcgag cttcacagacc 420
acggctcctt cccagaggt ttctgcagct gcacccatct ccttaatgac agacgagcct 480
ggccttagaca accctgccta cgtgtcctcg gcagaggacg ggcagccagc aatcagccca 540
gtggactctg gccggagcaa ccgaactagg gcacggccct ttgagagatc cactattaga 600
agcagatcat ttaaaaaaat aaatcgagct ttgagtgttc ttcaaggac aaagagcggg 660
agtgcagttt ccaaccatgc cgaccaggc aggaaaatt ctgaaaacat cactgccct 720
gaagtctttc caaggttgtt ccacctgatt ccagatggt aaattaccag catcaagatc 780
aatcgagtag atcccagtga aacccctctt attaggctgg tgggaggtg cggaaacccca 840
ctggccata tcattatcca acacattat cgtgatgggg tgatgcctag agacggccgg 900
ctactgccag gagacatcat tctaaaggc aacgggatgg acatcagcaa tgcgttccac 960
aactacgctg tgcgttccct gcggcagccc tgccaggtgc tggctgtac tggatgcgt 1020
gaacagaagt tccgcagcag gaacaatggc cagggccccc atgcctacag accccgagat 1080
gacagcttc atgtgattct caacaaaagt accccggagg agcagcttgg aataaaaactg 1140
gtgcgcaagg tggatgagcc tggggttttc atttcaatg tgcgttggatgg cgggtgtggca 1200
tatcgacatg gtcagttgtt ggagaatgac cgtgtgttag ccatcaatgg acatgatctt 1260
cgatatggca gcccagaaag tgcggctcat ctgattcagg ccagtgaaag acgtgttccac 1320
ctcgtcgtgt cccggcaggt tccgcagcgg agccctgaca tcttcagga agccggctgg 1380
aacagcaatg gcagctggc cccagggcca ggggagagga gcaacactcc caagcccctc 1440
catcctacaa ttacttgtca tgagaagggtg gtaaatatcc aaaaggaccc cggtaatct 1500
ctcggcatgg cctgtcgcagg gggagcatca catagagaat gggatttgc tatctatgtc 1560
atcagtgtt agccggagg agtcataaggc agagatggaa gaataaaaac aggtgacatt 1620
ttgttgaatg tggatgggtt cgaactgaca gaggtcagcc ggagtgaggc agtggcatta 1680
ttaaaagaa cttttttttt gatagtactc aaagctttgg aagtcaaaga gtatgagccc 1740
caggaagact gcagcagccc agcagccctg gactccaaacc acaacatggc cccacccagt 1800
gactggccc cttttttttt catgtggctg gaattaccac ggtgttgc taactgtaaa 1860
gatattgtat tacgaagaaa cacagctggc agtctggct tctgcattgt aggaggttat 1920
gaagaataaca atggaaacaa accttttttcc atcaaatcca ttgttgaagg aacaccagca 1980
tacaatgtat gaagaattag atgtgggtat attttttttt ctgtcaatgg tagaagtaca 2040
tcaggaatga tacatgcttg ctggcaaga ctgctgaaag aacttaaagg aagaattact 2100
ctaactattt tttcttggcc tggcactttt ttatagaatc aatgtatgggt cagaggaaaa 2160
cagaaaaatc acaaataatag gctaagaagt tgaaaacacta tatttatctt gtccagttt 2220
atatttaaaat aaaaatataca ttgtaaaaat gtcaggaaaa gtatgatcat ctaatgaaag 2280
ccagttacac ctcagaaaat atgattcc
  
```

2308

<210> 42
 <211> 1881
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1311833CB1

<400> 42

ccacactcgc ccctgcaagc aagcttgaaa tgggcttctg tctgagcggc accggatga 60
 ccaatgggtc tgtgtttgg accggcgaac caatggcgcg acaggaaagg cgggcccggag 120
 atgggttagg gtgtccttgc agggtgtctg agctaactt caccaaataa tagctgtttg 180
 tattttggct gctgcaggag ccattttaga aataaatatc ttcccttcaat agatgaaaat 240
 gaaaatacag aaaaaagaga agcagttgtc aaatttaaaa gtttgaatc acccccat 300
 gtctgatgcc tctgtcaatt ttgactacaa atctccatcc ccatttgact gcagcactga 360
 tcaagaagag aaaattgaag atgttgc tag tcactgtctg cctcagaagg acctgtatac 420
 tgctgaagag gaagctgcta ccctttcc taggaaaatg acatcccata atgggatgga 480
 ggacagtggta ggaggaggta ctggagtgaa gaagaaacgg aaaaaaagg agccaggaga 540
 ccaagagggt gcagcaaggaa gaagcaagga cagagagccc aagccaaaga ggaaacgaga 600
 accgaaaagag ccaaaggAAC ccagaaaggc caaggagccg aagaaggcca aggacacaa 660
 ggagccgaag caaaaagatg gggcaagaa ggcacggaag ccccgggagg cctcgggcac 720
 caaggaggcc aaagagaaga ggagctgcac tgactctgca gcaggagc agtccaggaa 780
 ggccagcaag gagcaaggac caaccccagt ggagaaaaag aagaaaggaa aaagaaaaag 840
 tgaaactaca gtggagagtt tagagctgga tcagggctg acgaacccat ctctgcggag 900
 tcctgaggag tccactgagt ctacagacag ccagaaacga cgctcgggaa gcgaagtaaa 960
 gcgcagaaaa tacaatgagg acctggactt caaagtggtg gatgatgatg gggaaacaat 1020
 tgctgttctt ggagctggc gaacatctgc actctcagcc tctacactgg cctggcaggc 1080
 ggaggaggct ccagaagatg atgaaacat cattgagaag atcctggcat ctaagactgt 1140
 ccaggagggtt caccaggag aacctccgtt cgacttggag ctgttctacg tttaagtatag 1200
 aaattttcc tacttacatt gtaaatggc cacaatggaa gagctcgaaa aggatcctcg 1260
 catcgacag aagatcaagc gatttagaa taaacaagcc cagatgaagc acatttttac 1320
 ggaggtgaag caatatttc tgactcattt gactgtgtt tttcttgcag cagtaaatac 1380
 tigtgtttagt tttctaagtc caagttaaat tcttatacag atctgttgc caagtcaaat 1440
 tgataaatgt gtgctgatTT gcaacaaaac tagtctagat tcaagtcaaa gaaaactatc 1500
 caccAAAGTT aaggatcaaa ctttataaaac tgacaactca taacggcgtg catctggc 1560
 tgaatactaa taaatagcta gagtgagagg aatacgcaca caattcttt gtccctgctc 1620
 cctcaaccca ctgcaaccca aaaaggacat ttcaagaaggt cttaaagttt gaatgaaaa 1680
 aacaaaacaa atctaaaagt gagagaaagt aaacaaataa ataattttat ttatgtaaac 1740
 ttgggaattt ctaagtattt tacttatagc aagaggaagg actgatggat tttaatatta 1800
 aacaaatcta taatgctata tatcagaaaa tgccacaaac cttaacctta atgtgttatt 1860
 cttggataaa agactaaacc a 1881

<210> 43

<211> 1974

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1342819CB1

<400> 43

ccagaaggcca gcagtgggt tgcacacgacg cctcttacg aggtggaaac aagatggagg 60
 attccggcctc ggcctcgctg tcttctgcag ccgtactgg aacctccacc tcgactccag 120
 cggccccgac agcacggaaag cagctggata aagaacaggt tagaaaggca gtggacgctc 180
 tcttgcacgc ttgcaagtcc aggaaaaaca attatgggtt gctttgaat gagaatgaaa 240
 gtttattttt aatgggtgta ttatggaaaa ttccaagtaa agaactgagg gttagattga 300
 ctttgcctca tagtattcga tcagattcag aagatatctg tttatTTacg aaggatgaac 360
 ccaattcaac ttctgaaaag acagaacagt tttatagaaa gcttttaac aagcatggaa 420
 ttaaaaccgt ttctcagatt atctccctcc aaactctaaa gaaggaatat aaatccatg 480
 aagccaagct ccgccttctg agcagttttg atttcttct tactgatgcc agaatttaggc 540
 ggcttacc ctcactcatt gggagacatt tctatcaaag aagaaagtt ccagatctg 600

taaacattct gtcacaagaat ttatcaagag agatcaatga ctgtataggc ggaacggctc 660
 taaacatttc taaaagtggt tcttgcagtg cttatcgat tggtcacgtt ggaatgcaaa 720
 ttgagcacat cattgaaaac atttgtctg tcaccaaagg actttcagaa aaattgcac 780
 agaagtggg gaggcgtggaa ctcccttttgc tgaaaactga gaaatcggtc gcacttccc 840
 tctttccctc gttgtcagc aattggatg aagccaccaa aagatcttg cttataaaga 900
 agaaaaaaga ggcaaggaga aaacgaagag aaagaaattt tgaaaaacaa aaggagagga 960
 agaagaagag gcagcaggct aggaagactg catcagtct tagtaaagat gatgtggcac 1020
 ctgaaaagtgg tgatactaca gtgaagaaac ctgaatcaaa gaaggaacag accccagagc 1080
 atgggaagaa aaaacgtggc agaggaaaag cccaagttaa agcaacaaat gaatccgaag 1140
 acgaaatccc acagctggta ccaataggaa agaagactcc agctaataa 1200
 ttcaaaaaca tgccacagga aagaagtctc cagcaaagag tcctaataccc agcacaccc 1260
 gtgggaagaa aagaaaggct ttgccagcat ctgagacccc aaaagctgca gagtctgaga 1320
 ccccaggaga aagccccagag aagaagccaa aatcaaaga agaggcagtg aaggaaaaaa 1380
 gtccttcgct gggaaaaaaa gatgcgagac agactccaa aaagccagag gccaagttt 1440
 tcaccactc tagtaaatct gtgagaaaag ctcccacac ccccaaaaaa tggcccaaaa 1500
 aacccaaagt accccagtc acctaaagtc agtgattca ctggaaggaa acctcaatgc 1560
 tgcctccaga gcttttggaa aatactcaga tcctggccgc cttttaacc ttctctaaac 1620
 gtcaggcctg gactttaaaag atttttaaa acctccataa gtatccagg ggcgggtggct 1680
 cacgcctgtt atcccagcac ttgggaggc cgaggcaggc ggatcacaag gtcaacgaga 1740
 tcgagaccat cctggccaaac atggtaaac cctgtctgtt cccaaaatac aaaaattaat 1800
 tgggcattgt ggtggacacc tgaatccc gctacttaggg aggctgaggc aggagaattt 1860
 cttgaacctg ggaggcggag gttgcagtga gccactgcac tccagctgtg tgacagagca 1920
 agactcagtc tcaaaaataa ataaaataa taaaacctca aaaaaaaaaa aaaa 1974

<210> 44
 <211> 1061
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1871288CB1

<400> 44
 tccttcctgg gttcggttga aagcgcttgg gggttcagtg gggcatgatc cccgagctgc 60
 tggagaactg aaggcggacg gtccctcg 7¹ 7² 7³ 7⁴ 7⁵ 7⁶ 7⁷ 7⁸ 7⁹ 7¹⁰ 7¹¹ 7¹² 7¹³ 7¹⁴ 7¹⁵ 7¹⁶ 7¹⁷ 7¹⁸ 7¹⁹ 7²⁰ 7²¹ 7²² 7²³ 7²⁴ 7²⁵ 7²⁶ 7²⁷ 7²⁸ 7²⁹ 7³⁰ 7³¹ 7³² 7³³ 7³⁴ 7³⁵ 7³⁶ 7³⁷ 7³⁸ 7³⁹ 7⁴⁰ 7⁴¹ 7⁴² 7⁴³ 7⁴⁴ 7⁴⁵ 7⁴⁶ 7⁴⁷ 7⁴⁸ 7⁴⁹ 7⁵⁰ 7⁵¹ 7⁵² 7⁵³ 7⁵⁴ 7⁵⁵ 7⁵⁶ 7⁵⁷ 7⁵⁸ 7⁵⁹ 7⁶⁰ 7⁶¹ 7⁶² 7⁶³ 7⁶⁴ 7⁶⁵ 7⁶⁶ 7⁶⁷ 7⁶⁸ 7⁶⁹ 7⁷⁰ 7⁷¹ 7⁷² 7⁷³ 7⁷⁴ 7⁷⁵ 7⁷⁶ 7⁷⁷ 7⁷⁸ 7⁷⁹ 7⁸⁰ 7⁸¹ 7⁸² 7⁸³ 7⁸⁴ 7⁸⁵ 7⁸⁶ 7⁸⁷ 7⁸⁸ 7⁸⁹ 7⁹⁰ 7⁹¹ 7⁹² 7⁹³ 7⁹⁴ 7⁹⁵ 7⁹⁶ 7⁹⁷ 7⁹⁸ 7⁹⁹ 7¹⁰⁰ 7¹⁰¹ 7¹⁰² 7¹⁰³ 7¹⁰⁴ 7¹⁰⁵ 7¹⁰⁶ 7¹⁰⁷ 7¹⁰⁸ 7¹⁰⁹ 7¹¹⁰ 7¹¹¹ 7¹¹² 7¹¹³ 7¹¹⁴ 7¹¹⁵ 7¹¹⁶ 7¹¹⁷ 7¹¹⁸ 7¹¹⁹ 7¹²⁰ 7¹²¹ 7¹²² 7¹²³ 7¹²⁴ 7¹²⁵ 7¹²⁶ 7¹²⁷ 7¹²⁸ 7¹²⁹ 7¹³⁰ 7¹³¹ 7¹³² 7¹³³ 7¹³⁴ 7¹³⁵ 7¹³⁶ 7¹³⁷ 7¹³⁸ 7¹³⁹ 7¹⁴⁰ 7¹⁴¹ 7¹⁴² 7¹⁴³ 7¹⁴⁴ 7¹⁴⁵ 7¹⁴⁶ 7¹⁴⁷ 7¹⁴⁸ 7¹⁴⁹ 7¹⁵⁰ 7¹⁵¹ 7¹⁵² 7¹⁵³ 7¹⁵⁴ 7¹⁵⁵ 7¹⁵⁶ 7¹⁵⁷ 7¹⁵⁸ 7¹⁵⁹ 7¹⁶⁰ 7¹⁶¹ 7¹⁶² 7¹⁶³ 7¹⁶⁴ 7¹⁶⁵ 7¹⁶⁶ 7¹⁶⁷ 7¹⁶⁸ 7¹⁶⁹ 7¹⁷⁰ 7¹⁷¹ 7¹⁷² 7¹⁷³ 7¹⁷⁴ 7¹⁷⁵ 7¹⁷⁶ 7¹⁷⁷ 7¹⁷⁸ 7¹⁷⁹ 7¹⁸⁰ 7¹⁸¹ 7¹⁸² 7¹⁸³ 7¹⁸⁴ 7¹⁸⁵ 7¹⁸⁶ 7¹⁸⁷ 7¹⁸⁸ 7¹⁸⁹ 7¹⁹⁰ 7¹⁹¹ 7¹⁹² 7¹⁹³ 7¹⁹⁴ 7¹⁹⁵ 7¹⁹⁶ 7¹⁹⁷ 7¹⁹⁸ 7¹⁹⁹ 7²⁰⁰ 7²⁰¹ 7²⁰² 7²⁰³ 7²⁰⁴ 7²⁰⁵ 7²⁰⁶ 7²⁰⁷ 7²⁰⁸ 7²⁰⁹ 7²¹⁰ 7²¹¹ 7²¹² 7²¹³ 7²¹⁴ 7²¹⁵ 7²¹⁶ 7²¹⁷ 7²¹⁸ 7²¹⁹ 7²²⁰ 7²²¹ 7²²² 7²²³ 7²²⁴ 7²²⁵ 7²²⁶ 7²²⁷ 7²²⁸ 7²²⁹ 7²³⁰ 7²³¹ 7²³² 7²³³ 7²³⁴ 7²³⁵ 7²³⁶ 7²³⁷ 7²³⁸ 7²³⁹ 7²⁴⁰ 7²⁴¹ 7²⁴² 7²⁴³ 7²⁴⁴ 7²⁴⁵ 7²⁴⁶ 7²⁴⁷ 7²⁴⁸ 7²⁴⁹ 7²⁵⁰ 7²⁵¹ 7²⁵² 7²⁵³ 7²⁵⁴ 7²⁵⁵ 7²⁵⁶ 7²⁵⁷ 7²⁵⁸ 7²⁵⁹ 7²⁶⁰ 7²⁶¹ 7²⁶² 7²⁶³ 7²⁶⁴ 7²⁶⁵ 7²⁶⁶ 7²⁶⁷ 7²⁶⁸ 7²⁶⁹ 7²⁷⁰ 7²⁷¹ 7²⁷² 7²⁷³ 7²⁷⁴ 7²⁷⁵ 7²⁷⁶ 7²⁷⁷ 7²⁷⁸ 7²⁷⁹ 7²⁸⁰ 7²⁸¹ 7²⁸² 7²⁸³ 7²⁸⁴ 7²⁸⁵ 7²⁸⁶ 7²⁸⁷ 7²⁸⁸ 7²⁸⁹ 7²⁹⁰ 7²⁹¹ 7²⁹² 7²⁹³ 7²⁹⁴ 7²⁹⁵ 7²⁹⁶ 7²⁹⁷ 7²⁹⁸ 7²⁹⁹ 7³⁰⁰ 7³⁰¹ 7³⁰² 7³⁰³ 7³⁰⁴ 7³⁰⁵ 7³⁰⁶ 7³⁰⁷ 7³⁰⁸ 7³⁰⁹ 7³¹⁰ 7³¹¹ 7³¹² 7³¹³ 7³¹⁴ 7³¹⁵ 7³¹⁶ 7³¹⁷ 7³¹⁸ 7³¹⁹ 7³²⁰ 7³²¹ 7³²² 7³²³ 7³²⁴ 7³²⁵ 7³²⁶ 7³²⁷ 7³²⁸ 7³²⁹ 7³³⁰ 7³³¹ 7³³² 7³³³ 7³³⁴ 7³³⁵ 7³³⁶ 7³³⁷ 7³³⁸ 7³³⁹ 7³⁴⁰ 7³⁴¹ 7³⁴² 7³⁴³ 7³⁴⁴ 7³⁴⁵ 7³⁴⁶ 7³⁴⁷ 7³⁴⁸ 7³⁴⁹ 7³⁵⁰ 7³⁵¹ 7³⁵² 7³⁵³ 7³⁵⁴ 7³⁵⁵ 7³⁵⁶ 7³⁵⁷ 7³⁵⁸ 7³⁵⁹ 7³⁶⁰ 7³⁶¹ 7³⁶² 7³⁶³ 7³⁶⁴ 7³⁶⁵ 7³⁶⁶ 7³⁶⁷ 7³⁶⁸ 7³⁶⁹ 7³⁷⁰ 7³⁷¹ 7³⁷² 7³⁷³ 7³⁷⁴ 7³⁷⁵ 7³⁷⁶ 7³⁷⁷ 7³⁷⁸ 7³⁷⁹ 7³⁸⁰ 7³⁸¹ 7³⁸² 7³⁸³ 7³⁸⁴ 7³⁸⁵ 7³⁸⁶ 7³⁸⁷ 7³⁸⁸ 7³⁸⁹ 7³⁹⁰ 7³⁹¹ 7³⁹² 7³⁹³ 7³⁹⁴ 7³⁹⁵ 7³⁹⁶ 7³⁹⁷ 7³⁹⁸ 7³⁹⁹ 7⁴⁰⁰ 7⁴⁰¹ 7⁴⁰² 7⁴⁰³ 7⁴⁰⁴ 7⁴⁰⁵ 7⁴⁰⁶ 7⁴⁰⁷ 7⁴⁰⁸ 7⁴⁰⁹ 7⁴¹⁰ 7⁴¹¹ 7⁴¹² 7⁴¹³ 7⁴¹⁴ 7⁴¹⁵ 7⁴¹⁶ 7⁴¹⁷ 7⁴¹⁸ 7⁴¹⁹ 7⁴²⁰ 7⁴²¹ 7⁴²² 7⁴²³ 7⁴²⁴ 7⁴²⁵ 7⁴²⁶ 7⁴²⁷ 7⁴²⁸ 7⁴²⁹ 7⁴³⁰ 7⁴³¹ 7⁴³² 7⁴³³ 7⁴³⁴ 7⁴³⁵ 7⁴³⁶ 7⁴³⁷ 7⁴³⁸ 7⁴³⁹ 7⁴⁴⁰ 7⁴⁴¹ 7⁴⁴² 7⁴⁴³ 7⁴⁴⁴ 7⁴⁴⁵ 7⁴⁴⁶ 7⁴⁴⁷ 7⁴⁴⁸ 7⁴⁴⁹ 7⁴⁵⁰ 7⁴⁵¹ 7⁴⁵² 7⁴⁵³ 7⁴⁵⁴ 7⁴⁵⁵ 7⁴⁵⁶ 7⁴⁵⁷ 7⁴⁵⁸ 7⁴⁵⁹ 7⁴⁶⁰ 7⁴⁶¹ 7⁴⁶² 7⁴⁶³ 7⁴⁶⁴ 7⁴⁶⁵ 7⁴⁶⁶ 7⁴⁶⁷ 7⁴⁶⁸ 7⁴⁶⁹ 7⁴⁷⁰ 7⁴⁷¹ 7⁴⁷² 7⁴⁷³ 7⁴⁷⁴ 7⁴⁷⁵ 7⁴⁷⁶ 7⁴⁷⁷ 7⁴⁷⁸ 7⁴⁷⁹ 7⁴⁸⁰ 7⁴⁸¹ 7⁴⁸² 7⁴⁸³ 7⁴⁸⁴ 7⁴⁸⁵ 7⁴⁸⁶ 7⁴⁸⁷ 7⁴⁸⁸ 7⁴⁸⁹ 7⁴⁹⁰ 7⁴⁹¹ 7⁴⁹² 7⁴⁹³ 7⁴⁹⁴ 7⁴⁹⁵ 7⁴⁹⁶ 7⁴⁹⁷ 7⁴⁹⁸ 7⁴⁹⁹ 7⁵⁰⁰ 7⁵⁰¹ 7⁵⁰² 7⁵⁰³ 7⁵⁰⁴ 7⁵⁰⁵ 7⁵⁰⁶ 7⁵⁰⁷ 7⁵⁰⁸ 7⁵⁰⁹ 7⁵¹⁰ 7⁵¹¹ 7⁵¹² 7⁵¹³ 7⁵¹⁴ 7⁵¹⁵ 7⁵¹⁶ 7⁵¹⁷ 7⁵¹⁸ 7⁵¹⁹ 7⁵²⁰ 7⁵²¹ 7⁵²² 7⁵²³ 7⁵²⁴ 7⁵²⁵ 7⁵²⁶ 7⁵²⁷ 7⁵²⁸ 7⁵²⁹ 7⁵³⁰ 7⁵³¹ 7⁵³² 7⁵³³ 7⁵³⁴ 7⁵³⁵ 7⁵³⁶ 7⁵³⁷ 7⁵³⁸ 7⁵³⁹ 7⁵⁴⁰ 7⁵⁴¹ 7⁵⁴² 7⁵⁴³ 7⁵⁴⁴ 7⁵⁴⁵ 7⁵⁴⁶ 7⁵⁴⁷ 7⁵⁴⁸ 7⁵⁴⁹ 7⁵⁵⁰ 7⁵⁵¹ 7⁵⁵² 7⁵⁵³ 7⁵⁵⁴ 7⁵⁵⁵ 7⁵⁵⁶ 7⁵⁵⁷ 7⁵⁵⁸ 7⁵⁵⁹ 7⁵⁶⁰ 7⁵⁶¹ 7⁵⁶² 7⁵⁶³ 7⁵⁶⁴ 7⁵⁶⁵ 7⁵⁶⁶ 7⁵⁶⁷ 7⁵⁶⁸ 7⁵⁶⁹ 7⁵⁷⁰ 7⁵⁷¹ 7⁵⁷² 7⁵⁷³ 7⁵⁷⁴ 7⁵⁷⁵ 7⁵⁷⁶ 7⁵⁷⁷ 7⁵⁷⁸ 7⁵⁷⁹ 7⁵⁸⁰ 7⁵⁸¹ 7⁵⁸² 7⁵⁸³ 7⁵⁸⁴ 7⁵⁸⁵ 7⁵⁸⁶ 7⁵⁸⁷ 7⁵⁸⁸ 7⁵⁸⁹ 7⁵⁹⁰ 7⁵⁹¹ 7⁵⁹² 7⁵⁹³ 7⁵⁹⁴ 7⁵⁹⁵ 7⁵⁹⁶ 7⁵⁹⁷ 7⁵⁹⁸ 7⁵⁹⁹ 7⁶⁰⁰ 7⁶⁰¹ 7⁶⁰² 7⁶⁰³ 7⁶⁰⁴ 7⁶⁰⁵ 7⁶⁰⁶ 7⁶⁰⁷ 7⁶⁰⁸ 7⁶⁰⁹ 7⁶¹⁰ 7⁶¹¹ 7⁶¹² 7⁶¹³ 7⁶¹⁴ 7⁶¹⁵ 7⁶¹⁶ 7⁶¹⁷ 7⁶¹⁸ 7⁶¹⁹ 7⁶²⁰ 7⁶²¹ 7⁶²² 7⁶²³ 7⁶²⁴ 7⁶²⁵ 7⁶²⁶ 7⁶²⁷ 7⁶²⁸ 7⁶²⁹ 7⁶³⁰ 7⁶³¹ 7⁶³² 7⁶³³ 7⁶³⁴ 7⁶³⁵ 7⁶³⁶ 7⁶³⁷ 7⁶³⁸ 7⁶³⁹ 7⁶⁴⁰ 7⁶⁴¹ 7⁶⁴² 7⁶⁴³ 7⁶⁴⁴ 7⁶⁴⁵ 7⁶⁴⁶ 7⁶⁴⁷ 7⁶⁴⁸ 7⁶⁴⁹ 7⁶⁵⁰ 7⁶⁵¹ 7⁶⁵² 7⁶⁵³ 7⁶⁵⁴ 7⁶⁵⁵ 7⁶⁵⁶ 7⁶⁵⁷ 7⁶⁵⁸ 7⁶⁵⁹ 7⁶⁶⁰ 7⁶⁶¹ 7⁶⁶² 7⁶⁶³ 7⁶⁶⁴ 7⁶⁶⁵ 7⁶⁶⁶ 7⁶⁶⁷ 7⁶⁶⁸ 7⁶⁶⁹ 7⁶⁷⁰ 7⁶⁷¹ 7⁶⁷² 7⁶⁷³ 7⁶⁷⁴ 7⁶⁷⁵ 7⁶⁷⁶ 7⁶⁷⁷ 7⁶⁷⁸ 7⁶⁷⁹ 7⁶⁸⁰ 7⁶⁸¹ 7⁶⁸² 7⁶⁸³ 7⁶⁸⁴ 7⁶⁸⁵ 7⁶⁸⁶ 7⁶⁸⁷ 7⁶⁸⁸ 7⁶⁸⁹ 7⁶⁹⁰ 7⁶⁹¹ 7⁶⁹² 7⁶⁹³ 7⁶⁹⁴ 7⁶⁹⁵ 7⁶⁹⁶ 7⁶⁹⁷ 7⁶⁹⁸ 7⁶⁹⁹ 7⁷⁰⁰ 7⁷⁰¹ 7⁷⁰² 7⁷⁰³ 7⁷⁰⁴ 7⁷⁰⁵ 7⁷⁰⁶ 7⁷⁰⁷ 7⁷⁰⁸ 7⁷⁰⁹ 7⁷¹⁰ 7⁷¹¹ 7⁷¹² 7⁷¹³ 7⁷¹⁴ 7⁷¹⁵ 7⁷¹⁶ 7⁷¹⁷ 7⁷¹⁸ 7⁷¹⁹ 7⁷²⁰ 7⁷²¹ 7⁷²² 7⁷²³ 7⁷²⁴ 7⁷²⁵ 7⁷²⁶ 7⁷²⁷ 7⁷²⁸ 7⁷²⁹ 7⁷³⁰ 7⁷³¹ 7⁷³² 7⁷³³ 7⁷³⁴ 7⁷³⁵ 7⁷³⁶ 7⁷³⁷ 7⁷³⁸ 7⁷³⁹ 7⁷⁴⁰ 7⁷⁴¹ 7⁷⁴² 7⁷⁴³ 7⁷⁴⁴ 7⁷⁴⁵ 7⁷⁴⁶ 7⁷⁴⁷ 7⁷⁴⁸ 7⁷⁴⁹ 7⁷⁵⁰ 7⁷⁵¹ 7⁷⁵² 7⁷⁵³ 7⁷⁵⁴ 7⁷⁵⁵ 7⁷⁵⁶ 7⁷⁵⁷ 7⁷⁵⁸ 7⁷⁵⁹ 7⁷⁶⁰ 7⁷⁶¹ 7⁷⁶² 7⁷⁶³ 7⁷⁶⁴ 7⁷⁶⁵ 7⁷⁶⁶ 7⁷⁶⁷ 7⁷⁶⁸ 7⁷⁶⁹ 7⁷⁷⁰ 7⁷⁷¹ 7⁷⁷² 7⁷⁷³ 7⁷⁷⁴ 7⁷⁷⁵ 7⁷⁷⁶ 7⁷⁷⁷ 7⁷⁷⁸ 7⁷⁷⁹ 7⁷⁸⁰ 7⁷⁸¹ 7⁷⁸² 7⁷⁸³ 7⁷⁸⁴ 7⁷⁸⁵ 7⁷⁸⁶ 7⁷⁸⁷ 7⁷⁸⁸ 7⁷⁸⁹ 7⁷⁹⁰ 7⁷⁹¹ 7⁷⁹² 7⁷⁹³ 7⁷⁹⁴ 7⁷⁹⁵ 7⁷⁹⁶ 7⁷⁹⁷ 7⁷⁹⁸ 7⁷⁹⁹ 7⁸⁰⁰ 7⁸⁰¹ 7⁸⁰² 7⁸⁰³ 7⁸⁰⁴ 7⁸⁰⁵ 7⁸⁰⁶ 7⁸⁰⁷ 7⁸⁰⁸ 7⁸⁰⁹ 7⁸¹⁰ 7⁸¹¹ 7⁸¹² 7⁸¹³ 7⁸¹⁴ 7⁸¹⁵ 7⁸¹⁶ 7⁸¹⁷ 7⁸¹⁸ 7⁸¹⁹ 7⁸²⁰ 7⁸²¹ 7⁸²² 7⁸²³ 7⁸²⁴ 7⁸²⁵ 7⁸²⁶ 7⁸²⁷ 7⁸²⁸ 7⁸²⁹ 7⁸³⁰ 7⁸³¹ 7⁸³² 7⁸³³ 7⁸³⁴ 7⁸³⁵ 7⁸³⁶ 7⁸³⁷ 7⁸³⁸ 7⁸³⁹ 7⁸⁴⁰ 7⁸⁴¹ 7⁸⁴² 7⁸⁴³ 7⁸⁴⁴ 7⁸⁴⁵ 7⁸⁴⁶ 7⁸⁴⁷ 7⁸⁴⁸ 7⁸⁴⁹ 7⁸⁵⁰ 7⁸⁵¹ 7⁸⁵² 7⁸⁵³ 7⁸⁵⁴ 7⁸⁵⁵ 7⁸⁵⁶ 7⁸⁵⁷ 7⁸⁵⁸ 7⁸⁵⁹ 7⁸⁶⁰ 7⁸⁶¹ 7⁸⁶² 7⁸⁶³ 7⁸⁶⁴ 7⁸⁶⁵ 7⁸⁶⁶ 7⁸⁶⁷ 7⁸⁶⁸ 7⁸⁶⁹ 7⁸⁷⁰ 7⁸⁷¹ 7⁸⁷² 7⁸⁷³ 7⁸⁷⁴ 7⁸⁷⁵ 7⁸⁷⁶ 7⁸⁷⁷ 7⁸⁷⁸ 7⁸⁷⁹ 7⁸⁸⁰ 7⁸⁸¹ 7⁸⁸² 7⁸⁸³ 7⁸⁸⁴ 7⁸⁸⁵ 7⁸⁸⁶ 7⁸⁸⁷ 7⁸⁸⁸ 7⁸⁸⁹ 7⁸⁹⁰ 7⁸⁹¹ 7⁸⁹² 7⁸⁹³ 7⁸⁹⁴ 7⁸⁹⁵ 7⁸⁹⁶ 7⁸⁹⁷ 7⁸⁹⁸ 7⁸⁹⁹ 7⁹⁰⁰ 7⁹⁰¹ 7⁹⁰² 7⁹⁰³ 7⁹⁰⁴ 7⁹⁰⁵ 7⁹⁰⁶ 7⁹⁰⁷ 7⁹⁰⁸ 7⁹⁰⁹ 7⁹¹⁰ 7⁹¹¹ 7⁹¹² 7⁹¹³ 7⁹¹⁴ 7⁹¹⁵ 7⁹¹⁶ 7⁹¹⁷ 7⁹¹⁸ 7⁹¹⁹ 7⁹²⁰ 7⁹²¹ 7⁹²² 7⁹²³ 7⁹²⁴ 7⁹²⁵ 7⁹²⁶ 7⁹²⁷ 7⁹²⁸ 7⁹²⁹ 7⁹³⁰ 7⁹³¹ 7⁹³² 7⁹³³ 7⁹³⁴

<210> 45
<211> 505
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 2587338CB1

<400> 45	ggagcctgga ggagccacg cagtctgttc ccggcacccg gtgcgtgtga agggacttga	60
gggcagcgag atggaatca g caagagaaaa catgcacctt caacctggaa gctccgaccc	120	
caggagccag cccatcaacc tgaaccatta cgccaccaag aagagcgtgg cggagagcat	180	
gctggacgtg gccctgttca tgtccaacgc catgcggctg aaggcggtgc tggagcaggg	240	
accatctct cactactaca ccacccttgtt caccctcatc agctctctc tgctccctgca	300	
ggtgtcatc ggtgtcctgc tcgtggcatc tgacggctg aacctgaatg aggtagaaaa	360	
gcagtggcga ctcaaccaggc tcaacaacgg cagccacatc ttgttcttct tcactgtgg	420	
catcaatggt ttcatcattacag gcttcggggc acataaaaca agggtcctgg cctgccagga	480	
ctcccaatggat cctctctqaa tggag	505	

<210> 46
<211> 1099
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 2821211CB1

<210> 47
<211> 1727
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 2824832CB1

<400> 47

gttgcgtccgc	ggctcgccgctc	catgttccag	tttcatgcag	gctcttgaa	aagctgggtc	60
tgcgtctgcc	tgattcccgc	cgacagaccc	tgggaccggg	gccaacactg	gcagctggag	120
atggcgacca	cgagatccgt	gcacgagact	agggttgggg	cggccgtgaa	ggtgatccag	180
agtttggcga	agaatggttc	attccagccca	acaatgaaa	tgatgcttaa	attttatagc	240
ttctataaagc	aggcaactga	aggaccctgt	aaactttcaa	ggcctggatt	ttgggatcct	300
attggaagat	ataaatggga	tgcttggagt	tcactgggtg	atatgaccaa	agaggaagcc	360
atgattgcat	atgttgaaga	aatgaaaaag	attattgaaa	ctatgccaat	gactgagaaa	420
gttgaagaat	tgctgcgtgt	cataggccta	ttttatgaaa	ttgtcgagga	caaaaagagt	480
ggcaggagtt	ctgatataaac	ctcagatctt	gttaatgttc	tcacttctac	tccgaacgcc	540
aaaaccgtta	atggtaaaggc	tgaaagcagt	gacagtggag	ccgagtctga	ggaagaagag	600
gccccagaag	aagtggaaagg	agcagaacaa	agtgataatg	atataaatga	tgatcatgtt	660
gaagatgtta	caggaattca	gcatttgaca	agcgattcag	acagtgaagt	ttactgtgat	720
tctatggAAC	aatttggaca	agaagagtct	ttagacagct	ttacgtccaa	caatggacca	780
tttcagtttatt	acttgggtgg	tcattccagt	caacccatgg	aaaattctgg	attcgtgaa	840
gatattcaag	tacctcctgg	aaatggcaac	attgggataa	tgccagggtgt	tgccagttgaa	900
ggaaaaagggtg	aagtcaagca	tggaggagaa	gatggcagga	ataacacgccc	agcacccacac	960
cggggagaagc	gaggcggaga	aactgacgaa	ttctctaaatg	ttagaagagg	aagaggacat	1020
aggatgcAAC	acttgagcga	aggaaccaag	ggccggcagg	tgggaagtgg	aggtgatggg	1080
gagcgtctggg	gctccgacag	agggtcccga	gycagcctca	atgagcagat	cggccctcggt	1140
ctgatgagac	tgccaggagga	catgcagaat	gtccttcaga	gactgcagaa	actggaaacg	1200
ctgactgctt	tgccaggcaaa	atcatcaaca	tcaacattgc	agactgctcc	ttagccacc	1260
tcacagagac	catttgggt	gcccttcgag	atgtctccgt	gtgtgctaac	gtttgccatc	1320
atatggcctt	ttattgcaca	gtgggtgggt	tatttataact	atcaaagaag	gagaagaaaa	1380
ctgaactgag	gaaaatgggt	ttttccctcaa	gaagactact	ggaactggat	gacctcgagaa	1440
tgaactggat	tgtgggtttc	acaagaaaaat	cttagtttgt	gatgattaca	ttgtcttttg	1500
ttgtccagta	gttttagtttg	tgtacatata	tacacatata	tatttgcac	tacacaaacg	1560
ataacatttt	aaggactaat	attgctgata	cttgaataat	caatctctac	taggttataa	1620
gtagtataca	cagatttacc	ctgcccctgta	acttgaagga	cattaaatta	ttaatgatca	1680
tttggttaaca	tgtttacctg	attatctcc	atagagtaac	ataaggg		1727

<210> 48

<311> 951

2211 931
1212 DNA

<212> DNA

12301

~~22203~~ 22212 Miss Feature

<221> misc_feature

-14-

<400> 48

ggggactgg

cccgaaaaga gaagggggaa

atggtcct

```

gggtgcctcg  gaagcggggc  cacatctcac  ctaagtcccg  ccccatggcc  aattccactc  300
tcctagggct  gctggccccg  actggggagg  cttggggcat  tcttgggcag  ccccccaccc  360
gcccaacca  cagcccccca  ccctcagcca  aggtgaagaa  aatctttggc  tggggcgact  420
tctactccaa  catcaagacg  gtggccctga  acctgctcgt  cacagggaaag  atttgtggacc  480
atqqcaatgg  gaccttcagc  gtccacttcc  aacacaatgc  cacaggccag  ggaaacatct  540

```

ccatcagcct cgtgcccccc agtaaagctg tagagttcca ccaggaacag cagatttca 600
 tcgaagccaa ggcctccaaa atttcaact gccggatgga gtgggagaag gaaaaacggg 660
 gcccggac ctcgcttgc accacgacc cagccaagat ctgctcccgaa gaccacgctc 720
 agagctcagc cacctggagc tgctcccgac cttcaaagt cgtctgtgtc tacatcgct 780
 tctacagcac ggactatcggt ggttccaga aggtgtccc agattacaac taccatagt 840
 ataccccta ctacccatct gggtagccgg gggcaggcca cagaggccag gccagggctg 900
 gaaggacagg cctgcccattt caggagacca tctggacacc gggcagggaa g 951

<210> 49
 <211> 1624
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3271841CB1

<400> 49
 ctcctcccgcc ttcgcagccg ccgtcatccc gcggaggagc ggcacgccc ggggaggccg 60
 gaggacgcgc ccatagaatg cccagggcg acaaactgtc ctgagccct ctgggtgcagc 120
 cacatgcctg tccatacgc cccgcccacc atggagtcca gaggaaagtc agccagcagc 180
 cccaaagcccg acaccaaggt gcccagggtc accaccgagg ccaaggtaacc cccggcagcc 240
 gatggaaag ccccttgac caagccctcg aagaaggagg ccccgccga gaagcagcag 300
 cccgcaggcag ccccccacac ggacacctgca aagaagaccc cggccaaggc cgaccctgcc 360
 cttctcaaca accacagcaa cctgaagcca gcccccacgg tccccagcag tcccgatgca 420
 accccggagc ccaagggtcc tggggacggg ggggaggaaatgagggtgc cagtgggggg 480
 cctgggggccc gaggtccctg gtcttgtgag aacttcaacc ccctgtgtt ggctgggggt 540
 gtggccgtgg cagccatagc cctgattctc ggtgtggct tctgtggccg gaaaaaataa 600
 tacctggggg ccaggcgggg ggcacggagc cacttctgt acagacccga gaaagccagt 660
 gcatgcagag ttccaccccta cctattcgta cacacgcaca ttccattacac aactacatat 720
 gcccccaaca cacgcgcacg gtgaagagga cggccggagcc caccctgtc gaccaggac 780
 ttcccaacc tccaggccag aaagagccca ggctccgggg tccacagcac aggatgtggg 840
 gcgagggcac agctggggaa cggcaagaaa ggaatggacc ctgtgtgtgg ccccccacc 900
 cctggcggtt ggggtatctt gggcccccag ggctggctgt agtgcagggt ggggtgcccgg 960
 gatgggttgg gcttggggcc gcccctcg gggacattaa agggcgccgtt ggctccactc 1020
 gccccatttc tgctcttgc gtaccccccgg ggggtctgca tgggcgaatg cagtgggacg 1080
 gacctggggt gggcaactcac ctcagcagag cctcaatgccc acctccccac accacccaag 1140
 cctagctggg tgggaagacg gagccctgaa ggctgcgtgt ggaggggggtg ctgccaagg 1200
 gtcgccttcc ccagcttgc ttccaggggg gccccgacgc cggcggggag gcaaggatgt 1260
 cgagggcccc tcacagctgt gcccgcctg ccccgctaga ctgccccctcc agcttgcacc 1320
 cagcaccacc tgagtctaac cagcgtataa tgcaataaca ggttagatgt aactgtttt 1380
 ggcggcgacc gtcacacact gtcctcagcc cactgcaccc ggggaagccc ctcgtgcagc 1440
 ccctcttag cacaatccagt cccagcgtgg cccttggcgc gcagcagcag gcgaactccc 1500
 agaagggtgtt ggtggggact gtgagaacgt ggcctgcct cactggccag tggccacagg 1560
 aaccccgggc ctgagtggag gctgagtctg aaataaactc tgtcgtctga aaaaaaaaaa 1620
 aaaa 1624

<210> 50
 <211> 2080
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3537827CB1

<400> 50
 gtcaaggta cctccctct ccagtagcag caggactgag tgattccatc tatttgagt 60
 cgccgaagcg gtgaatttggg ggggaggagc tgacccagat gaggaaactg agacccagaa 120
 aggtggaaagc acttgtctaa ggtcacgcct ccaggaagca gtgtgtccac gactccagtc 180
 caagtggta ggctccagag cccacagtcc caggggtcca tgatgccgag ctgcaatcgt 240
 tcctgcagct gcagccgcgg ccccagcgtg gaggatggca agtggatgg ggtccgctcc 300
 tacctgcacc tcttctatga ggactgtgca ggcactgctc tcagcgcacga ccctgaggga 360
 cctccggtcc tgtgcccccg cggccctgg ccctcactgt gttggaagat cagcctgtcc 420
 tcggggaccc tgcttctgtc gctgggtgtg gggctctga ccactggcta tgcagtgcc 480
 cccaagctgg agggcatcggtg tgagggtgag ttccctgggtg tggatcagcg ggcagccgac 540
 tacaaccagg ccctgggcac ctgtcgccctg gcaggcacag cgctctgtgt ggcagctgg 600
 gttctgctcg ccatctgcct cttctggggcc atgataggct ggctgagcca ggacaccaag 660
 gcagagccct tggaccccgaa agccgacacgc cacgtggagg tcttcgggaa tgagccagag 720
 cagcagttgtt caccatccc cgcataatgc agtggccagt catgggtctc gccacccgccc 780
 agcccccttg ggcaatcttc tgtgcagact atccagccca agagggactc ctgagctgcc 840
 cacatggcct aagatgtggg tcctggatcc ttcccccttc tcaccataac cccctctcag 900
 tggggccctt acttctccct tttagcaggg tccctttaga gccaaactcc aggtcaaattc 960
 tggagctcaa atcccagtgc tccctccca ggagtggggc cccaaactttt ccaagataacc 1020
 agcattccctc aagtccctcc aaaacttccct acccacaccc tcttcccaag gccctcaggg 1080
 gcagaaaaaca tctccttcaa cccgtcccca ctcttcctc tgcatgaccc tgggcaaacc 1140
 cttggccctt caagccatca gtcctgcct ctctgcccattt agggctttgg atcagattcc 1200
 tcttctcgcc aggatgagga cacgcactgc cttccataga cacagatgaa ggggtgggg 1260
 tcattcagct cgaatgggtc ccagatgtc acttggccctt tccctgcagg atgagtgaag 1320
 acgtttgcct ctcacagtgt gtcttctacc tgcattttgg catcagagcc ccccaagccca 1380
 cccaccacag gcaattacta gcccctagttt ataggtgagg tgggtgaaga aggctggagg 1440
 tgacatgtcc gaggtcacac aacaaagcag catgcaggaa cttagaaacac atcttcagcc 1500
 tcctcctggg ccagctcttg tgctacaggt gggcggagc cagccctca ctttcctgg 1560
 tccctgaggg tccctcagggt ggaggacagg tttggcccaag aaagacttagc cagaggcctg 1620
 atggtcccaag gtggctctgg atataacttgc gatatggatt taaatggct ctaagagccg 1680
 ggggttagggg gcagggaaaag tgggttgc tttggccctca aagtccaccc acctagaaac 1740
 caagcccaacg gtctggccg tgaccctgat aataaatggg ctctctcaga ggcgccagcc 1800
 cttccctccca cagccggagg cgtcatctt ctctgttacc actagaggaa gctctgtatgc 1860
 agctggagag cagcgctcaa ggctctgccc cttccctcc ctaaccctta ctttcagtct 1920
 ccaccagccct gaagggcctc cttagggatc ctcaggcggc ccccaccagg gcacacccta 1980
 ctgtccttgc tgcctcacgccc ccctcctcat cctgcacccccc ttccatccca cttcccttt 2040
 caataaacag ctgggatgga tactaaaaaa aaaaaaaaaa 2080

<210> 51
 <211> 1420
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3729267CB1

<400> 51
 cttccagcgc cgcttgcgtt ccggagcgct ggctctgctg ggcgtgagaa atggaccaat 60
 tttgacaaga tataatgtgtc cagcgtgcctt gatggatattt attcagtcat ggcgtccgaa 120
 ctttgcataa cgtatctctgtt ggcaaggcttta gaaaaggcaca agaattttgtt cttaaatttat 180

aggaatctgc accatttcc attggaggtta ctgaaagatg agggactgca gtacttggag 240
 agactctata taaaaggaa ctcctgaca tccttgcag aaaaacctgc tcagaagctt 300
 ccaaaccttg tggactata cctgcaactca aataacatag ttgtggttcc ggaaggcatt 360
 gggctcttg taaaactcca atgtctggat cttagtaca atgccttaga aattgtttgc 420
 ccagaaattg gtcgtcttag agcttacgt catcttcgtat tagctaataa ccaactgcaa 480
 ttccctaccc cagaggttgg cgatttgaag gagctgcaga cactagacat ttctaccaat 540
 cgtttgcata ctttaccga gaggcttcac atgtgcctt ctctgcagta cctcactgtg 600
 gaccgaaatc gtctatggta tggccgcgc catctctgcc agctgcccag cctcaatgag 660
 ctctccatgg ctggaaaccg tcttcattt tgccacttg atttaggtcg atctcgagaa 720
 ctacagtatg tatacggttga taacaacatt cacctgaaag gttgcacat ttatctgtac 780
 aataaagtca tcgggtgcag tggctgtggt gctcccattc aagttccgaa ggtgaagctg 840
 ctttcccttt catcaggcga gcgaaccgtt ttccctccag ctgaggtgaa ggccataggg 900
 acggagcatg atcacgtctt ccctctgcag gaattgctt tgagagggct gtatcatacc 960
 taccacagct tgctgaaaga tttgaaactt ctgtctccaa ttcatttacc cagaagtctc 1020
 ctagagctgc tgcactgccc tctggggcac tgcactcggt gtatgttacc 1080
 atcgcttacc ccaagcttcc tcccttgaga gagacgccaat tgccagggttgc gatccagtgg 1140
 aagacaactg ttatgtttgt ggcttactgc tgctccaccc agtgtctgca gatctttgac 1200
 ctgctgagtt gataaacact caagaacctc aggagcgctg ccagcttgac aatggggat 1260
 ccagccagtc cagcacactc ttccatcctg tcctgtccaa tgccggggca ctgcagaact 1320
 ctctagaaat gtcatgattt agcttcagag ctaaaatgcc ttccaccccttc ccccaagttg 1380
 gaatatatcc tcccccaat taaggaaaaa aaaaaaaaaa 1420

<210> 52
 <211> 2703
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3768771CB1

<400> 52
 gctgattacc ttcccttaaa ccagtccatc taaagggttgg tggtaagagg ctccatgg 60
 gaggggtggc cccaggtaat acccatctt cttcccccag gctctgaaga gcccattc 120
 ctcagattcg aagctgaaca catctccaaac tacacagccc ttctgttag cagggatggc 180
 aggaccctgt acgtgggtgc tggagaggcc ctcttgcac tcaatgttccaa cttcagctt 240
 ctgcaggcg gggagtttca ggagctgtt tgggtgcag acgcagagaaa gaaacagcag 300
 tgcagcttca agggcaagga cccacagcgc gactgtcaaa actacatcaa gatccctctg 360
 cccgtcagcg cagntcacct gttcacctgt ggcacagcag cttcagccc catgtgtacc 420
 tacatcaaca tggagaactt caccctggca agggacgaga agggaaatgt ctccctggaa 480
 gatggcaagg gccgttgcctt cttcgaccccg aatttcaagt ccactgcctt ggtgggttat 540
 ggcgagctct acactggAAC agtcagcgc ttccaaaggaa atgacccggc catctcgccg 600
 agccaaagcc ttccgtccac caagaccgag agctccctca actggctgca agaccagct 660
 tttgtggct cagcctacat ttccgttgcg acgtggcttccat tggcaggttgcg tgatgacaag 720
 atctacttt ttccatcgca gactggccag gaatttgat ttttgcgat caccattgtt 780
 tcccgatctg cccgcacatcg caagggcgat gagggtggag agcgggtgtc agacgacgc 840
 tggacctctt ttccatcgatcc ccaatgttgc tggatgttgc cccacgttgc ctcccttc 900
 aacgtgtgc aggtatgtttt caccgttgcg cccacccccc aggactggcg tgacaccctt 960
 ttctatgggg ttccatctt ccaatgttgcg acgtggccat cagaaggctc tgccgtctgt 1020
 gtcttcacaa tgaaggatgtt gcaatgttgc ttccatcgatcc ttttgcgat caccattgtt 1080
 gagacacagc agtggatcac cgttgcacccac cccgttgcggca ccccccggcc tggagcgtgc 1140
 atcaccacaca gtggccggga aaggaagatc aactcatccc tggatgttgc cccacccccc 1200
 ctgaactttc tcaaggatcc ttccatcgatcc gacggggcagg tccatgttgc catgtgtacc 1260
 ctgcagcccccc aggttgcata ccacgttgcgtt gctgttgcacc cccatgttgc 1320

acctacgatg tccttttccct gggcactgggt gacggccggc tccacaaggc agtgagcgtg 1380
 ggccccccggg tgacatcat tgaggagctg cagatctt catcgggaca gcccgtgcag 1440
 aatctgtcc tggacaccca cagggggctg ctgtatgcgg ctcacactc gggcgtagtc 1500
 caggtgccca tggccaactg cagcctgtac cggagctgtg gggactgcct ctcgccccgg 1560
 gaccctact gtgttggag cggctccagc tgcaagcagc tcagcctcta ccagcctcag 1620
 ctggccacca gggcggtggat ccaggacatc gagggagcca ggcggcaagga cctttgcagc 1680
 gcgttccgg ttgtgtcccc gtctttgtt ccaacagggg agaaggccatg tgagcaagtc 1740
 cagttccagc ccaacacagt gaacactttg gcctgcccgc tccttccaa cctggcgacc 1800
 cgactctggc taacgcaacgg ggcggccgtc aatgcctcg ctcctgcca cgtgctaccc 1860
 actggggacc tggatgtggt gggcacccaa cagctgggg agttccagtg ctgggtcacta 1920
 gaggagggct tccagcagct ggttagccagc tactgcccag aggtggtgg a gacgggggtg 1980
 gcagacccaaa cagatgaggg tggcagtgtt cccgttattta tcagcacatc gcgtgtgagt 2040
 gcaccagctg gtggcaaggc cagctggggt gcagacaggt cctactggaa ggagtccctg 2100
 gtgtatgtca cgcctttgtt gtcggccgtg ctgctcccaag ttttattttt gtcctaccgg 2160
 cacccggaaaca gcatgaaagt ttccctgaag cagggggaaat gtgccagcgt gaccccaag 2220
 acctgccctg tggatgtggcc ccctgagacc cggccactca acggcctagg gccccttagc 2280
 accccgtcg atcaccgagg gtaccagtcc ctgtcagaca gccccccggg gtcccgagtc 2340
 ttcactgagt cagagaagag gccactcagc atccaagaca gcttcgtgg a gtatccca 2400
 gtgtgcccccc gggccgggtt ccgccttggc tggagatcc gtgactctgt ggtgtgagag 2460
 ctgacttcca gaggacgctg ccctggcttc aggggctgtg aatgctcgg a ggggtcaac 2520
 tggacctccc ttccgctctg ctcttcgtgg aacacgaccg tggtggccgg cccttggag 2580
 ccttggagcc agctggcctg ctgctcttcca gtcaagttagc gaactcttac cacccagaca 2640
 cccaaacagc cgtggcccca gaggtcctgg ccaaataatgg gggcctgcct aggttggtgg 2700
 aaa 2703

<210> 53
 <211> 571
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 4248993CB1

<400> 53
 ctgtgtttag gtaaccatggg gaggaagctg gacctgtctg gtttactga tgatgaaaca 60
 gagcatgttc ttcagggtgt tcaaagagac ttcaatctt gcaaaaaaga agaagaacga 120
 ctaagtgagc tgaagcagaa gctggatgag gaaggcagca agtgcagcat ctcctcgaag 180
 caccagcagt ttgtggagca ctgctgcattt cgctgtgtc cgccttcac ttccctcgtc 240
 aacaccaagc gccagtgtgg agattgaaa ttcaatgtct gcaagagctg ctgctcttac 300
 cagaagcagc aaaaggcctg ggtctgtgc gtctgccagc aagcggggct tctgagggcc 360
 caatctctgg aatgggtctta caataatgtg aagagccgt tcaagcgctt tggcagtgtca 420
 aggttctgaa gaaacctgtac agggagacc ggctggagag tggcgcgtgc ttgcacattc 480
 taggaggaag tttttgacg tcaaccctgg agatgagggc gatttgcctt agtgattcac 540
 atttataggc agtcagagga catagtgtgt g 571

<210> 54
 <211> 1293
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 5402418CB1

<400> 54

cccagctcta gcgaaaagcc gccggattt ctccatctgg ctctcctcta cc~~t~~ccaggca 60
 ggctcacccg agatccccgc cccgaacccc ccctgcacac tcggcccagc gctgttgc 120
 cccgagcggc cgtttctgca gctattctga gcacacccctg acgtcggctg agggagcggg 180
 acagggtcag cggcgaagga ggcaggcccc gcgcggggat ctcggaagcc ctgcgggtc 240
 tcatgaagtt ccagtacaag gaggaccatc ccttgagta tcggaaaaag gaaggagaaa 300
 agatccggaa gaaatatccg gacagggtcc ccgtgattgt agagaaggct cc~~a~~aaagcca 360
 ggggtccctga tctggacaag aggaagtacc tagtgcctc tgaccttact gttggccagt 420
 tctacttctt aatccggaag agaatccacc tgagacctga ggacgcctta ttcttcttg 480
 tcaacaacac catccctccc accagtgcta ccatgggcca actgttatgag gacaatcatg 540
 aggaagacta ttttctgtat gtggcctaca gtgatgagag tgcataatggg aaatgagtgg 600
 ttggaaagccc agcagatggg agcacctgga cttggggta ggggaggggt gtgtgtgcgc 660
 gacatgggga aagagggtgg ctcccacccgc aaggagacag aaggtgaaga catctagaaa 720
 cattacacca cacacaccgt catcacattt tcacatgctc aattgatatt ttttgcgtct 780
 tcctcgcccc agggagaaag catgtcagga cagagctgtt ggattggctt tgatagagga 840
 atggggatga tgtaagttt cagtattctt ggggttaat tgggtgcag tttcatagat 900
 gggtcaggag gtggacaagt tggggccaga gatgatggca gtccagcgc aactccctgt 960
 gtccttctt cttgggcag agattctatt ttgacattt gcacaagaca ggtaggaaa 1020
 ggggacttgt ggttagtggac catacctggg gacaaaaga gacccactgt aattgatgca 1080
 ttgtggcccc ttagtctccc tgcacatc ttctttctc ccaccccggt tgcaatctca 1140
 ctcagacatc acagtaccac cccagggtg gcagtagaca acaacccaga aatttagaca 1200
 gggatctttt acctttggaa aataggggtt aggcatgaag gtgggtgtga ttaagaagat 1260
 ggttttgtta ttaataaca ttaaactagg att 1293

<210> 55

<211> 375

<212> PRT

<213> Homo sapiens

<300>

<308> g3002527

<400> 55

Met	Glu	Phe	Ser	Leu	Leu	Leu	Pro	Arg	Leu	Glu	Cys	Asn	Gly	Ala
1														15
Ile	Ser	Ala	His	Arg	Asn	Leu	Arg	Leu	Pro	Gly	Ser	Ser	Asp	Ser
														30
Pro	Ala	Ser	Ala	Ser	Pro	Val	Ala	Gly	Ile	Thr	Gly	Met	Cys	Thr
														45
His	Ala	Arg	Leu	Ile	Leu	Tyr	Phe	Phe	Leu	Val	Glu	Met	Glu	Phe
														60
Leu	His	Val	Gly	Gln	Ala	Gly	Leu	Glu	Leu	Pro	Thr	Ser	Asp	Asp
														75
Pro	Ser	Val	Ser	Ala	Ser	Gln	Ser	Ala	Arg	Tyr	Arg	Thr	Gly	His
														90
His	Ala	Arg	Leu	Cys	Leu	Ala	Asn	Phe	Cys	Gly	Arg	Asn	Arg	Val
														105
Ser	Leu	Met	Cys	Pro	Ser	Trp	Ser	Pro	Glu	Leu	Lys	Gln	Ser	Thr
														120
Cys	Leu	Ser	Leu	Pro	Lys	Cys	Trp	Asp	Tyr	Arg	Arg	Ala	Ala	Val

	125	130	135
Pro Gly Leu Phe Ile Leu Phe Phe Leu Arg His Arg Cys Pro Thr			
140	145	150	
Leu Thr Gln Asp Glu Val Gln Trp Cys Asp His Ser Ser Leu Gln			
155	160	165	
Pro Ser Thr Pro Glu Ile Lys His Pro Pro Ala Ser Ala Ser Gln			
170	175	180	
Val Ala Gly Thr Lys Asp Met His His Tyr Thr Trp Leu Ile Phe			
185	190	195	
Ile Phe Ile Phe Asn Phe Leu Arg Gln Ser Leu Asn Ser Val Thr			
200	205	210	
Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln Pro Leu			
215	220	225	
Pro Pro Gly Phe Lys Leu Phe Ser Cys Pro Ser Leu Leu Ser Ser			
230	235	240	
Trp Asp Tyr Arg Arg Pro Pro Arg Leu Ala Asn Phe Phe Val Phe			
245	250	255	
Leu Val Glu Met Gly Phe Thr Met Phe Ala Arg Leu Ile Leu Ile			
260	265	270	
Ser Gly Pro Cys Asp Leu Pro Ala Ser Ala Ser Gln Ser Ala Gly			
275	280	285	
Ile Thr Gly Val Ser His His Ala Arg Leu Ile Phe Asn Phe Cys			
290	295	300	
Leu Phe Glu Met Glu Ser His Ser Val Thr Gln Ala Gly Val Gln			
305	310	315	
Trp Pro Asn Leu Gly Ser Leu Gln Pro Leu Pro Pro Gly Leu Lys			
320	325	330	
Arg Phe Ser Cys Leu Ser Leu Pro Ser Ser Trp Asp Tyr Gly His			
335	340	345	
Leu Pro Pro His Pro Ala Asn Phe Cys Ile Phe Ile Arg Gly Gly			
350	355	360	
Val Ser Pro Tyr Leu Ser Gly Trp Ser Gln Thr Pro Asp Leu Arg			
365	370	375	

<210> 56

<211> 309

<212> PRT

<213> Homo sapiens

<300>

<308> g847722

<400> 56

Met Val Ser Phe Val Ser Asn Tyr Ser His Thr Ala Asn Ile Leu			
1	5	10	15
Pro Asp Ile Glu Asn Glu Asp Phe Ile Lys Asp Cys Val Arg Ile			
20	25	30	
His Asn Lys Phe Arg Ser Glu Val Lys Pro Thr Ala Ser Asp Met			
35	40	45	
Leu Tyr Met Thr Trp Asp Pro Ala Leu Ala Gln Ile Ala Lys Ala			
50	55	60	
Trp Ala Ser Asn Cys Gln Phe Ser His Asn Thr Arg Leu Lys Pro			
65	70	75	
Pro His Lys Leu His Pro Asn Phe Thr Ser Leu Gly Glu Asn Ile			

	80	85	90
Trp Thr Gly Ser Val Pro Ile Phe Ser Val Ser Ser Ala Ile Thr			
95	100	105	
Asn Trp Tyr Asp Glu Ile Gln Asp Tyr Asn Phe Lys Thr Arg Ile			
110	115	120	
Cys Lys Lys Val Cys Gly His Tyr Thr Gln Val Val Trp Ala Asp			
125	130	135	
Ser Tyr Lys Val Gly Cys Ala Val Gln Phe Cys Pro Lys Val Ser			
140	145	150	
Gly Phe Asp Ala Leu Ser Asn Gly Ala His Phe Ile Cys Asn Tyr			
155	160	165	
Gly Pro Gly Gly Asn Tyr Pro Thr Trp Pro Tyr Lys Arg Gly Ala			
170	175	180	
Thr Cys Ser Ala Cys Pro Asn Asn Asp Lys Cys Leu Asp Asn Leu			
185	190	195	
Cys Val Asn Asp Ser Glu Thr Lys Ser Asn Val Thr Thr Met Leu			
200	205	210	
Tyr Ile Arg Leu Ala His Ile Ser Thr			
215			

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, C07K 14/47, C12Q 1/68, A61K 38/17, C07K 16/18		A3	(11) International Publication Number: WO 00/34477																
			(43) International Publication Date: 15 June 2000 (15.06.00)																
(21) International Application Number: PCT/US99/30408																			
(22) International Filing Date: 10 December 1999 (10.12.99)																			
(30) Priority Data: <table> <tr><td>Not furnished</td><td>11 December 1998 (11.12.98)</td><td>US</td></tr> <tr><td>09/210,083</td><td>11 December 1998 (11.12.98)</td><td>US</td></tr> <tr><td>60/119,365</td><td>9 February 1999 (09.02.99)</td><td>US</td></tr> <tr><td>60/124,687</td><td>16 March 1999 (16.03.99)</td><td>US</td></tr> </table>				Not furnished	11 December 1998 (11.12.98)	US	09/210,083	11 December 1998 (11.12.98)	US	60/119,365	9 February 1999 (09.02.99)	US	60/124,687	16 March 1999 (16.03.99)	US				
Not furnished	11 December 1998 (11.12.98)	US																	
09/210,083	11 December 1998 (11.12.98)	US																	
60/119,365	9 February 1999 (09.02.99)	US																	
60/124,687	16 March 1999 (16.03.99)	US																	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications <table> <tr><td>US</td><td>Not furnished (CIP)</td></tr> <tr><td>Filed on US</td><td>11 December 1998 (11.12.98)</td></tr> <tr><td>US</td><td>60/119,365 (CIP)</td></tr> <tr><td>Filed on US</td><td>9 February 1999 (09.02.99)</td></tr> <tr><td>US</td><td>60/124,687 (CIP)</td></tr> <tr><td>Filed on US</td><td>16 March 1999 (16.03.99)</td></tr> <tr><td>US</td><td>09/210,083 (CIP)</td></tr> <tr><td>Filed on</td><td>11 December 1998 (11.12.98)</td></tr> </table>				US	Not furnished (CIP)	Filed on US	11 December 1998 (11.12.98)	US	60/119,365 (CIP)	Filed on US	9 February 1999 (09.02.99)	US	60/124,687 (CIP)	Filed on US	16 March 1999 (16.03.99)	US	09/210,083 (CIP)	Filed on	11 December 1998 (11.12.98)
US	Not furnished (CIP)																		
Filed on US	11 December 1998 (11.12.98)																		
US	60/119,365 (CIP)																		
Filed on US	9 February 1999 (09.02.99)																		
US	60/124,687 (CIP)																		
Filed on US	16 March 1999 (16.03.99)																		
US	09/210,083 (CIP)																		
Filed on	11 December 1998 (11.12.98)																		
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).																			
(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). LU, Dyoung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US).																			
(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).																			
(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).																			
Published With international search report.																			
(88) Date of publication of the international search report: 9 November 2000 (09.11.00)																			

(54) Title: NEURON-ASSOCIATED PROTEINS

1 **[MA-----GSPSRAAGRRLQLP-----2417014**
1 MEFSLLLPRLECNAGAISAHARNLRLPGSSDS GI 3002527

17 **[-----LLCLFLQ-----2417014**
31 PASASPVAGITGMCTHARLILYFFLVEEMEP GI 3002527

24 **[-----GATAVLFIAVE-----VRYNHKT 2417014**
61 LHV[GQAGLELPSTSDDPSVSASQSA[RYTGH GI 3002527

41 **[DAAL-----WH-----2417014**
91 HARLICLANFCGRNRVSLMCPSWSPELKQST GI 3002527

47 **[-----RSNHSNADNEYFRY-----PKESKS 2417014**
121 CLSLPKCWDYRRAVPGLFILFFLRHRCPT GI 3002527

68 **[VAQAGVORRNGLSQPSPPR-----2417014**
151 L[TQDEVQWCDSLOPSTPEIKHPPASA[S Q GI 3002527

88 **[-----W-----SEALVA 2417014**
181 VAGTKDMHHYTWLIFIFI[FNFLRQS[LNSVT GI 3002527

(57) Abstract

The invention provides human neuron-associated proteins (NEUAP) and polynucleotides which identify and encode NEUAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of NEUAP.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30408

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12Q1/68 A61K38/17 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 06554 A (LACROIX BRUNO ;DUCLERT AYMERIC (FR); GENSET (FR); DUMAS MILNE EDWA) 11 February 1999 (1999-02-11) SEQ ID NO 45,313, ---	1-6,9,10
X	NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): "Homo sapiens cDNA clone" EMEST DATABASE ENTRY AI022447, ACCESSION NUMBER AI022447, 19 June 1998 (1998-06-19), XP002136735 sequence --- -/-	3-6,9-11

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

2 May 2000

Date of mailing of the international search report

31.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

ESPEN, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30408

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US1996 BUCKEL ALEX ET AL: "Cloning of cDNA encoding human rapsyn and mapping of the RAPSN gene locus to chromosome 11p11.2-p11.1." Database accession no. PREV199699135023 XP002136769 abstract & GENOMICS 1996, vol. 35, no. 3, 1996, pages 613-616, ISSN: 0888-7543 cited in the application -----</p>	
A		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/30408

B x I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: 17, 18, 20
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

See additional sheet, Invention 1.

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FR M PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17,18,20

Claims 17 and 18 refer to an agonist/antagonist of the polypeptide of claim 1 without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6, PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the result to be achieved. In addition, claim 20 refers to a method for treating or preventing a disorder comprising administering to a subject the antagonist of claim 18. In consequence, the above comment also applies to claim 20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: in part: 1-16,19; all as far as applicable

Neuron-associated polypeptide and polynucleotide relating to SEQ ID NOS 1 and 28, and fragments thereof. Expression vector and host cells comprising at least a fragment of such a polynucleotide. Method for detecting such a polynucleotide. Method for producing such a polypeptide. Pharmaceutical composition comprising such a polypeptide, and method for treating or preventing a disorder by using said composition. Antibody specifically binding with such a polypeptide.

2-27. Claims: in part: 1-16,19; all as far as applicable

as invention 1 but limited to subject-matter relating to SEQ ID NOS 2-27, and 29-54; wherein
invention 2 is limited to SEQ ID NOS 2 and 29
invention 3 is limited to SEQ ID NOS 3 and 30, etc...
invention 27 is limited to SEQ ID NOS 27 and 54.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/US 99/30408

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9906554	A 11-02-1999	AU 8555798 A	EP 1000152 A	22-02-1999 17-05-2000